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Experimental evidence suggests that omega-6 (n-6) fatty acids have mammary tumor promoting 
effects whereas omega-3 (n-3) fatty acids inhibit tumor growth.  These two families of fatty acids 
may influence breast cancer development by impacting prostaglandin E2 (PGE2) formation and 
consequently estradiol synthesis. Whether this effect on estrogen production can be observed in 
the circulation or in breast tissue, as reflected on a mammogram, is unknown.  Therefore, using 
fatty acids in erythrocytes as a biomarker of recent dietary intake, we sought to establish the 
relationship between the n-6 and n-3 fatty acids with both serum estradiol and mammographic 
breast density, two well-established modifiable breast cancer risk factors.  We hypothesized that 
n-6 fatty acids are positively related and n-3 fatty acids negatively related to both risk factors.  
Nonsteroidal anti-inflammatory drugs (NSAIDs) also inhibit PGE2 formation, therefore we 
further hypothesized that estradiol levels would be lower among NSAID users.  NSAID data was 
not available at the time of mammogram; hence the relationship between NSAID use and 
mammographic density could not accurately be assessed.  To test our hypotheses we conducted 
several investigations ancillary to the Mammograms and Masses Study (MAMS), a case control 
study of the determinants of mammographic breast density.  Participants were eligible for this 
compilation of studies if they were breast cancer-free, postmenopausal and not taking exogenous 
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hormones. We observed significantly lower levels of serum estradiol among current users of 
NSAIDs as compared to non-users of NSAIDs. Further, as hypothesized, estradiol concentration 
decreased with increasing erythrocyte composition of total n-3 fatty acids and rose with 
increasing erythrocyte composition of total n-6 fatty acids. However, these findings were noted 
only among non-users of NSAIDs and not among NSAID users.  No relationship was observed 
between any of the n-6 or n-3 fatty acids measures and mammographic breast density.  In 
summary, lowering consumption of n-6 fatty acids, increasing n-3 intake, or taking a NSAID 
may result in reduced estradiol synthesis and potentially breast cancer risk.  Further research is 
needed to validate our results.  If confirmed, these findings could have a substantial impact on 
public health as it could lead to the development of chemopreventive guidelines, and ultimately 
prevent the development of estrogen-dependent breast cancer.  
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 1 
1.0 INTRODUCTION 
1.1 BREAST CANCER EPIDEMIOLOGY 
Breast cancer incidence rates, in the United States, are among the highest in the world (Figure 1) 
[1]. The American Cancer Society estimates that approximately 178,480 new cases of invasive 
and 62,030 cases of in situ breast cancer will be diagnosed in women residing in the United 
States in 2007 [2]. Although early diagnosis and adjuvant chemohormonal therapy have resulted 
in significant improvements in breast cancer survival rates, breast cancer still ranks second in 
female cancer mortality in the United States, and is expected to account for approximately 
40,460 deaths in 2007 [2]. 
With the exception of gender, age is generally the most acknowledged and scientifically 
proven risk factor to be linked with breast cancer. Breast cancer is seldom diagnosed before age 
25; however, soon after this age the incidence rates rise linearly until around the age of 
menopause, where rates begin to plateau [3].  Even though the rising breast cancer rate tapers 
after menopause, older women remain at increasing risk over time, with more than 80% of breast 
cancer cases occurring in women 50 years of age and older [4].    
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Figure 1. Global incidence of female breast cancer: ASR, 2002  
 
Age-adjusted breast cancer incidence rates vary greatly around the globe, with 
approximately a 3-5 fold difference between high and low risk countries [1]. Greater risk is 
associated with the industrialized nations of North America and Western Europe, and far lower 
rates are found among the developing nations in Asia and Africa [5].  Unfortunately, the huge 
geographical variation between countries is difficult to explain.  
For decades, studies have shown breast cancer rates rise among women that migrate from 
countries with low incidence rates to countries with high breast cancer rates.  For instance, Asian 
women have one of the lowest breast cancer rates of any population in the world.  In contrast, 
Asian women who have migrated to North America acquire incidence rates similar to the women 
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in the host country [6-8].   Although these women share a common genetic background, they 
experience different rates of disease when living in dissimilar geographic and cultural settings.  
Thus, it appears that exposure to the “Western” lifestyle has a significant impact on breast cancer 
risk, and therefore breast cancer may be a preventable disease.   
1.1.1 Breast cancer risk factors 
While the etiology of breast cancer is poorly understood, it is believed to be the result of 
environmental, reproductive, hormonal, and genetic factors.  Epidemiological research has 
identified a number of factors that may either predispose or protect a woman from developing 
this disease (Table 1). However, it should be noted that many individuals who develop breast 
cancer have established risk factor values very similar to the population average.  Furthermore, 
the majority of women exposed to multiple well-established breast cancer risk factors never 
develop breast cancer, and some women that develop this disease have no apparent breast cancer 
risk factor [9].  
 Risk factors fall into one of two categories, modifiable or non-modifiable. Modifiable 
risk factors include diet and obesity, whereas nonmodifiable risk factors include one’s age and 
family history of breast cancer. Of particular interest in cancer prevention research, are those that 
are modifiable; however, a major modifiable lifestyle risk factor has yet to be recognized which 
can be used as a means for primary prevention. 
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Table 1. Selected established and potential breast cancer risk factors 
RISK FACTOR 
REFERENCE 
GROUP 
COMPARISON 
GROUP 
OR, RR, HR* 
 (95%CI) † 
 
Family History [10] 
    
   One first degree relative Women without an 
affected relative 
Women with 1 1st 
degree relative‡ 
OR: 1.80  
(1.69, 1.91) 
   Two first degree relatives Women without an 
affected relative 
 
Women with 2 1st 
degree relatives 
 
OR: 2.93 
(2.36, 3.64) 
Benign Breast Disease [11]     
   Atypical hyperplasia 
 
Iowa SEER registry 
population 
Women with 
proliferative 
fibrocystic changes 
with atypia 
RR: 4.24 
(3.26, 5.41) 
   Proliferative no atypia Iowa SEER registry 
population 
Women with 
proliferative 
fibrocystic changes 
without atypia 
RR:  1.88  
(1.66, 2.12) 
   Nonproliferative  Iowa SEER registry 
population 
Women with non-
proliferative 
fibrocystic changes 
 
RR: 1.27  
(1.15, 1.41) 
Reproductive Factors     
     Age at menarche [12] <12 years of age 15+ years of age RR: 0.84  
(0.70, 1.02) 
     Full-term pregnancy [12] Women with no 
full-term pregnancy 
Women with 1 full-
term pregnancy 
RR: 0.76  
(0.61, 0.95) 
     Age at first pregnancy [12] Women with first 
full term pregnancy 
< 22 years of age 
Women with first 
full term pregnancy 
> 30 years of age 
RR: 1.46  
(1.18, 1.81) 
     Breast-feeding  [13] Parous women that 
never breastfed 
Parous women that 
breastfed for a 
median of 12 
months 
OR: 0.94§ 
     Abortion [14]     
           Spontaneous No record of a 
spontaneous 
abortion 
Record of  a 
spontaneous 
abortion 
OR: 0.98  
(0.92, 1.04) 
           Induced No self-reported 
induced abortion 
Self-reported 
induced abortion 
OR: 0.93 
(0.89, 0.96) 
     Age at menopause [15] <40 years of age ≥55 years of age OR: 1.71  
(1.37, 2.12) 
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Table 1 (continued)    
RISK FACTOR 
REFERENCE 
GROUP 
COMPARISON 
GROUP 
OR, RR, HR 
 (95%CI) 
 
Hormonal Factors 
    
     Exogenous hormones     
           Oral contraceptives [16] Never user of oral 
contraceptives 
Current user of oral 
contraceptives 
OR:1.24 
(1.15, 1.33) 
           Hormone Therapy [17] Randomized to 
placebo 
Randomized  
treatment with 
E+P# 
HR: 1.24 
(1.02, 1.50) 
     Endogenous hormones     
           Sex steroid hormones     
                Premenopausal [18]     
                     Estradiol Lowest quartile Highest quartile OR: 1.00 
(0.66, 1.52) 
                     Estrone Lowest quartile Highest quartile OR: 1.16 
(0.72, 1.85) 
                     SHBG** Lowest quartile Highest quartile OR:  0.95 
(0.65, 1.40) 
                     Testosterone Lowest quartile Highest quartile OR: 1.73 
(1.16, 2.57) 
                Postmenopausal [19]     
                     Estradiol Lowest quintile Highest quintile RR: 2.00 
(1.47, 2.71) 
                     Estrone Lowest quintile Highest quintile RR: 2.19 
(1.48, 3.22) 
                     SHBG  Lowest quintile Highest quintile RR: 0.66 
(0.43, 1.00) 
                     Testosterone Lowest quintile Highest quintile RR: 2.22 
(1.59, 3.10) 
           Estrogen metabolites [20]     
                Premenopausal     
                     2-OHE†† Lowest quintile Highest quintile OR: 1.23 
(0.45, 3.35) 
                     16-OHE†† Lowest quintile Highest quintile OR: 1.90 
(0.68, 5.31) 
                     2:16OHE Lowest quintile Highest quintile OR: 0.55 
(0.23, 1.32) 
                Postmenopausal     
                     2-OHE Lowest quintile Highest quintile OR: 1.61 
(0.66, 3.94) 
                     16-OHE Lowest quintile Highest quintile OR: 1.34 
(0.55, 3.27) 
                     2:16OHE Lowest quintile Highest quintile OR:  1.31 
(0.53, 3.18) 
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Table 1 (continued)    
 
RISK FACTOR 
REFERENCE 
CATEGORY 
COMPARISON 
CATEGORY 
OR, RR, HR 
 (95%CI)  
            
          IGF-1 [21] 
    
                Premenopausal 25th percentile 75th percentile OR: 1.93 
(1.38, 2.69) 
                Postmenopausal 25th percentile 75th percentile OR: 0.95 
(0.62, 1.33) 
           IGFBP-3 [21]     
                Premenopausal 25th percentile 75th percentile OR: 1.96 
(1.28, 2.99) 
                Postmenopausal 25th percentile 75th percentile OR: 0.97 
(0.53, 1.77) 
      Factors effected by hormones     
           Bone mineral density [22] lowest quartile of 
bone density at 3 
skeletal sites 
highest quartile of 
bone density at 3 
skeletal sites 
RR: 2.70 
(1.4, 5.3) 
           Breast density [23] lowest quartile of 
density 
highest quartile of  
density  
OR 4.04  
(2.12, 7.69) 
Anthropometry [24]     
     Premenopausal     
           Weight (kg) <60.0  ≥80.0 RR: 0.58 
(0.40, 0.83) 
           Height (cm) <1.60  ≥1.75 RR: 1.42 
(0.95, 2.12) 
           BMI (kg/m2) <21.0 ≥33.0 RR: 0.58 
(0.34,1.00) 
     Postmenopausal     
           Weight (kg) <60.0  ≥80.0 RR: 1.25 
(1.02, 1.52) 
           Height (cm) <1.60 ≥1.75  RR:1.28 
(0.94, 1.76) 
           BMI (kg/m2) <21.0 ≥33.0 RR:1.27 
(1.03, 1.55) 
Environmental Factors     
     Ionizing Radiation [25] never exposed to 
radiation to treat or 
monitor a condition 
radiation  exposure 
between  10 and 19 
years of age 
OR: 1.6 
(0.5, 2.5) 
  Physical Activity [26]    
           Premenopausal lowest tertile of 
average lifetime 
activity 
highest tertile of 
average lifetime 
activity 
OR: 0.74 
(0.52,1.05) 
           Postmenopausal lowest tertile of 
average lifetime 
activity 
highest tertile of 
average lifetime 
activity 
OR: 0.81 
(0.64, 1.02) 
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Table 1 (continued) 
   
 
RISK FACTOR 
REFERENCE 
CATEGORY 
COMPARISON 
CATEGORY 
OR, RR, HR 
 (95%CI) 
      
     Smoking [27] 
    
           Postmenopausal Never smoker Smoked >40 years RR: 1.5 
(1.2, 1.9) 
     Dietary Factors     
           Alcohol [28] 0g/day ≥45g/day OR: 1.46 
(1.33, 1.61) 
           Total Fat [29] lowest quantile highest quantile OR: 1.13 
(1.03, 1.25) 
           Saturated Fat [29] lowest quantile highest quantile OR: 1.19 
(1.06, 1.35) 
           Meat intake [29] lowest quantile highest quantile OR:1.17 
(1.06, 1.29) 
           Soy [30] lowest quantile highest quantile OR: 0.86 
(0.75, 0.99) 
           Calcium (dietary) [31] ≤500 mg/d >1,250 mg/d RR: 0.80 
(0.67, 0.95) 
           Vitamin D (dietary) [31] ≤100 IU/d >300 IU/d RR: 0.89 
(0.76, 1.03) 
           Folate (total) [32] 150-299µg/d ≥600µg/d RR: 0.93 
(0.83,  1.03) 
           Total Fruit [33] lowest quintile highest quintile RR: 1.09 
(0.94, 1.25) 
           Total Vegetables [33] lowest quintile highest quintile RR: 0.98 
(0.84, 1.14) 
     Night work [34] no nightshift work any nightshift work OR: 1.48 
(1.36, 1.61) 
* OR=Odds Ratio; RR=Relative Risk; HR=Hazards Ratio  
†CI=Confidence Interval  
‡ First degree relative=mother, sister, or daughter  
§CI not provided  
# E+P= estrogen + progestin  
**Sex hormone binding globulin  
††2-OHE=2-hydroxyestrone;  16-OHE=16-hydroxyestrone 
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1.1.2 Circulating estradiol 
Experimental data strongly support the hypothesis that estrogen plays a causal role in the 
development of some breast cancers.  The mechanisms through which estrogens contribute to the 
carcinogenic process are complex; however, evidence exists confirming estrogens cause both 
normal and malignant breast cell proliferation [35]. Many established breast cancer risk factors 
can be attributed to some means of elevated estrogen exposure. For example, both an early age 
of menarche and a late age of menopause are related to prolonged exposure to the high levels of 
estrogen that occur during the menstrual cycle, and both are associated with increased breast 
cancer risk [12, 15].  Surgical menopause, which results in an abrupt arrest of estrogen secretion 
by the ovaries, is protective against breast cancer [36].  Moreover, the rate of age specific breast 
cancer slows around the time of menopause, a time when estrogen levels decline [3]. Increased 
bone mineral density, a potential reflection of cumulative estrogen exposure, is associated with 
increased breast cancer development in menopausal women [22]; and obesity, which is 
positively correlated with circulating estrogen levels is associated with postmenopausal breast 
cancer risk [22, 24].  
  Treatment with estrogens may cause an increase in risk of postmenopausal breast cancer.  
A meta-analysis found an increased risk of breast cancer risk associated with the use of estrogen-
replacement therapy (ET) [37]. In contrast, the Women’s Health Initiative Study did not find 
increased risk associated with participants receiving ET; however, the study may not have been 
long enough [38]. Within the Nurse’s Health Study breast cancer risk increased with the duration 
of ET use, the multivariate relative risks (RRs) and 95% confidence intervals (CIs) for breast 
cancer with current ET use for less than 5 years, 5 to 9.9 years, 10 to 14.9 years, 15 to 19.9 years, 
and 20 years or more were, respectively, 0.96 (0.75-1.22), 0.90 (0.73-1.12), 1.06 (0.87-1.30), 
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1.18 (0.95-1.48), and 1.42 (1.13-1.77) (P for trend <0.001) [39]. The relationship was more 
notable among estrogen receptor positive (ER+) and progesterone receptor positive (PR+) 
tumors, and became statistically significant after 15 years of use (RR, 1.48; 95% CI, 1.05-2.07).   
Further, there is ample evidence that endogenous levels of estradiol are strongly linked with 
breast cancer in postmenopausal women [40]. Ten of 11 prospective studies reported higher 
circulating estradiol concentrations in postmenopausal women who subsequently developed 
breast cancer than in controls (Table 2).  However, 4 of the 11 risk estimates were not 
significant, as to be expected given the small number of cases.  A reanalysis pooling data from 9 
of these studies found an OR=2.0 (95%CI: 1.4, 2.1) for breast cancer risk when comparing 
women in the upper versus the lowest quintile of estradiol levels [41].  
In addition to the observational studies linking circulating estradiol concentrations and 
breast cancer risk, convincing data from large clinical trials exist showing drugs that block the 
action of estrogen reduces breast cancer incidence. The risk reduction is more pronounced in 
women with higher estrogen levels than in those with lower levels; thus further strengthening the 
evidence that estrogen exposure is associated with the development of breast cancer [42, 43].  In 
the Multiple Outcomes of Raloxifene Evaluation (MORE) trial, it was found that women in the 
highest tertile of estradiol levels had a 2.1 fold risk of breast cancer in comparison to women 
with the lowest levels of estradiol [44]. Women in the placebo arm of the trial had 6.8 times the 
risk of developing breast cancer than women with estradiol levels lower than the assays detection 
limit (0.6%/year, 95%CI: 0%-1.1%), and women with circulating levels of estradiol >10pmol/L 
in the Raloxifene group had a breast cancer rate 76% lower (95%CI: 53%, 88%) than women 
with similar levels of estradiol in the placebo group; thus, inhibiting the action of estrogen plays 
an obvious
 
role in the risk reduction 
 
of breast cancer [43]. 
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Table 2. Nested case control studies of circulating estradiol and breast cancer risk in postmenopausal women 
Author (year) Country 
 
Cases/ 
Controls 
Partition 
(pmol/L) 
Specimen 
Type Adjustments & Matching 
 
OR (95%CI)* 
 
Garland  
(1992) [45] 
 
 
USA 
 
15/400 
 
<36.7 vs. ≥62.4 
 
Plasma 
 
Adjusted for age 
 
OR=0.6† 
Helzlsouer  
(1994)  [46] 
 
USA 29/58 <44.1 vs. >66.1 Serum Matched on age, time since 
last natural menstrual 
period, time of blood draw, 
and fasting status at the 
time of blood draw 
 
OR=4.0 (0.4, 34.8) 
Berrino  
(1996) [47] 
 
Italy 24/88 <66.8 vs. >89.6 Serum Matched on study 
recruitment center, date of 
enrollment, daylight savings 
period at time of blood 
draw, location of freezer 
storage (i.e. freezer and 
level on freezer); adjusted 
for age 
 
OR= 5.5 (0.8, 37.6) 
Dorgan  
(1996) [48] 
 
USA 71/133 <28.6 vs. ≥88.1 Serum Matched for age, date of 
blood draw, and time of 
blood draw; adjusted for 
years since last natural 
menstrual period, height, 
weight, first degree family 
history of breast cancer, and 
parity 
 
OR=2.7 (0.8, 9.1) 
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Table 2 (continued) 
Author (year) Country 
 
Cases/ 
Controls 
Partition 
(pmol/L) 
Specimen 
Type Adjustments & Matching 
 
OR (95%CI)* 
 
Thomas 
(1997) [49] 
 
 
Guernsey 
 
61/179 
 
<30.8 vs. >41.1 
 
Serum 
 
Matched for age, year of 
blood draw and number of 
years postmenopausal 
 
OR= 5.0 (2.0, 12.5) 
 
Hankinson 
(1998) [50] 
 
 
USA 
 
154/306 
 
≤18.4 vs. ≥ 44.1 
 
Plasma 
 
Matched for age, month and 
time of day and fasting 
status of blood draw;  
adjusted for BMI at age 18, 
family history of breast 
cancer, age at menarche, 
parity, age at first birth, age 
at menopause, and past HT 
use 
 
 
OR=1.9 (1.1, 3.5) 
Cauley  
(1999) [40] 
 
USA 97/243 <18.4 vs. ≥29.4 Serum Adjusted for age, BMI, age 
at menarche, first birth, and 
menopause, nulliparity, 
family history of breast 
cancer, physical activity, 
surgical menopause, and 
alcohol consumption 
 
OR=2.9 (1.2, 7.2) 
Kabuto  
(2000) [51] 
 
Japan 26/56 Lowest quintile 
vs. highest quintile 
Serum Matched for city, age (±3 
years), date (±3 months) of 
blood collection, and 
radiation dose 
 
OR=2.5 (0.2, 40.2) 
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Table 2 (continued) 
Author (year) Country 
 
Cases/ 
Controls 
Partition 
(pmol/L) 
Specimen 
Type Adjustments & Matching 
 
OR (95%CI)* 
 
Missmer  
(2004) [52] 
 
 
USA 
 
319/637 
 
Batch  specific 
cutpoints: 
 
1990-1995 
<22.0 vs. ≥40.1 
 
1996-1998 
<18.4 vs. ≥33.0 
 
 
Plasma 
 
Matched for age, month and 
time and fasting status of 
blood draw; adjusted for 
BMI at 18 years, family 
history of breast cancer, 
age at first birth, parity, age 
at menopause, duration of 
HT use 
 
OR= 2.1 (1.5, 3.2) 
Zeleniuch-Jacquotte 
(2004) [53]  
USA 294/558 <62.9 vs. >116.3 Serum Matched on age, date of 
enrollment, number and 
dates of subsequent blood 
draws;  adjusted for age at 
menarche, family history of 
breast cancer, parity, age at 
first birth, surgical 
menopause, previous breast 
biopsy, BMI, and height 
 
OR=2.1 (1.2, 3.6) 
Kaaks  
(2005) [54] 
 
9 
European 
countries 
672/1297 Lowest quintile 
vs. highest quintile 
Serum Matched on study center, 
age, time of day of blood 
draw, fasting statu at blood 
draw 
OR=2.3 (1.6, 3.2) 
* OR=Odds ratio; CI=Confidence interval 
† Not statistically significant.  CI not reported 
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1.1.3 Mammographic breast density 
The mammographic image of the breast differs according to the amounts of each type of breast 
tissue. Fatty
 
breast tissue is radiolucent, allowing x-ray beams to
 
pass through resulting in dark 
areas on a mammogram whereas fibroglandular tissue, which is comprised of stroma, ductal, and 
glandular tissue, is denser and absorbs x-rays, thus appearing
 
lighter on the film. The dense tissue 
in the breast decreases the visibility of tumors thus hindering mammogram interpretation and 
consequently reducing mammography sensitivity and specificity [55]. 
 Mammographic breast density is an estimate of the proportion of dense tissue in the 
breast as opposed to fatty tissue. There is not a standardized means to assess the degree of 
density in the breast, and a range of subjective and semi-objective classification systems have 
been developed. Common qualitative measurements include Wolfe’s patterns and Tabar’s 
categories. The less subjective quantitative breast density measurements include visual 
estimation, planimetry, and computerized thresholding. 
Wolfe’s parenchymal patterns classify the breast into four categories (N1, P1, P2, and 
DY) according to the relative amounts of fat, epithelial and connective tissue observed on the 
mammogram: N1 signifies breast tissue predominantly comprised of fatty tissue and no duct 
pattern is visible; P1 category
 
refers to mainly fatty tissue, but ductal prominence is visible in up 
to 25% of the breast; P2 displays a prominent ductal pattern in more than 25% of the breast; and 
DY, denotes dense tissues spread throughout the majority of the breast [56].  Similarly, Tabar's 
classification consists of categories, as follows:
 
breast image composed of scalloped contours 
with some lucent
 
areas of fatty replacement, and 1mm evenly distributed nodular
 
densities 
(represents the typical appearance of a premenopausal woman’s breast); composed almost 
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entirely of lucent
 
areas of fatty
 
replacement, and 1 mm evenly distributed nodular
 
densities; 
prominent ducts in the retroareolar area; extensive nodular and linear densities, with nodular size
 
larger
 
than normal lobules, and; homogeneous, ground glass-like appearance
 
with no perceptible
 
features [57]. 
In hopes to improve interrater agreement, more objective measurements to assess the 
radiographic appearance of the breast were established.  Among the first of these methods was 
visual estimation
 
of the proportion of the breast area occupied by dense tissue [23].  More recent 
studies have used planimetry, both manual and computerized, to assess breast density.  This 
method involves tracing the total breast area and areas of dense tissue. The percentage of density
 
is then calculated by dividing the area of the dense breast tissue
 
by the total area of the breast 
[58].  Another adopted method for the quantitative assessment of breast density is through 
interactive thresholding.  In this method, using digitized images of the breast, an observer selects 
a gray-level value as a threshold to
 
define the edge of the breast from the darker background, and 
subsequently selects the region of dense tissue [59].  The areas defined are then measured by the 
computer, and total breast area, dense breast area, nondense breast area and percent density are 
calculated. 
Regardless if density is defined by qualitative or quantitative measurement, numerous 
epidemiological investigations have shown breast density to be a strong risk factor for breast 
cancer in the general population; however, studies using a quantitative measure of breast density 
usually report a stronger association with breast cancer risk [60, 61]. The risk of developing 
breast cancer is estimated to be 2 to 6 times greater among women with the highest partition of 
density as compared to women with little or no visible density (Table 3).  A recent meta-analysis 
found an increased risk (OR=4.64; 95%CI=3.64-5.91) for breast cancer among women with a 
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breast density of 75% as compared to women with breast density <5% [61].  This phenomenon is 
dose dependent and notable in both pre- and postmenopausal women [23].  For each 1% 
increment in percent breast density an estimated 1.5-2% increase in breast cancer risk occurs  
[62, 63]; thus, mammographic density is a stronger predictor of breast cancer risk than most 
traditional risk factors. 
Mammographic density is believed to be a result of both genetic and lifestyle factors.  
Aside from age and BMI [64], two well-established breast cancer risk factors among 
postmenopausal women, several reproductive and hormonally-related breast cancer risk factors 
are positively associated with mammographic density.  Increased density has been linked to an 
early age at menarche, late age of menopause, nulliparity and late age at first full-term birth [64-
70]. Mammographic density can also be modified with treatments known to alter breast cancer 
risk such as increased density with HT use, with combined formulations of estrogen and 
progesterone having the most obvious effects [71-85] and decreased density with use of  estrogen 
receptor modulators (SERMs) [86-90].  The effects of both HT [83] and SERMs [91] cease with 
discontinuation of use. Additionally, changes in density are observed among oral contraceptive 
users and by phase of the menstrual cycle [92-94].  Because of the above-mentioned associations 
between reproductive and hormonal exposures and breast density, it has long been hypothesized 
that mammographic density may, in part, be a marker of estrogen and other hormonal effects on 
the breast tissue.   
Contrary to what would be expected, the limited cross-sectional information available on 
the relationship between circulating endogenous estradiol concentrations and breast density 
suggests a strong relationship between the two factors does not exist.  Among postmenopausal 
women, one study found a positive association between estradiol levels and percent 
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mammographic breast density, two studies found an inverse relationship between estradiol and 
mammographic breast density, and two observed null relationships [95-99]. It has been 
suggested that localized estrogen production in the breast tissue may be more relevant to breast 
density than circulating estrogen levels. As with endogenous estrogens and breast density, the 
relationship between breast density and bone mineral density, an established breast cancer risk 
factor and surrogate marker of estrogen exposure, remains unclear [100-102] . 
1.1.4 Potential intermediate markers 
Circulating estradiol and mammographic breast density have been proposed as potential 
intermediate markers of postmenopausal breast cancer.  Unlike most other established breast 
cancer risk factors they have also been shown to be modifiable.  Factors that alter estradiol levels 
and mammographic breast density may also alter breast cancer risk; hence the identification of 
such factors may lead to a greater understanding in the etiology of breast cancer and the 
development of prevention strategies.  In addition, assessment of endogenous estradiol levels and 
mammographic breast density is not very invasive and both can be objectively measured, which 
strengthens the use of these endpoints in epidemiological studies.   
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Table 3. Summary of quantitative studies of mammographic density and breast cancer risk 
Author  
(year) Country 
 
Cases/ 
Controls 
Age 
Range Partition (%) 
Method of 
Measurement 
Adjustments & 
Matching 
Adjusted  
OR or RR  
(95%CI)* 
        
Case Control 
Studies 
        
Boyd 
(1982) [103] 
Canada 183/183 40-65 <10 vs. ≥ 75 Observer 
estimation 
Age at first birth, 
parity, family history 
 
OR=2.8† (1.4, 5.6) 
OR=3.7 (1.7, 4.1) 
OR=6.0 (2.5, 14.1) 
 
Brisson 
(1982) [104] 
USA 408/1,021 20-69 0 vs.  ≥ 60 Observer 
estimation 
Parity, age at first birth, 
family history of breast 
cancer, age at 
menopause, HT use 
 
OR=3.8‡ (1.6, 8.7) 
OR=5.4‡ (2.5,11.4) 
Brisson 
(1984)  [105] 
USA 362/686 -------- 0 vs.  ≥ 60 Observer 
estimation 
 
Weight and height 
 
OR=4.4  (2.5,7.9) 
Wolfe  
(1987) [58] 
USA 160/160 30-85 <20 vs. ≥ 70 Manual 
planimetry 
 
Parity OR=4.3 (1.8, 10.4) 
Brisson 
(1989) [106] 
Canada 290/645 40-67 0 vs.  ≥ 60 Observer 
estimation 
Age, parity, education, 
weight, height 
OR=3.2 (1.6, 6.5)§ 
OR=4.6 (2.4, 8.5)§ 
OR=5.5 (2.3, 13.2)§ 
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Table 3 (continued) 
Author 
(year) Country 
 
Cases/ 
Controls 
Age 
Range Partition (%) 
Method of 
Measurement 
Adjustments & 
Matching 
Adjusted  
OR or RR  
(95%CI) 
 
(2000) [107] 
 
USA 
 
647/647 
 
-------- 
 
<10 vs. > 50 
 
Computer 
assisted 
thresholding 
 
Matched by age, 
ethnicity, year of 
mammogram; adjusted 
for age at menarche, 
parity, age at first birth, 
menopausal status, HT 
use, family history of 
breast cancer, prior 
breast problems 
 
 
OR=1.8 (1.1, 3.0) 
Ursin  
(2003) [63] 
USA 622/443 35-64 <1 vs. > 75 Computer 
assisted 
thresholding 
Age, BMI, HT use, age 
at menarche, family 
history of breast cancer, 
parity, age at first birth, 
menopausal status 
OR=5.2 (1.7, 16.1) 
Nested 
Studies 
 
       
Saftlas  
(1991) [108] 
 
USA 266/301 35-74 <5 vs. ≥ 65 Manual 
planimetry 
Age, weight, parity OR= 4.3 (2.1, 8.8) 
Boyd  
(1995) [23] 
Canada 354/354 40-59 0 vs.  ≥ 75 Observer 
estimation & 
computer 
assisted 
Age, parity, age at first 
birth, weight, height, 
age at menarche, family 
history of breast cancer 
OR=4.0 (2.1, 7.7)# 
OR= 6.0(2.8, 13.0)# 
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Table 3 (continued) 
Author  
(year) Country 
 
Cases/ 
Controls 
Age 
Range Partition (%) 
Method of 
Measurement 
Adjustments & 
Matching 
Adjusted  
OR or RR  
(95%CI) 
 
Kato  
(1995) [109] 
 
USA 
 
197/521 
 
35-65 
 
≤28.5 vs. ≥ 44.0 
 
Manual 
planimetry 
 
BMI, parity, 
menopausal status 
 
 
OR=2.1 (1.1, 3.8) 
Byrne  
(1995) [110] 
USA 1,880/2,152 -------- 0 vs.  ≥ 75 Computerized 
planimetry 
Matched for age and 
race, adjusted  for age 
first birth, weight, 
family history of breast 
cancer, education, 
alcohol use, number 
breast biopsies, 
reproductive years 
 
OR= 4.3 (3.1, 6.1) 
van Gils 
(1999) [111] 
Netherlands 108/400 50+ <5 vs. >25 Computerized BMI, menopausal 
status 
 
OR= 3.3 (1.5, 7.2) 
 
Kerlikowske 
(2005) [102] 
 
USA 200/431 28+ <23.9 vs. ≥ 66.8 Computer 
assisted 
thresholding 
Age, family history of 
breast cancer, age first  
birth, BMD, race, BMI 
 
OR= 2.7 (1.4, 5.4) 
Maskarinec 
(2005) [112] 
USA 607/667 -------- <10  vs. ≥ 50 Computer 
assisted 
thresholding 
Ethnicity, age at 
mammogram,  BMI, 
age at first birth, parity, 
age at menarche, age at 
menopause, HT use, 
family history of breast 
cancer 
OR= 3.1 (2.0, 4.9) 
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Table 3 (continued) 
Author 
 (year) Country 
 
Cases/ 
Controls 
Age 
Range Partition (%) 
Method of 
Measurement 
Adjustments & 
Matching 
Adjusted  
OR or RR  
(95%CI) 
        
Prospective 
Studies 
       
  Thomas 
(2002) [113] 
USA 472/547 50+ <26.7 vs. ≥70.3 Manual 
Planimetry 
 
Age and study RR= 4.4 (3.0, 6.7) 
  Torres-Mejia 
(2005)  [114] 
UK 111/3,100 35+ <18.7  vs. ≥45.9 Computer 
assisted 
thresholding 
Age, age at leaving full     
time education, social 
class, job status, parity, 
height, BMI, and 
change in BMI 
RR=3.5 (1.7, 7.2) 
* OR=Odds ratio; RR=Relative risk; CI=Confidence interval 
† OR estimation for each of 3 observers who estimated percent density. OR for total density unless noted otherwise 
‡ OR for percentage of nodular density and percentage of homogenous density, respectively  
§OR for percentage of nodular density, percentage of homogenous density, and percentage for total density, respectively 
#OR for observer estimation and computer estimation, respectively 
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1.2 OMEGA-6 AND OMEGA-3 FATTY ACIDS 
1.2.1 Biological properties and nomenclature of fatty acids 
As a class, fatty acids are simple hydrocarbon structures and can be grouped into well 
defined families. All fatty acids have a common basic structure, consisting of a chain of 
carbon atoms with hydrogen atoms attached, a methyl group (CH3) at one end of the 
chain, and a carboxylic acid group at the other end (COOH) (Figure 2). Although, there 
are four common chemical naming systems for fatty acids, only one will be reviewed in 
this section, the “n-minus” system, which denotes the chain length and the number and 
positions of any double bonds.  The number of carbon atoms in the fatty acid chain is the 
first number, followed by a colon with the second number denoting the number of double 
bonds (unsaturation level) in the chain. After the second number, "n -" and a third 
number may appear, this specifies the position of the first carbon double bond from the 
methyl end (omega end) of the molecule.   Thus, 20:5n-3 denotes a 20-carbon fatty acid 
with five double bonds, the first of which is located three carbons from the terminal 
methyl group of the fatty acid (Table 4) [115].  
 
Figure 2. Structure of a fatty acid 
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Table 4. Naming of omega-6 and omega-3 polyunsaturated fatty acids 
Common name Shorthand Systematic name 
Linoleic acid 18:2 n-6 9,12-octadecadienoic acid 
Gamma-linolenic acid 18:3 n-6 6,9,12-octadecatrienoic acid 
Eicosadienoic acid 20:2 n-6 11,14-eicosadienoic acid 
Dihomo-gamma-linolenic acid 20:3 n-6 8,11,14-eicosatrienoic acid 
Arachidonic acid 20:4 n-6 5,8,11,14-eicosatetraenoic acid 
Docosapentaenoic acid 22:5 n-6 4,7,10,13,16-docosapentaenoic acid 
Alpha-linolenic acid 18:3 n-3 9,12,15-octadecatrienoic 
Eicosatetraenoic acid 20:4 n-3 8,11,14,17-eicosatetraenoic 
Eicosapentaenoic acid 20:5 n-3 5,8,11,14,17-eicosapentaenoic 
Docosapentaenoic acid 22:5 n-3 7,10,13,16,19-docosapentaenoic 
Docosahexaenoic acid 22:6 n-3 4,7,10,13,16,19-docosahexaenoic 
  
Fatty acids fall into one of three major categories saturated fatty acids, 
monounsaturated fatty acids and polyunsaturated fatty acids (PUFAs). The difference 
between these families of fatty acids is in the type of chemical bonds they contain.  
Saturated fatty acids have no double bonds in the carbon chain and carry the maximum 
number of hydrogen atoms, monounsaturated fatty acids have one double bond, and 
PUFAs have more than one double bond that is methylene-interrupted. 
There are only two essential fatty acids encountered in the diet critical to human 
health, both of which are PUFAs.  The omega-6 (n-6) fatty acid linoleic acid (18:2n-6; 
LA) and the omega-3 (n-3) fatty acid, alpha-linolenic acid (18:3n-3; ALA), are necessary 
fats that must be obtained through the diet, because humans cannot synthesize these fatty 
acids de novo.  Moreover, the human body cannot interconvert these fatty acids because 
it lacks enzymes for forming double bonds (desaturase enzymes) past the delta 9 position 
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(9th carbon atom from carboxyl group).   The remaining PUFAs in the n-6 and n-3 
families are not necessarily essential because the human body can produce a modest 
amount on its own, via the desaturase and elongase enzymes (enzymes for lengthening 
the carbon chain) given that an adequate supply of the parent fatty acids, LA and ALA, 
are readily available (Figure 3). Both the n-6 and n-3 families of PUFAs play vital roles 
in diverse biological processes, including serving as substrates for a number of biological 
actions that oversee a wide range of functions, including blood pressure regulation, 
diuresis, muscle contractions, blood platelet aggregation, inflammatory responses to 
injury and infection, and the manufacturing and repair of cellular membranes [116]. 
Figure 3. Metabolic pathways of the omega-6 and omega-3 fatty acids 
1.2.2 Sources of the omega-6 and omega-3 fatty acids 
The intake of various fatty acids differs widely among countries.  In the typical 
“Western” diet, approximately 5-20 times more n-6 fatty acids are consumed compared 
to n-3 fatty acids [117], whereas coastal countries, such as Japan, consume considerably 
lower quantities of n-6 fatty acids, and much higher intakes of the n-3 PUFAs [118].  
Omega-6 Fatty Acid Metabolic Pathway Enzyme Omega-3 Fatty Acid Metabolic Pathway
Linoleic Acid (LA) Alpha-linolenic Acid (ALA)
Delta-6 desaturase
Gamma-linolenic Acid (GLA) Steroidonic Acid
Elongase
Dihomo-gamma-linolenic Acid (DGLA) Eicosatraenoic Acid
Delta-5 desaturase
Arachidonic Acid (AA) Eicosapentaenoic Acid (EPA)
Cyclooxygenase (COX)
Prostaglandin E2 (PGE2) Prostaglandin E3 (PGE3)
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This substantial excess of n-6 fatty acids found in the United States population diet, is 
largely due to the high intake of LA.  Approximately 85-95% (approximately 12 to 
17g/day for men and 9 to 11g/ day for women) of total n-6 PUFA consumption, is in the 
form of LA [119].  The majority of LA intake is hidden in prepackaged foods such as 
cereals, snack foods, and baked goods. 
LA is the principal member of the n-6 PUFA family, and from this fatty acid, the 
human body can manufacture all other members of the n-6 PUFA family.  LA is 
predominantly found in commonplace seed and vegetable oils such as safflower oil, 
sunflower oil, sesame oil, cottonseed and corn oil; certain nuts (e.g. peanuts, pistachios, 
almonds); seeds (e.g. pumpkin, sesame); meat from corn-fed animals (e.g. chicken), and 
dairy products.  Blackcurrant seed oil, borage oil, and evening primrose oil are 
particularly rich sources of the n-6 PUFA, gamma-linolenic acid (18:3n-6; GLA).  The 
long chain n-6 fatty acid, dihomo-gamma-linolenic acid (20:3n-6; DGLA) is found in 
high doses in liver and certain fish.  However, GLA is not typically consumed in large 
quantities in the United States, and DGLA is near non-existent in the diet.  LA, GLA, and 
DGLA can be converted in the human body, through a serious of enzymatic reactions, to 
form the n-6 PUFA arachidonic acid (20:4n-6; AA).  AA can also be obtained through 
dietary intake and is derived from the consumption of animal products including poultry, 
meat, dairy, eggs and some tropical fish, but not from plant-derived fats and oils.  AA is 
not found in plant products because unlike animal cells, plant cells lack enzymes that are 
capable of the conversion of LA to AA. 
The essential fatty acid, ALA, is the predominant plant-derived dietary n-3 PUFA 
in the United States diet, and given this fatty acid, the human body can make all other 
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members of the n-3 PUFA family.  In contrast to LA, ALA is not consumed in great 
quantity in the United States (approximately 1.3 to 1.8g/day for men and 1.0 to 1.2g/day 
for women) [119].  A selection of fats (e.g. margarine, shortening); vegetable and seed 
oils such as soybean, canola, and flaxseed oils; legumes, primarily soybeans and navy 
beans; and leafy green vegetables (e.g. kale, broccoli, salad greens) are rich sources of 
ALA. ALA is the metabolic precursor for eicosapentaenoic acid (20:5n-3; EPA) and 
thence to docosahexaenoic acid (22:6n-3; DHA); however, the elongation rate of ALA to 
these longer chained (20 or more carbon atoms) highly unsaturated n-3 PUFAs is 
believed to be inefficient (0.2-15% conversion); thus, ALA is not believed to be a viable 
source of either EPA or DHA [120, 121].  The major food sources for the human supply 
of EPA and DHA, are marine plants (kelp and seaweed), shellfish, and cold water fatty 
fish (salmon, mackerel, anchovies and sardines) [122, 123].  Another important source of 
EPA and DHA in the Western diet is egg-yolks; however, concentrations of these fatty 
acids are dependent upon the feed given to the animals [124].  Adult intake of EPA 
(approximately 0.004 to 0.007 g/day for men and 0.052 to 0.093 g/day for women) and 
DHA (approximately 0.066-0.093 g/day for men and 0.052-0.069 g/day for women) is 
minimal in the United States [119]. 
N-3 fatty acid levels vary substantially among different types of fish and have a 
propensity to be found in much higher concentrations in fatty fish as compared to lean 
fish [125].  Moreover, the n-3 fatty acid composition within a single species of fish is 
likely to differ, as it is effected to a great extent by the eating habits, geographic location 
and maturity of the fish as well as the canning oils and preparation and cooking methods 
used [126].  The differences in fatty acid profiles within species is particularly 
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pronounced when comparing cultivated and wild fish [127].  For example, wild catfish 
contain twice the amount of EPA as catfish bred in captivity (Table 5).  Additionally 
some fish types, such as farmed Atlantic salmon, contain substantially more n-6 AA than 
either the long chain n-3 PUFAs, EPA and DHA. 
Table 5. Fatty acid composition of various foods 
 Food* n-3  n-6  Food* n-3  n-6  
Finfish †   Oils‡    
Catfish      Canola 1.302 2.842 
   Farmed, raw 0.067 0.085    Corn 0.714 5.530 
   Wild, raw 0.130 0.149    Flaxseed 7.249 1.727 
Cod       Rapeseed 0.014 9.466 
   Atlantic, raw 0.064 0.022    Olive 0.103 1.318 
   Pacific, raw  0.080 0.017    Peanut 0.000 4.320 
Flounder       Safflower 0.000 10.149 
    Raw 0.093 0.038    Sunflower 0.000 8.935 
Halibut       Walnut 1.414 7.194 
   Atlantic and Pacific, raw 0.071 0.139 Vegetable/Fruits†    
   Greenland, raw 0.526 0.061    Apple 0.009 0.043 
Herring       Avocado 0.125 1.674 
   Atlantic, raw 0.709 0.060    Banana 0.027 0.046 
   Pacific, raw 0.969 0.096    Broccoli 0.021 0.017 
Mackerel       Cauliflower 0.104 0.029 
   Atlantic, raw 0.898 0.183    Lettuce, Romaine 0.113 0.047 
   King, raw 0.136 0.136    Kale 0.180 0.138 
Salmon       Peas 0.035 0.152 
   Atlantic, farmed, raw 0.618 1.152    Raspberries 0.126 0.249 
   Atlantic, wild, raw 0.287 0.267    Spinach 0.138 0.026 
   Pink,  raw 0.096 0.078      
Trout    Animal Products†    
    Rainbow, farmed, raw 0.260 0.025    Beef 0.015 0.227 
    Rainbow, wild, raw 0.167 0.109    Cheese, Swiss 0.352 0.620 
Tuna       Chicken 0.090 1.980 
   Bluefin, raw    0.283 0.043    Milk, 2% 0.028 0.043 
   Yellowfin, raw 0.037 0.028    Turkey 0.190 3.180 
* Data from the USDA Nutrient Database for Standard Reference 
†Per 100g 
‡Per 1Tbsp 
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1.2.3 Erythrocytes as markers of the omega fatty acids 
Dietary semiquantitative food frequency questionnaires, dietary records, and dietary 
recalls are standard tools used in nutritional epidemiological investigations. Subject to 
widespread misreporting of fat intake, these instruments may play a role in the conflicting 
results of dietary fat and breast cancer.  In fact, a recent publication from a prospective 
study found a statistically significant association between dietary fat intake and breast 
cancer risk when analyzing participants’ food records, but did not find a smiliar 
association when analyzing the same populations’ food frequency questionnaires [128].   
Food preparation is often not entirely conducted by the participant under study 
making it difficult, if not impossible, to determine the quantity of each fatty acid in all 
foods consumed, through the use of a questionnaire [129].  Additionally, dietary 
instruments for the long chain n-3 PUFAs, such as EPA, typically do not make a 
distinction between types of fish consumed, but rather measure total fish consumption; 
thus, they do not capture the large differences in n-3 fatty acid composition within and 
between species of fish. Use of biochemical indicators of fat reduces error resulting from 
human perceptions, opinions, and memories [130, 131]. Therefore, studying biological 
specimens rather than self-reported estimates could possibly reduce the chance of over or 
underestimation of dietary fat intake, which has been shown to be particularly vulnerable 
to bias [132].  
Fatty acid levels in erythrocytes, represent dietary intake of fatty acids that cannot 
be produced endogenously (LA and ALA). Furthermore, because erythrocytes have a 
long half-life (~120days) and lack the ability for de novo fatty acid elongation and 
desaturation, they are a good reflection of medium term intake of the “nonessential” n-6 
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and n-3 PUFAS which are derived from elongation of both LA and ALA as well as from 
the diet [133, 134].  Hence measures of all erythrocyte n-3 and n-6 fatty acids reflect 
dietary intake, and perhaps more importantly, internal dose [135-137].     
Intervention with flaxseed, one of the richest dietary sources of n-3 ALA, results 
in raised ALA levels in erythrocyte membranes [138, 139]. Comparison among two 
populations, one with high cold water fatty fish intake and the other without, 
demonstrated higher n-3 PUFA levels in the erythrocyte phospholipid membranes of the 
population with greater marine fat intake [133]. Supplementation with fish oil, high in 
EPA and DHA, results in a rise of these fatty acids in erythrocytes [140-145], and for 
EPA incremental increases were proportional to the amount supplied [144].  
Randomization to consumption of either fresh fish, fish oil, DHA oil, as compared to the 
control group, resulted in an elevation in total n-3 PUFA, EPA and DHA in erythrocytes 
[146].  In an experimental study, a strong correlation (r = 0.91 at 6 weeks) was found 
between EPA measured in erythrocytes and the amount of EPA ingested over a 6-week 
period [147]. Not only does supplementation of EPA result in elevated erythrocyte levels 
of this fatty acid, but erythrocyte EPA levels return to baseline values after 18 weeks of 
discontinuation [148].  EPA and DHA in erythrocytes are also correlated with fatty fish 
consumption, estimated via a food frequency questionnaire [149]. 
Less interest has been taken in the association between self-reported dietary 
intake of the n-6 PUFAs and fatty acids measured in erythrocytes. The correlation of LA 
in erythrocytes of postmenopausal women with their reported LA intake in food 
frequency questionnaires is good (r=0.44 and r=0.40) [148, 150]. Supplementation with 
corn oil, which is high in LA, results in a rise in this fatty acid in erythrocytes, and to a 
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much lesser extent, LA’s elongated product, AA [151]. In pregnant women erythrocyte 
AA levels were related to reported dietary intake (β=0.49; p=0.04) [152].  Furthermore, 
AA which is found only in animal products, is minimal in the erythrocytes of individuals 
who eat no products of animal origin [153, 154].   Dietary supplementation with AA, 
results in an erythrocyte fatty acid profile significantly enriched in AA [151, 155].  
Erythrocyte fatty acid levels, unlike plasma and serum fatty acid compositions, do 
not change rapidly after dietary treatment, and obtaining blood samples from participants 
is not as an invasive measurement as obtaining fatty acids from adipose tissue [156-159].  
Given that fatty acids in erythrocytes are easily obtainable and are able to express 
habitual dietary patterns of individuals over several weeks, they are a useful molecular 
tool in epidemiologic studies when assessing n-6 and n-3 PUFA intake  [130, 160-164]. 
1.3 OMEGA-6 AND OMEGA-3 FATTY ACIDS AND BREAST CANCER  
1.3.1 AA, EPA, and prostaglandins  
The release of n-6 AA and n-3 EPA from phospholipids in the cell membrane is the first 
step in their conversion into prostaglandins (PG), short-lived hormone-like lipids, and 
occurs in all cells except for erythrocytes [165]. The conversion occurs by the addition of 
molecular oxygen via cyclooxygenase-1 (COX-1) or cyclooxygenase-2 (COX-2) [166], 
which are the rate limiting enzymes in PG biosynthesis.  In general, COX-1 is 
constitutive, overseeing regular bodily functions such as blood flow in the kidneys; COX-
2 is inducible and activated only under certain conditions.  Conversion of AA by COX 
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results in PGE2, primarily known for its role as a pro-inflammatory mediator; whereas 
conversion of EPA, the
 
n-3 homologue of AA, results in PGE3 which is deemed anti-
inflammatory [167].    
AA and EPA are competitive inhibitors of each other. EPA competes with AA at 
the level of incorporation into cell membrane phospholipids, for desaturase and elongase 
enzymes, as well as for substrates for COX enzymes once they are incorporated into the 
membrane [168-171], thus resulting in PGs of different series [171, 172]. An 
experimental study on rat mammary tumors demonstrated that a diet supplemented with 
long chain n-3 (EPA+DHA) fatty acids compared to a diet high in n-6 fatty acids 
suppressed COX-2 protein levels by 36% [170]. Moreover, n-3 supplementation has been 
shown to significantly lower PGE2 production in cancer cells [173, 174].  In fact, 
supplementation with fish oil, high in EPA and DHA, not only decreases PGE2, but 
increases PGE3 levels [175] which have not been linked to processes in carcinogenesis 
and may be protective [176].  Suppression of PGE2 synthesis in animal models has also 
been shown to be dependent on a decreased shift of the n-6:n-3 ratio [177, 178], thus, the 
relative proportion of the n-6 PUFAs to n-3 PUFAs may also be of relevance to breast 
carcinogenesis. Blood PGE2 levels were 41% lower among individuals taking EPA 
supplements, in comparison to individuals not supplemented with EPA [179].  Humans 
prescribed a diet with a low AA:EPA ratio had lower urinary levels of PGE2 in 
comparison to individuals prescribed a diet with a high AA:EPA ratio [151].  
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1.3.2 Inhibition of prostaglandin E2 
COX-2 and PGE2 are overexpressed in a spectrum of human malignant lesions [180-
184], including breast cancer [185-188], and are highly correlated with one another [187] 
as well as with poorer prognosis [188]. Several mechanisms have been proposed by 
which COX-2 and its by-product, PGE2, might contribute to tumor progression, and 
include promotion of cell proliferation, inhibition of apoptosis, and increased 
angiogenesis [189, 190]. The anti-carcinogenic activities of the n-3 PUFAs have been 
attributed to their ability to inhibit PGE2 synthesis.  
Intervention with pharmacological agents that block PGE2 biosynthesis, such as 
nonsteroidal anti-inflammatory agents (NSAIDs) and COX-2 selective inhibitors, are 
protective against breast cancer in animal models [191] and possibly in human 
populations [192-196]. These agents appear to exert their chemopreventive effects by 
inhibiting COX-2 activity and ultimately PGE2 production [197].  Harris et al. found a 
reduced risk of breast cancer associated with the use of NSAIDs at least three times a 
week for one year (RR=0.66; 95%CI 0.52-0.83), and the effect was dose-dependent 
[198]. Long-term aspirin use is also found to be chemopreventive, specifically towards 
hormone receptor positive tumors (OR = 0.74; 95%CI, 0.60-0.93) when compared to 
hormone receptor negative tumors (OR = 0.97; 95%CI, 0.67-1.40), and in 
postmenopausal women (OR = 0.77, 95% CI, 0.62-0.97) in comparison to premenopausal 
women (OR = 0.83; 95% CI, 0.56-1.22).  Notably when stratified by menopausal status 
and receptor status a protective effect occurred in postmenopausal, hormone receptor 
positive breast cancer (OR 0.70; 95%CI, 0.54-0.91), but not among hormone receptor 
negative postmenopausal breast cancer (OR= 0.91; 95% CI, 0.58-1.42). Therefore, the 
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chemopreventive effect of PGE2 inhibition may be the result of an effect on estrogen 
production; particularly since PGE2 has recently been found to increase aromatase 
activity, which is the primary source of estrogen production in postmenopausal women 
[199, 200].  Indeed,  decreases in aromatase activity were observed in breast cancer cells 
following treatment with NSAIDs, a COX-1 selective inhibitor, and COX-2 selective 
inhibitors [201].  Further, experimental evidence has shown that estradiol production is 
decreased in breast cells that are exposed to a selective COX-2 inhibitor [202]. 
Considering the profound impact on COX-2 production of PGE2 via the AA cascade, it 
would be reasonable to assume that dietary reduction of n-6 fatty acids and/or increased 
intake of n-3 PUFAs could modify one’s risk of developing estrogen-dependent breast 
cancer. 
1.3.3 CYP19, estrogen and breast cancer 
 At menopause, when estrogen synthesis of the ovary ceases, estrogen continues to be 
produced among various tissues of the body from androgens [203]. The aromatase gene, 
CYP19, catalyzes the conversion of testosterone and androstenedione, to estradiol and 
estrone respectively by catalyzing three consecutive hydroxylation reactions.  The 
majority of aromatization takes place in peripheral tissues and particularly in adipose 
tissue and, as previously stated, is the primary source of estrogen exposure in 
postmenopausal women [204].  Localized estrogen production via aromatase activity has 
been positively associated with malignant lesions in the breast [205-207] and appears to 
promote cancerous growth in both an autocrine and a paracrine fashion [208].  In vitro 
studies demonstrated that 72% of human breast cancer specimens had aromatase activity 
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greater than that of other tissue [209], therefore, hormonal therapies have been developed 
targeting this activity. Aromatase inhibitors prevent the development of breast tumors in 
Sprague-Dawley rats, in a dose-dependent manner [210] and are used in the treatment of 
postmenopausal estrogen receptor positive breast cancer [211-213]. A 5 year comparison 
of aromatase inhibitor, Letrozole, found reduced recurrence of breast cancer compared 
with the placebo group (RR=0.57, CI 0.43-0.75) [214], and Anastrozole reduces serum 
estradiol levels in postmenopausal Caucasians by 87% [215]. Thus, inhibition of 
aromatase activity in postmenopausal women has a desirable impact on breast cancer 
risk.   
1.3.4 The relationship between COX-2, PGE2, and CYP19 
PGE2 within human breast cells significantly increases aromatase activity in adipose 
stromal cells (p<0.05) [216].  Additionally, aromatase is strongly correlated with COX-2 
expression in breast tumors (r=0.80, p=0.001) [217], but neither are strongly expressed in 
normal breast tissue [185-188, 218, 219]. COX-2, via production of PGE2,  rapidly 
activates aromatase expression by the enhancement of CYP19 transcription [199, 200]. 
Since CYP19 is responsible for both peripheral and intratumoral estrogen synthesis this 
upregulation will ultimately lead to increased estrogen production, and potentially breast 
carcinogenesis [220]. Therefore, the significant linear correlation between COX-2 and 
aromatase in breast cancer tissues suggests that they may be involved in the advancement 
of hormonally-dependent breast cancers [221]. NSAIDS and COX-2 inhibitors inhibit 
aromatase activity in human breast cancer cells in a dose-dependent fashion, likely by 
diminishing PGE2 production and consequently CYP19 upregulation [222].  Therefore, 
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blocking n-6 AA conversion to PGE2 by increasing n-3 intake, a competitive inhibitor of 
n-6 fatty acids, would theoretically inhibit aromatase induction and result in lowered 
estrogen production (Figure 4). Whether the effects would be systemic or localized to 
breast tissue is unknown; however, it is critical that this relationship be investigated in 
human populations. 
 
Figure 4. Potential n-6 and n-3 PUFA pathway leading to breast cancer 
1.3.5 Animal and experimental evidence  
Extensive laboratory and animal model data suggest that high intake of n-6 PUFAs 
promotes breast tumor development [178, 223-229], while increasing n-3 PUFAs inhibits 
mammary tumor growth and metastasis [178, 223, 225-228, 230-236]. N-6 AA, has been   
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shown to stimulate human breast cancer cell growth [237], and numerous studies have 
shown EPA to inhibit breast cancer cell growth [226, 227, 230, 232-236, 238] including 
the growth of estrogen-dependent breast cancer cell lines [231].    
Levels of estradiol were approximately 30% higher in rats consuming the largest 
quantities of n-6 PUFAs in their  diet (46% fat)  than in the females consuming the lowest 
n-6 fat (12% fat) (p < 0.01) [239], and by week 18 the rats fed the high n-6 PUFA diet 
developed significantly more mammary tumors than the rats fed a low n-6 PUFA diet 
(40% vs. 10%; p<0.05) [229]. A meta-analysis on mammary tumor incidence in over 
12,800 mice and rats, extracted from 97 reports, indicated that n-6 PUFAs had a strong 
tumor enhancing effect and n-3 PUFAs a protective effect [228]. The results further 
indicated that the tumor promoting activity of n-6 PUFAs may be abrogated by the 
competitive inhibition of the n-3 PUFAs.  This inhibitory effect has been observed in 
numerous experimental studies [178, 233, 236, 240]; moreover, the association appears to 
be dose dependent [178]. Rodents fed a diet with the lowest 6:3 PUFA ratio in 
comparison to rodents with the uppermost 6:3 ratio had the greatest reduction in tumor 
growth rate (p< 0.01) [178].   
1.3.6 Ecological and epidemiological evidence 
In contrast to the abundance of experimental evidence relating n-6 and n-3 PUFAs to 
mammary carcinogenesis, epidemiological evidence is sparse. The majority of 
information supporting this hypothesis evolves from international findings of low breast 
cancer rates in populations with high n-3 fat intake, and elevated rates in populations with 
high consumption of products containing n-6 PUFAs [241-245].  Significant inverse 
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associations between n-3 intake and breast cancer risk have previously been reported 
[246-248]; yet, a recent systematic review of the literature concluded that no association 
existed between n-3 consumption, primarily from fish, and breast cancer risk [249].  
However, this study did not take into account the varying levels of n-3 fatty acids found 
within and between species of fish.  Although explored less intensively than the n-3 fatty 
acids, the relationship between n-6 PUFAs and breast cancer has also been subject to 
investigation, and found to be positively associated with risk of breast cancer [250, 251].  
Few population based studies have attempted to look at the 6:3 PUFA ratio and breast 
cancer risk.  Nonetheless, epidemiological data using subjective measures of dietary 
intake suggest a protective effect of a decreased 6:3 PUFA ratio on breast cancer risk 
[248, 251-253].   
N-6 fatty acids and LA in adipose tissue have been  positively associated with 
breast cancer [254, 255], and adipose n-3 fatty acid levels negatively associated with risk 
of breast cancer [254, 255]. However, null relationships have also been observed between 
adipose tissue levels of the n-6 PUFAs and n-3 PUFAs and breast cancer risk [254, 256, 
257]. In contrast to the relationship observed between adipose n-6 fatty acids and breast 
cancer, levels of LA and total n-6 in serum have been inversely related to breast cancer 
risk [258-261].  Further, null relationships have also been observed for n-3 PUFAs in 
serum and risk of breast cancer [258-260].  The erythrocyte composition of AA has been 
positively linked to breast cancer risk [262]. In contrast, total erythrocyte n-6 fatty acids 
have been negatively related to breast cancer [262-265]. The n-3 fatty acid composition 
of erythrocytes has consistently been inversely linked to breast cancer occurrence [263, 
264]. In fact, a review of biomarkers of fatty acids and breast cancer risk assessed the 
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relationship between fatty acids in biospecimens (adipose, serum and erythrocytes) and 
risk of breast cancer in studies published from 1966-2002.  The authors concluded that a 
significant protective effect was found for total n-3 PUFAs [266]. 
 The ratio of n-6 to n-3 fatty acids in biospecimens and breast cancer risk has been 
explored to some extent.  The fatty acid composition in adipose tissue was compared 
between 241 women with breast cancer and 88 women with benign breast disease.  
Women in the highest tertile of total n-6 to total long chain n-3 PUFAs had an increased 
risk of breast cancer compared to women in the lowest tertile (OR=3.03; p trend=0.0002) 
[255].   Bagga et al., observed a positive association between the ratio of n-6 PUFAs 
(AA+LA) to long chain n-3 PUFAs (EPA+DHA) (OR=1.68; p trend =0.09) in adipose 
tissue and breast cancer [256].  In the EURAMIC study there was little consistency 
across the five study sites between n-6 or n-3 fatty acid content in breast adipose tissue 
and breast cancer risk; however, among four of the sites a nonsignificant positive 
association was observed between the 6:3 ratio and breast cancer risk (pooled OR =1.4; 
p=0.19) [254]. This effect was more marked when focusing on the long chain n-3 PUFAs 
from fish oil. A low total n-6 to long chain n-3 (EPA+DHA) ratio was protective for 
breast cancer in women in the highest tertile compared to the lowest tertile (OR= 0.33; 
95% CI, 0.17-0.66; trend p = 0.0002) [255].  Four studies have investigated the 6:3 
PUFA ratio in blood specimens, either serum or erythrocytes, and breast cancer risk.  
Two studies presented no evidence of a relationship between the 6:3 ratio and breast 
cancer [258, 265], whereas the other two studies found significant positive relationships 
between the 6:3 ratio [263, 264].  The ratio of AA to EPA in erythrocytes has also been 
positively related to breast cancer risk [263]. 
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1.3.7 Dietary fat and serum estradiol  
Varying levels of fat consumption may influence incidence of hormonally dependent 
breast cancer by modifying levels of circulating estrogens [267-277].  In fact, free fatty 
acids added to plasma can significantly increase levels of estradiol in vitro [272, 273]. 
Among women with a prior history of breast cancer, a significant decrease in estradiol 
concentration from baseline was observed in those randomized to a one year, low-fat, 
high-fiber diet (-13pmol/L in intervention group vs. +3pmol/L in control group; p<0.05) 
[274].) A meta-analysis of 13 intervention trials found serum estradiol levels to be 23% 
(95%CI: -27.7%, -18.1%) lower in healthy postmenopausal women consuming the least 
amount of dietary fat when compared to women with the highest fat intake [270]. Among 
these studies, the greatest estradiol reductions occurred in the two trials with the largest 
reduction in dietary fat, 10-12% of calories [268, 275]. Nonetheless, when these two 
studies were excluded from the meta-analysis, the results remained significant.  The Diet 
and Androgens (DIANA) Randomized Trial found a non-significant reduction in serum 
estradiol (-18.0% in intervention group vs. -5.5% in control group; p=0.13) among 
postmenopausal women consuming a low animal fat and high n-3 diet [276]. 
Additionally, an inverse association between n-3 fatty acids from fish consumption and 
serum estradiol levels has been observed [277]. However, not all studies evaluating 
dietary fat and estrogen levels have observed reductions in circulating estradiol levels; it 
has been hypothesized that inadequate dietary assessment may be one cause of 
contradiction. No epidemiological study has examined the association between 
erythrocyte fatty acids in relation to circulating estradiol levels. 
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1.3.8 Dietary fat and mammographic breast density 
The few studies that have assessed the role of dietary fat on mammographic density have 
revealed that diet may influence breast density.  A two year intervention with a low-fat, 
high-carbohydrate diet, reduced breast density by 6.1% in the experimental group as 
compared to 2.1% in the control group (p=0.02) [278]. Positive associations between 
total fat intake and high mammographic density have been observed [106, 279-281].  
However, decreased density and null findings have also been associated with total fat 
intake [282-285]. As with total fat, positive and null relationships have been found 
between total PUFA intake and breast density [106, 279-283, 285].  Women with the 
highest mammographic pattern reported significantly higher consumption of n-6 PUFAs 
when compared to women with the lowest mammographic pattern (4.7 % energy vs. 
3.8% energy; p<0.001) [281].  Two studies assessed the effects of total meat intake, 
which is correlated with n-6 AA intake, and breast density.  A nonsignificant, positive 
association (OR=1.59; 95%CI: 0.83, 3.04.) was observed in one study; however, no 
relationship was found between total meat intake and density in the other [283, 284].  
Fish consumption has not been linked to mammographic density in postmenopausal 
women; however, these studies measured total fish consumption rather than fatty fish 
intake which better mirrors intake of n-3 PUFAs [282-284]. There was no difference in 
means of percent breast density when comparing quartiles of n-3 intake or long chain n-3 
intake [279, 283],  nor was an association observed between n-3 intake and Wolfe’s 
parenchymal patterns in women with breast cancer [281].  Only one study has 
investigated the effects of the individual fatty acids of the n-6 and n-3 families with 
breast density.  No association was found between mammographic density and n-6 LA, 
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but a significant inverse association was observed between n-3 ALA and percent breast 
density (OR=0.69: 95%CI: 0.47, 0.99) [282].  As is the case with circulating estradiol 
concentrations, no study has examined the association between erythrocyte fatty acids in 
relation to mammographic breast density. 
 
1.4 SUMMARY OF INTRODUCTION  
N-6 and n-3 PUFAs are competitive inhibitors of one another, resulting in different 
prostaglandin products. PGE2, the result of COX mediated n-6 AA metabolism, 
stimulates the biosynthesis of estrogen, a causal breast cancer risk factor, by upregulation 
of the enzyme aromatase.  The suppression of aromatase activity via aromatase inhibitors 
results in lower circulating serum estradiol levels and reduced breast cancer risk in 
postmenopausal women. Since both low n-6 PUFA consumption and elevated n-3 PUFA 
consumption reduces the production of PGE2, intake of these fatty acids may influence 
estradiol synthesis and estrogen dependent breast cancer incidence.   
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2.0 SPECIFIC AIMS AND HYPOTHESES 
The relationship between the n-6 and n-3 fatty acids in breast cancer development is well 
established in animal models. However, the mechanisms by which these factors affect the 
development of breast cancer are currently unknown.  Few epidemiological studies have 
examined the relationship between the n-6 and n-3 fatty acids and well-established, 
modifiable breast cancer risk factors, specifically serum estradiol and mammographic 
breast density. Further, the studies that did assess these relationships did so by measuring 
dietary intake via self-report dietary assessment instruments, and limitations of these 
assessment tools and nutrient composition tables are well-known. Measuring n-6 and n-3 
fatty acids in biological specimens provides a useful alternative to self-reported dietary 
intake, and allows for the objective measurement of individual fatty acid levels. The 
relationship between circulating levels of estradiol, mammographic breast density, and 
breast cancer risk is greatly documented; hence, identifying agents capable of altering 
these risk factors could have a substantial impact on public health. 
Therefore, the research goal of this body of work was to investigate the 
relationship between n-6 and n-3 fatty acids in erythrocytes and postmenopausal serum 
estradiol levels and mammographic breast density, both modifiable, well-established 
breast cancer risk factors.  An additional research goal was to investigate the relationship 
between current NSAID use and serum estradiol. Similarly to elevated n-3 fatty acid 
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intake, NSAID use reduces the production of PGE2, thus decreasing upreguation of 
aromatase and estrogen synthesis. Therefore, if it is through alteration of the PGE2 
pathyway that n-6 and n-3 fatty acids influence estradiol synthesis, then we would also 
expect to observe differences in estradiol levels by NSAID use.  NSAID data was not 
available at the time of mammogram; therefore, the relationship between NSAID use and 
breast density could not accurately be assessed.  The specific research questions 
addressed and corresponding hypotheses are outlined below. 
 
1. Are n-6 and n-3 fatty acids in erythrocytes associated with serum estradiol 
levels in cancer-free, postmenopausal women not using exogenous hormones?  
The hypothesis is that erythrocyte n-6 fatty acids are positively related to 
postmenopausal serum estradiol levels and erythrocyte n-3 fatty acids negatively 
related to postmenopausal serum estradiol levels. 
 
2. Is current NSAID use associated with serum estradiol levels in cancer-free, 
postmenopausal women not using exogenous hormones?  The hypothesis is 
that current NSAID users have lower circulating serum estradiol levels than 
NSAID non-users. 
 
3. Are n-6 and n-3 fatty acids in erythrocytes associated with mammographic 
breast density in cancer-free, postmenopausal women not using exogenous 
hormones? The hypothesis is that erythrocyte n-6 fatty acids are positively 
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related to mammographic breast density and erythrocyte n-3 fatty acids negatively 
related to mammographic breast density. 
 
In order to answer these questions, three cross-sectional analyses were undertaken 
ancillary to the Mammograms and Masses Study (MAMS).  The findings from these 
three investigations are presented in separate manuscripts. These studies are important as 
the identification of modifiable lifestyle factors that favorably alter breast cancer risk 
factors may enable us to reduce the onset of breast cancer, via the development of safe, 
effective and easily adoptable primary prevention strategies. 
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3.1 ABSTRACT 
Elevated intake of omega-6 (n-6) polyunsaturated fatty acids (PUFAs) may promote 
breast cancer, whereas omega-3 (n-3) consumption may inhibit the growth of this disease.  
The mechanism by which these fatty acids impact breast cancer development is 
unknown; however, experimental evidence indicates that these two families of fatty acids 
may influence risk by impacting eicosanoid synthesis.  Specifically, when n-3 PUFAs 
displace n-6 PUFAs, prostaglandin E2 production (PGE2) is reduced, resulting in 
decreased aromatase activity and ultimately suppression of estrogen synthesis.  Thus, in 
this cross-sectional analysis, we sought to determine whether n-6 and n-3 fatty acids in 
erythrocytes, expressed as a percentage of total fatty acids, were associated with 
postmenopausal serum total estradiol concentrations. Because NSAIDs also inhibit PGE2 
formation, separate analyses were performed for participants using and not using 
NSAIDs. Among women not using NSAIDs (n=135), multivariate adjusted estimates 
revealed that mean estradiol concentrations decreased with increasing tertile of total 
erythrocyte n-3 fatty acids (24.3 pmol/L vs 18.4 pmol/L; p<0.05) and increased with 
increasing tertile of total n-6 fatty acids (16.0 pmol/L vs. 21.8 pmol/L; p=0.02), the total 
n-6:n-3 ratio (17.6 pmol/L vs. 22.9 pmol/L; p=0.06) and the ratio of n-6 arachidonic acid 
to n-3 eicosapentaenoic acid+docosahexaenoic acid (17.6 pmol/L vs. 24.9 pmol/L; 
p<0.01).  Among NSAID users (n=118), mean estradiol was greatest among women in 
the highest tertile of the n-6 linoleic acid to n-3 alpha-linolenic acid (ALA) ratio as 
compared to the lowest tertile (21.1 pmol/L vs. 14.2 pmol/L; p=0.01).  This finding was 
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primarily due to the inverse association noted between ALA and estradiol.  NSAID users 
in the highest tertile of ALA had a lower mean estradiol concentration than participants in 
the lowest tertile of ALA (15.2 pmol/L vs. 20.8 pmol/L; p=0.05). No other significant 
differences were noted among current NSAID users. Because circulating postmenopausal 
estradiol concentrations are causally related to breast carcinogenesis, these findings 
provide a mechanism through which the n-6 and n-3 fatty acids may alter breast cancer 
risk.   
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3.2 INTRODUCTION 
Breast cancer is a common form of cancer among women worldwide and despite 
substantial advances in the treatment of this disease breast cancer remains a leading cause 
of death among women.   Several lines of evidence implicate that dietary intake may 
influence breast cancer, and for many years it has been postulated that excessive dietary 
fat consumption may play a role in the etiology of this disease [286]. However, no clear 
consensus on this topic has been established.  One theory that addresses this debate is that 
a relationship may not exist between breast cancer risk and total fat intake, but an 
association may exist between breast cancer and the type of fat consumed.  Considerable 
interest has focused on the association between the omega-6 (n-6) and omega-3 (n-3) 
polyunsaturated fatty acids (PUFAs) and breast cancer risk, largely stemming from 
analysis of international data [242, 287].  
The majority of PUFAs in the United States diet, where breast cancer rates are 
among the highest in the world, consist of n-6 PUFAs found in abundance in corn and 
vegetable oils [117, 288].  Populations such as the Greenland Eskimos [289], the Alaskan 
Natives [290] and the Japanese [118] have high fish consumption, hence high n-3 intake.  
These populations also have substantially lower rates of breast cancer despite their 
overall high fat consumption [289, 291, 292]. Therefore, the higher rates of breast cancer 
observed in the United States may be explained, in part, by the elevated intake of n-6 
and/or insufficient intake of n-3 PUFAs.  This hypothesis is supported by some 
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experimental [178, 225, 227, 228, 232-235, 238, 293] and epidemiological data [251, 
253, 264, 266].  
Perhaps the most acknowledged mechanistic pathway through which the n-6 and 
n-3 fatty acids may influence breast cancer risk is via eicosanoid biosynthesis. 
Arachidonic acid (AA; 20:4n-6), which can be ingested or formed endogenously by 
desaturation and elongation of linoleic acid (LA; 18:2n-6), serves as the substrate for 
cyclooxygenase (COX) mediated prostaglandin E2 (PGE2) production.  PGE2 is an 
inflammatory eicosanoid that is upregulated in breast tumors [294] and is a potent 
inducer of aromatase activity [200], the key enzyme in postmenopausal estrogen 
synthesis. In contrast, prostaglandin E3 (PGE3), an anti-inflammatory eicosanoid, is 
derived from the metabolism of eicosapentaenoic acid (EPA; 20:5n3). EPA can be 
consumed, formed from the essential n-3 fatty
 
acid alpha-linolenic acid (ALA; 18:3n-3), 
or formed from retroconversion of docosahexaenoic acid (DHA; 22:6n-3).  Unlike PGE2, 
PGE3 has not been documented to upregulate aromatase and is signficiantly less 
mitogenic [176].  
The n-6 and n-3 PUFAs compete with each other for enzymes at multiple levels; 
therefore, increasing n-3 consumption ultimately suppresses the production of PGE2 
[176, 179].  This suggests that reducing n-6 or increasing n-3 intake, which results in 
lowered PGE2 formation [176, 179, 295], may result in lower circulating estradiol levels.  
Indeed, nonsteroidal anti-inflammatory drugs (NSAIDs), which also inhibit formation of 
PGE2, are associated with reduced estradiol production in breast cells [202] and lower 
serum estradiol concentrations in postmenopausal women (Research article 2).      
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Little is known about the relationship between n-6 and n-3 PUFAs and circulating 
postmenopausal estrogen levels, likely a result of the methodological issues with the 
estimation of individual fatty acids from self-reported dietary instruments.  Utilizing fatty 
acids in erythrocytes allows for individual fatty acid assessment, provides an objective 
measurement, and reflects recent dietary intake of the essential n-6 and n-3 fatty acids.  
Therefore, we evaluated the association between dietary habits of the n-6 and n-3 PUFAs, 
as inferred from erythrocyte fatty acid composition, and serum total estradiol 
concentration in postmenopausal women. 
3.3 MATERIALS AND METHODS 
3.3.1 Study Population 
Details of the Mammograms and Masses Study (MAMS) have been described previously 
[296].  The MAMS is a case-control study of estrogen metabolites, mammographic breast 
density and breast cancer risk.  A total of 869 cancer-free women and 264 recently 
diagnosed breast cancer cases were recruited into the MAMS through the Magee 
Womens Hospital Mammographic Screening and Diagnostic Imaging Program in the 
greater Pittsburgh area (Pennsylvania, USA) in 2001-2005.  The participants were all 
women aged 18 years or older and who reported no previous personal history of cancer, 
with the exception of nonmelanoma skin cancer. Participants in the MAMS include: 1) 
newly diagnosed breast cancer cases who were recruited from the Magee-Womens 
Surgical Clinic (n=264); 2) women who were undergoing outpatient needle breast biopsy 
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through the Breast Biopsy Service at Magee-Womens Hospital, but were not 
subsequently diagnosed with breast cancer (n=313); 3) cancer-free women who received 
screening mammography through Magee-Womens Hospital or through Magee 
Womancare Centers (n=538) and; 4) an additional 18 participants whose blood was 
dedicated solely to an ancillary study of intra-individual cytokine and hormone 
concentration reproducibility. To increase recruitment of the “healthy” control group, 
study flyers were attached to screened negative mammogram reports mailed to patients 
from 2003-2005.  The study was approved by the Institutional Review Board of the 
University of Pittsburgh and all participants provided written informed consent.  
3.3.2 Subsample Selection 
Inclusion criteria for entry into this ancillary study were as follows: 1) controls recruited 
only via study flyers through Magee-Womens Hospital or through Pittsburgh Magee 
Womancare Centers (n=453), as information on these participants was gathered on the 
day blood was drawn; 2) postmenopausal (having had no menstrual bleeding during prior 
year or having undergone a bilateral oophorectomy); 3) not using hormone therapy (HT) 
within three months of enrollment; and 4) not using vaginal estrogen creams, oral 
contraceptives, selective estrogen receptor modulators (SERMs) or corticosteroids at 
study enrollment. A total of 270 women met the inclusion criteria for the present 
analyses. Of those who were excluded, 98 were premenopausal, 84 were using exogenous 
hormones, SERMs, or corticosteroids, and 1 participant was later diagnosed with breast 
cancer.  
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3.3.3 Covariate Information  
We used a standardized, self-administered questionnaire to gather participants’ exposure 
information at study enrollment.  Information on demographic characteristics, current use 
of medication and supplements, reproductive history, family medical history, past 
exogenous hormone use, smoking status, and alcohol intake was obtained. Participants 
were asked to report all prescribed and over-the-counter medications that were currently 
being used on the questionnaire.  Women who listed using aspirin, COX-2 inhibitors, or 
other non-aspirin NSAIDs were considered "current NSAID users." Participants who did 
not list using a NSAID were considered “current NSAID non-users.”   Because 
acetaminophen is  generally reported to be a weak  inhibitor of the COX-1/COX-2 
enzymes [297], we classified acetaminophen users as non-users of NSAIDs unless they 
also reported taking a NSAID.  Regular alcohol use (g/day) in the past year was 
calculated as previously described [298].  Age of menopause was defined according to 
the methods reported by the Women’s Health Initiative [299], where age at menopause 
corresponded to the age of a woman’s last natural menstrual bleeding, bilateral 
oophorectomy, or age a woman began using HT. For a hysterectomized woman without a 
bilateral oophorectomy, age at menopause was the earliest age at which she began using 
HT or first had menopausal symptoms.  If neither occurred and her age at hysterectomy 
was 50 years or older, then age at menopause was her age at hysterectomy. Age at 
menopause could not be determined in 7 participants. Years since menopause were 
calculated by subtracting a woman’s age at menopause from her age at study enrollment. 
The questionnaire was reviewed for completeness by a trained research nurse.   
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3.3.4 Clinical Measures 
After participants removed shoes and heavy clothing, height and weight were measured 
by the study nurse.  Weight was measured at a standing position to the nearest 0.1 kg 
using a standard balance beam; standing height was measured at full inspiration to the 
nearest 0.1 cm. Measurements were taken twice and were repeated if the first two 
measurements differed by more than 0.5 cm or 0.5 kg.  The mean
 
of the measurements 
was used to derive final heights and weights. Body mass index (BMI) was calculated as 
weight (kg) divided by height squared (m
2
).   
 After anthropometric assessment, a 40 ml non-fasting blood sample was collected 
by the study nurse.  Samples were processed on site according to a standardized protocol. 
After processing, the samples were separated into red blood cell, serum, plasma and buffy 
coat and stored at or below -70°C until assayed. 
3.3.5 Measurement of Fatty Acids 
Erythrocyte fatty acid concentrations were identified using gas-liquid chromatography.  
Samples were analyzed at the University of Pittsburgh’s Heinz Laboratory. Total lipids 
(500μl of packed red blood cells) were extracted according to the general technique of 
Bligh and Dyer [300].  Briefly, the samples were homogenized in 4 ml of methanol, 2 ml 
of chloroform and 1.1 ml of water.  Two ml of chloroform and 2 ml of water were added 
to the samples after 15 min.  The tubes were then centrifuged at 1200 g for 30 min at 
16°C and the upper phase discarded.  The lower phase was dried under nitrogen and 
resuspended in 1.5 ml 14% boron trifluoride methanol.  The samples were heated at 90°C 
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for 40 min and after cooling extracted with 4.0 ml pentane and 1.5 ml water.  The 
mixtures were vortexed and the organic phase recovered [301].  The extracts were dried 
under nitrogen, resuspended in 50 μl heptane and 2 ml injected into a capillary column 
(SP-2380, 105 m x 53 mm ID, 0.20 um film thickness).  Gas chromatographic analyses 
were carried out on a Perkin Elmer Clarus 500 equipped with a flame ionization detector.  
Operating conditions were as follows: the oven temperatures were 140°C for 35 min; 
8°C/min to 220°C, held for 12 min; injector and detector temperatures were both at 
260°C; and helium, the carrier gas, was at 15 psi.  Identification of fatty acids was by 
comparison of retention times with those of authentic standards (Sigma).  A random 
subset of 27 samples was analyzed for reproducibility; laboratory personnel were blinded 
to duplicate samples and subject identification.  The inter-assay coefficients of variation 
(CV) for the fatty acid measures reported ranged between 1.7-15.2%.  CVs’s were 4.6% 
for LA, 3.4% for AA, and 1.7% for total n-6 fatty acids.  CV’s were higher for the n-3 
fatty acids, with CV’s of 15.2% for ALA, 5.3% for EPA, 7.5% for DHA and 5.3% for 
total n-3 fatty acids.  The CVs for the total n-6:n-3, LA:ALA, AA:EPA, and 
AA:EPA+DHA ratios were 5.2%, 11.1%, 4.5% and 5.7% respectively.  The individual 
and total n-6 and n-3 fatty acids are expressed as a percentage by weight of the total 
erythrocyte fatty acid content. 
3.3.6 Measurement of Total Estradiol 
Serum total estradiol was measured by radioimmunoassay (RIA) after diethyl ether 
extraction using a highly specific rabbit antiserum raised against an E2-6-
carboxymethyloxime-BSA conjugate (EIR, Wurenlingen, Switzerland) and Third 
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Generation Estradiol [I125] reagent DSL 39120 (Diagnostic Systems Laboratories Inc., 
Texas USA). Assays were conducted at the Royal Marsden Hospital in England [302].  
The lower detection limit of the assay was 3pmol/L by calculation
 
from the 95% 
confidence limits of the zero standard.  Twenty-seven replicate quality control samples 
were analyzed to assess reproducibility; the calculated CV between duplicates for 
estradiol was 14.5%.  Laboratory personnel were blinded to quality control status. 
3.3.7 Statistical Analyses 
Statistical analyses were performed using SAS software version 9.1 (SAS Institute, Inc., 
Cary, North Carolina). To improve normality for statistical tests, a log transformation 
was applied to serum total estradiol concentrations. One participant was excluded from 
analyses because total estradiol concentrations were deemed unreliable by the laboratory.  
An additional 9 participants with estradiol values greater than 150 pmol/L were removed 
from analyses because such high levels likely indicated the participants were not 
postmenopausal or incorrectly reported current hormone use. Analyses were repeated 
with extreme data points included (Appendix A), and because findings did not change 
substantially the 9 participants were not included in the final report. The final sample 
included 260 women. 
Descriptive results for continuous variables are expressed as means and standard 
deviations (SD). Categorical variables are reported as frequencies and percentages (%).  
Correlation relationships between n-6 and n-3 fatty acid measures and serum estradiol 
were examined with Spearman’s correlation coefficients, with no adjustments and 
controlling for the effects of age and BMI. 
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Multivariate associations for serum total estradiol according to tertile of fatty acid 
were assessed by analysis of covariance (ANCOVA) using the
 
general linear models 
(GLM) procedure of SAS (PROC GLM).  Adjusted geometric mean estradiol and 95% 
confidence intervals (CI) were calculated using least squares means, controlling for the 
effects of age (continuous), BMI (continuous), years menopausal (continuous), regular 
alcohol intake in the past year (0g/day, <12g/day, ≥12g/day, entered as a dummy 
variable), current smoking status (nonsmoker vs. smoker), and current NSAID use (non-
user vs. user). The comparisions were adjusted for these variables as they were strongly 
related to the majority of erythrocyte fatty acid measures, and with the exception of 
smoking status, were also related to serum estradiol levels (Appendix A). The geometric 
mean concentrations of estradiol were calculated by taking the anti-log of the least 
squares means after adjustment. NSAIDs reduce PGE2 synthesis and hence aromatase 
activation, thus, intake of the n-6 and n-3 PUFAs may have less of an effect on estradiol 
levels among NSAID users. Therefore, we performed analyses stratified by NSAID use 
to assess possible effect modification by this variable.   To formally test whether the 
effects of fatty acids were altered by current NSAID use, an interaction term between 
fatty acid (tertile) and NSAID use was entered into the unstratified multivariate model. 
Tests of linear trends were performed across fatty acid measures by modeling tertiles as 
consecutive integers (continuous variable).   
The assumptions of the models were checked by residual analysis. Plots of the 
residuals versus the predicted values were examined to check for heteroscedasticity.  The 
normal probability plot of the residuals was examined to assess the normality of the error 
terms.  Model assumptions of normality and homogeneity of variance were met for all 
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models presented. Tests of statistical significance were two-tailed and given the 
exploratory nature of this work, we reported
 
our results at the p<0.05 significance level, 
rather than
 
correct for multiple comparisons. Analyses were repeated excluding 
participants (n=13) reporting fatty acid supplementation at blood draw, but results did not 
differ substantially and are therefore not presented. 
3.4 RESULTS  
 
The characteristics of the study population are shown in Table 6. The mean (SD) age was 
62.8 (8.4) years and the mean (SD) BMI was 28.5 (6.0) kg/m
2
.  Only 6.9% of the women 
were non-white and 5.8% current smokers.  Close to half (47.7%) of the population 
indicated current use of a NSAID (aspirin, non-aspirin, and/or COX-2 inhibitor) at study 
enrollment.  The geometric mean serum estradiol concentration for the study population 
was 19.5 pmol/L, with levels ranging from 3.3-140.0 pmol/L.  
On average, the proportion of total n-6 fatty acids was higher than the proportion 
of total n-3 fatty acids in erythrocytes (Table 7). The average ratio of mean total n-6 fatty 
acids to mean total n-3 fatty acids was 5.2.  N-6 AA and LA were the most
 
abundant fatty 
acids, with AA composing 16.0% and LA 15.8% of total fatty acids.  Of the n-3 fatty 
acids, DHA accounted for the greatest percentage (4.5%) of total fatty acids.  
Table 8 presents the unadjusted and adjusted correlations between fatty acid 
measures and serum total estradiol for the entire study population.  Analyses revealed 
distinct differences in the relationships of the erythrocyte n-6 and n-3 fatty acids with 
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serum estradiol. Statistically significant positive correlations were observed for both total 
n-6 fatty acids (r=0.15, p=0.02) and AA (r=0.13, p=0.04) with estradiol.  A 
nonsignificant inverse association was observed for n-6 LA (r=-0.08, p=0.21). 
Erythrocyte total n-3 fatty acids and all individual n-3 fatty acids were inversely related 
with serum total estradiol. Correlation coefficients ranged from -0.17 to –0.24 and were 
statistically significant (p<0.05) for all n-3 fatty acid measures. The strongest inverse 
correlation was found for EPA (r = -0.24, p<0.0001), followed closely by total n-3 fatty 
acids (r=-0.22, p=0.0003). Highly significant positive correlations between serum 
estradiol and the four 6:3 ratios (total n-6:n-3, LA:ALA, AA:EPA, and AA:EPA+DHA) 
were found. Spearman correlation coefficients ranged from 0.18 (p
 
< 0.004) to 0.25 (p < 
0.0001).  However, adjustment for age and BMI attenuated the findings.  
Table 9 shows the estimated geometric mean of serum estradiol concentration 
across tertile of erythrocyte fatty acid. After adjustment for age, BMI, years menopausal, 
alcohol intake, current smoking status, and current NSAID use, no individual fatty acid 
was significantly related to estradiol concentration. However, a significant trend of 
increasing estradiol concentration with tertile of LA:ALA (p trend=0.03) was found. The 
adjusted total estradiol concentration was approximately 20.5% higher among 
participants in the highest tertile of LA:ALA as compared to those in the lowest tertile. 
Although a higher mean estradiol concentration was observed in the highest tertile as 
compared to the lowest tertile of all other 6:3 ratios (total n-6:n-3, AA:EPA, and 
AA:EPA+DHA), the findings were not statistically significant. A suggestive inverse 
trend for ALA tertiles (p trend =0.09) was noted. 
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Because NSAIDs inhibit the COX/PGE2/aromatase pathway, we next explored 
the associations between fatty acids and estradiol by NSAID use.  Table 9 shows the 
estimated geometric mean estradiol concentrations across tertile of fatty acid stratified by 
NSAID use. Among non-users of NSAIDs, multivariate adjusted analyses revealed 
several significant or borderline significant associations between fatty acid measures and 
estradiol. Total n-6 fatty acids was positively and significantly related to serum estradiol 
(p trend=0.02).  The adjusted geometric mean estradiol levels also rose with increasing 
tertile of n-6 AA among NSAID non-users, with mean estradiol levels 24.2% higher in 
the topmost tertile as compared to the lowest tertile (p trend=0.09). No association was 
observed between LA and estradiol (p trend=0.97).  On the contrary, geometric mean 
serum estradiol levels decreased with increasing tertile of total n-3 fatty acids (p=0.05), 
with mean estradiol levels 24.3% lower in the highest tertile as compared to the lowest.  
Mean estradiol levels were also lower in the highest tertile of all individual n-3 fatty acids 
(ALA, EPA, and DHA) as compared to the lowest tertile; however, the p for trend did not 
reach statistical significance for any of these measures. The total n-6:n-3 ratio was 
positively linked to estradiol and the finding approached statistical significance (p 
trend=0.06), with 30.1% greater mean estradiol levels in the upper tertile as compared to 
the lower tertile.  A positive relationship was observed between the AA:EPA+DHA ratio 
and estradiol, with mean estradiol concentrations 40.7% higher in the highest as 
compared to the lowest tertile (p=0.01).  The geometric mean estradiol levels were also 
higher in the AA:EPA and LA:ALA ratios’ uppermost tertiles as compared to the lowest 
tertiles; however, these trends were not statistically significant. 
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Among women reporting current NSAID use, a positive association between the 
LA:ALA ratio and estradiol was noted, with mean estradiol in the highest tertile 48.6% 
higher than the mean estradiol of the lowest tertile (p trend=0.01). This observation was 
largely attributable to n-3 ALA, which was inversely related to estradiol in NSAID users 
(p trend=0.05).  Estradiol was 26.9% lower in the highest tertile of ALA as compared to 
the lowest tertile.  No other fatty acid measure was related to serum total estradiol levels 
within the NSAID user stratam.  
Effect modification by NSAID use was formally tested by including interaction 
terms in the GLMs.  Despite substantial differences in the relationships between fatty 
acids and estradiol between NSAID users and non-users, the only signficant interaction 
was between NSAID use and total n-6 fatty acids with respect to circulating estradiol 
(p<0.02).  The interaction between NSAID use and the AA:EPA+DHA ratio was 
suggestive (p=0.12).  However, this study had limited power to detect interaction effects. 
3.5 CONCLUSIONS 
In this cross-sectional investigation, we examined the relationships between erythrocyte 
n-6 and n-3 fatty acids and postmenopausal serum total estradiol concentrations. In a 
population of women not reporting current NSAID use, we found a positive association 
between total n-6 fatty acids and estradiol and an inverse association between total n-3 
fatty acids and estradiol. We further observed positive relationships between the 
AA:EPA+DHA ratio and the total n-6:n-3 ratio with serum estradiol.  As high 
postmenopausal circulating estradiol concentrations are related to increased breast cancer 
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risk, these findings are consistent with the hypothesis that n-6 fatty acids may increase 
the risk of breast cancer and n-3 fatty acids may protect against this disease.  Similar 
associations were not noted among women who reported current NSAID use. Although, 
none of the significant findings observed among non-users of NSAIDs were found among 
current NSAID users, a significant positive relationship was noted between the LA:ALA 
ratio and estradiol levels.  This relationship was largely attributable to the inverse 
association between ALA and estradiol.  
A potential explanation for the null finding between n-6 fatty acids and estradiol 
among NSAID users is that since NSAIDs inhibit PGE2 formation, limiting the amount 
of substrate available (n-6 fatty acid AA) for PGE2 synthesis is not of biological 
importance. In addition, a relationship between total n-3 fatty acid measures and estradiol 
might not have been observed among NSAID users, because both n-3 consumption and 
NSAID use reduce PGE2 production, and therefore exposure to both anti-inflammatory 
agents might not offer additional benefit.  The strong inverse relationship noted between 
ALA and estradiol in conjunction with the speculations offered above, may be suggestive 
that an additional pathway is involved other than ALAs ability to compete for COX 
enzymes (i.e. through elongation to EPA) among NSAID users.  Possible mechanisms of 
action include ALA’s ability to reduce TNF-alpha and IL-6 [303], which have also been 
shown to stimulate aromatase activity [304]. Although this finding may be biologically 
plausible, we also must acknowledge the potential role chance plays when multiple 
comparisons are made.   
Although the majority of interactions between fatty acid measures and NSAID 
use were not statistically significant, the effect sizes suggest that there are differences in 
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the strengths of the relationships between NSAID non-users and users. Thus the lack of 
significance of the interaction terms may be attributable to the low statistical power of 
our study. However, it should also be acknowledged that given the nonsignificant 
interaction terms, the effect modification noted may be a result of chance findings.  
Nonetheless, given the biological plausibility of an interaction and because no study has 
previously reported on these associations, we chose to present the data stratified by 
NSAID use. 
We are unaware of any study reporting weaker effects of the n-6 and n-3 fatty 
acids on breast cancer risk among NSAID users; however, long chain n-3 PUFA levels in 
blood were associated with decreased colorectal cancer risk among aspirin non-users, but 
not among aspirin users [305]. Futher a statistically significant interaction between 
total fat intake and NSAID use (p=0.007)  has been noted.  Among non-users  of 
NSAIDs, decreasing fat intake was inversely related to recurrence of adenomous polyps 
[306].  A similar finding was also noted in relation to squamous cell carcinoma of the 
skin.  Erythrocyte levels of n-6 AA were significantly greater among cases than controls 
and this relationship was more apparent among NSAID non-users [307]. 
 To our knowledge this is the first study to report on the relationship between the 
essential fatty acids found in biospecimens and endogenous estradiol levels.  Further, 
there is a paucity of data on the impact of n-6 and n-3 fatty acids, as measured via self-
report, on concentrations of postmenopausal estradiol levels. Consistent with our 
findings, estradiol levels have been found to be significantly inversely related to n-3 fat 
from fish [277]. We are not aware of any epidemiological investigation that assessed the 
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relationship between individual or total n-6 fatty acids or n-6:n-3 ratios and 
postmenopausal estradiol levels. 
A key limitation of this study is its cross-sectional nature, which does not allow 
causal inference.  Hormone and erythrocyte fatty acid concentrations were measured once 
and a single measure may be inadequate to some degree because of variability within 
individuals over time; for that reason, assaying multiple samples over time might better 
characterize levels in these women.  However, use of a single measurement of 
erythrocyte membranes is capable of reflecting recent n-6 and n-3 fatty acid intake [161]. 
We cannot rule out that perhaps n-6 and n-3 levels are simply markers of poor or healthy 
lifestyles. While we adjusted for BMI, alcohol intake and smoking in multivariate 
analyses, relations between the fatty acids and estradiol levels could be due to residual 
confounding by unmeasured lifestyle characteristics rather than real dietary effects.   
Additionally, the MAMS participants included in this analysis are a relatively 
homogenous sample as all are postmenopausal, not using hormone therapy, and 
predominantly white, thus the study results may have limited generalizability.  In spite of 
these limitations, this study is unique in that we believe no other epidemiological study 
has assessed the relationship between circulating fatty acids and serum estradiol levels. 
Additional study strengths include the use of an objective measure of dietary fat intake 
and standardized assessment of participant characteristics. 
 In summary, this study provides modest evidence supporting a positive 
association between n-6 PUFAs and a negative association between n-3 PUFAs and 
serum estradiol levels. However, given the cross-sectional design of the study, the 
observed relationships should be viewed as hypothesis generating and interpreted with 
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caution. The answers to the role of the essential n-6 and n-3 PUFAs in breast cancer 
development are not definitive, the data being too insufficient to be convincing. Because 
of limitations in current research, chemoprotective dietary recommendations for women 
cannot be issued.  Given this study’s findings and the limitations listed above, 
prospective studies assessing the relationship between the n-6 and n-3 PUFAs and 
circulating estrogens using validated dietary assessment instruments along with repeated 
blood sampling for fatty acid and estradiol analysis are warranted. 
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Table 6. Distribution of selected characteristics among 
postmenopausal women in the Mammograms and Masses Study   
Continuous variables mean SD 
Age at blood draw (years) 62.8 8.4 
BMI (kg/m
2
) 28.5 6.0 
Age at menopause (years)* 48.7 5.1 
Years menopausal* 14.1 10.0 
Categorical variables n % 
Race   
  White 242 93.1 
  Non-white 18 6.9 
Surgical menopause *   
  No  229 88.4 
  Yes 30 11.6 
Prior hormone therapy use   
  No  100 38.5 
  Yes 160 61.5 
Regular alcohol intake in past year   
  None 188 72.3 
  < 12 g/day 46 17.7 
  ≥ 12 g/day 26 10.0 
Current Smoker   
  No 245 94.2 
  Yes 15 5.8 
Current NSAID use   
  No  136 52.3 
  Yes 124 47.7 
NOTE: BMI, body mass index; NSAID, nonsteroidal anti-
inflammatory drug 
* Mean and prevalence estimates were determined on nonmissing 
data; missing n=7 for age at menopause, n=7 for years menopausal, 
and n=1 for surgical menopause  
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Table 7. Mean fatty acid composition in erythrocytes   
Fatty Acids (wt. %) mean (SD) 
Total n-6 PUFA* 38.3 (2.6) 
  18:2n-6 (LA) 15.8 (2.4) 
  20:4n-6 (AA) 16.0 (2.0) 
Total n-3 PUFA † 7.9 (2.0) 
  18:3n-3 (ALA) 0.2 (0.1) 
  20:5n-3 (EPA) 0.9 (0.4) 
  22:6n-3 (DHA) 4.5 (1.5) 
6:3 Ratios  
  Total n-6:n-3 5.2 (1.5) 
  LA:ALA 72.7 (19.3) 
  AA:EPA 21.8 (9.0) 
  AA:EPA+DHA 3.3 (1.2) 
NOTE: N=260. Data are expressed as mean (SD). Fatty acids 
are reported as a percentage by weight of the total fatty acids 
(weight percent, wt. %). PUFA, polyunsaturated fatty acid; LA, 
linoleic acid; AA, arachidonic acid; ALA, alpha-linolenic acid; 
EPA, eicosapentaenoic acid; and DHA, docosahexaenoic acid.  
*18:2n-6+18:3n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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Table 8.  Spearman rank order correlation coefficients between n-6 and n-3 fatty 
acids in erythrocytes and serum estradiol concentrations 
Fatty Acids (wt. %) r* p r† p 
n-6 PUFAs      
  Total n-6 PUFAs‡ 0.15 0.02 0.09 0.13 
  18:2n-6 (LA) -0.08 0.21 -0.04 0.57 
  20:4n-6 (AA) 0.13 0.04 0.09 0.13 
n-3 PUFAs      
  Total n-3 PUFAs§ -0.22 0.0003 -0.11 0.06 
  18:3n-3 (ALA) -0.18 0.004 -0.13 0.04 
  20:5n-3 (EPA) -0.24 <0.0001 -0.15 0.02 
  22:6n-3 (DHA) -0.17 0.006 -0.06 0.31 
6:3 Ratios     
  Total n-6:n-3 0.23 0.0002 0.12 0.05 
  LA:ALA 0.18 0.004 0.14 0.03 
  AA:EPA 0.25  <0.0001 0.16 0.01 
  AA:EPA+DHA 0.22 0.0004 0.11 0.07 
NOTE: N=260.  Fatty acids are reported as a percentage by weight of the total fatty 
acids (weight percent, wt. %). PUFA, polyunsaturated fatty acid; LA, linoleic acid; AA, 
arachidonic acid; ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; and DHA, 
docosahexaenoic acid 
*Unadjusted Spearman correlation coefficient   
†Age- and BMI- adjusted Spearman correlation coefficient   
‡18:2n-6+18:3n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6   
§18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3   
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Table 9. Multivariable-adjusted geometric mean (95% confidence interval) estradiol concentrations (pmol/L) by 
tertile of erythrocyte fatty acid according to NSAID use 
Fatty Acids 
 (wt. %) N 
All  
(N=253) 
p for 
trend N 
NSAID 
Non-user  
(N=135) 
p for 
trend N 
NSAID 
User  
 (N=118) 
p for 
trend 
n-6 PUFAs          
  Total n-6   0.18   0.02   0.44 
    ≤37.32 83 16.7 (14.4, 19.3)  49 16.0 (13.4, 18.9)  34 18.5 (14.5, 23.7)  
    37.33-39.49 86 22.8 (19.8, 26.1)  40 27.9 (23.2, 33.6)  46 18.8 (15.4, 23.1)  
    ≥39.50 84 19.3 (16.7, 22.3)  46 21.8 (18.3, 26.1)  38 16.3 (13.0, 20.5)  
          
  18:2n-6 (LA)   0.71   0.99   0.66 
    ≤14.69 83 19.3 (16.6, 22.2)  40 20.1 (16.4, 24.7)  43 17.8 (14.4, 22.1)  
    14.70-16.84 86 20.8 (18.0, 23.9)  47 22.5 (18.7, 27.0)  39 19.3 (15.4, 24.1)  
    ≥16.85 84 18.5 (16.0, 21.3)  48 20.2 (16.8, 24.3)  36 16.6 (13.2, 20.9)  
          
  20:4n-6 (AA)   0.20   0.09   0.95 
    ≤15.24 83 18.8(16.3, 21.7)  51 19.0 (16.0, 22.6)  32 18.8 (14.7, 24.0)  
    15.25-16.57 86 18.3 (15.9, 21.0)  38 20.7 (16.8, 25.4)  48 16.6 (13.6, 20.2)  
    ≥16.58 84 21.5 (18.6, 24.9)  46 23.6 (19.6, 28.5)  38 18.9 (15.0, 23.8)  
          
n-3 PUFAs          
  Total n-3    0.17   0.05   0.89 
    ≤6.68 85 21.3 (18.5, 24.6)  46 24.3 (20.1, 29.3)  39 18.7 (14.9, 23.6)  
    6.69-8.36 83 18.7 (16.2, 21.6)  45 20.4 (17.0, 24.6)  38 16.7 (13.3, 20.8)  
    ≥8.37 85 18.4 (16.0, 21.3)  44 18.4 (15.2, 22.3)  41 18.3 (14.6, 22.9)  
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Table 9 (continued)         
Fatty Acids 
 (wt. %) N 
All  
(N=253) 
p for 
trend N 
NSAID 
Non-user  
(N=135) 
p for 
trend N 
NSAID 
User  
 (N=118) 
p for 
trend 
  18:3n-3(ALA)   0.09   0.57   0.05 
    ≤0.19 84 21.2 (18.4, 24.5)  42 21.5 (17.7, 26.2)  42 20.8 (16.8, 25.8)  
    0.20-0.25 86 19.5 (17.0, 22.4)  43 21.5 (17.7, 26.0)  43 17.5 (14.2, 21.5)  
    ≥0.26 83 17.8 (15.4, 20.5)  50 20.0 (16.8, 23.9)  33 15.2 (12.0, 19.3)  
          
  20:5n-3 (EPA)   0.39   0.31   0.89 
    ≤0.64 83 19.4 (16.8, 22.5)  48 20.9 (17.5, 25.1)  35 17.6 (13.8, 22.4)  
    0.65-0.90 85 21.4 (18.6, 24.6)  43 24.3 (20.0, 29.3)  42 18.9 (15.2, 23.3)  
    ≥0.91 85 17.7 (15.4, 20.5)  44 18.2 (15.1, 21.9)  41 17.2 (13.8, 21.5)  
          
  22:6n-3 (DHA)   0.35   0.14   0.92 
    ≤3.69 84 20.8 (18.0, 24.0)  48 23.1 (19.2, 27.8)  36 18.3 (14.4, 23.2)  
    3.70-4.91 84 18.9 (16.4, 22.0)  40 21.1 (17.4, 25.8)  44 17.0 (13.8, 20.9)  
    ≥4.92 85 18.8 (16.3, 21.7)  47 18.8 (15.7, 22.7)  38 18.6 (14.7, 23.5)  
          
6:3 Ratios          
  Total n-6:n-3   0.21   0.06   0.98 
    ≤4.48 84 17.7 (15.3, 20.3)  46 17.6 (14.6, 21.2)  38 17.7 (14.0, 22.4)  
    4.49-5.72 84 20.5 (17.8, 23.6)  43 22.9 (19.0, 27.7)  41 18.2 (14.6, 22.5)  
    ≥5.73 85 20.3 (17.5, 23.4)  46 22.9 (19.0, 27.8)  39 17.8 (14.2, 22.3)  
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Table 9 (continued)         
Fatty acids 
 (wt. %) N 
All  
(N=253) 
p for 
trend N 
NSAID 
Non-user  
(N=135) 
p for 
trend N 
NSAID 
User  
 (N=118) 
p for 
trend 
  LA:ALA   0.03   0.51   0.01 
    ≤64.00 85 17.6 (15.3, 20.3)  51 20.4 (17.0, 24.3)  34 14.2 (11.3, 17.9)  
64.01-78.05 85 19.0 (16.5, 21.8)  46 20.5 (17.0, 24.7)  39 18.1 (14.6, 22.5)  
    ≥78.06 83 22.1 (19.2, 25.5)  38 22.4 (18.2, 27.4)  45 21.1 (17.3, 25.8)  
          
  AA:EPA   0.11   0.10   0.59 
    ≤16.92 84 17.3 (15.0, 20.0)  47 17.6 (14.7, 21.1)  37 17.1 (13.5,21.8)  
    16.93-25.89 84 20.7 (18.0, 23.9)  41 24.5 (20.1, 29.7)  43 17.7 (14.4,21.8)  
    ≥25.90 85 20.5 (17.7, 23.7)  47 21.7 (18.1, 26.1)  38 18.9 (14.9,23.9)  
          
  AA:EPA+DHA   0.18   0.01   0.63 
    ≤2.68 84 18.6 (16.1, 21.5)  50 17.7 (14.8, 21.1)  34 19.9 (15.6, 25.5)  
    2.69-3.77 84 18.5 (16.1, 21.3)  41 21.5 (17.8, 26.0)  43 16.2 (13.2, 20.0)  
    ≥3.78 85 21.4 (18.6, 24.7)  44 24.9 (20.6, 30.0)  41 18.1 (14.5, 22.7)  
NOTE: Fatty acids are expressed as a percentage by weight of the total fatty acids (weight, percent, wt.%). Tertile 
cutpoints were determined from entire study population (n=260). NSAID, nonsteroidal anti-inflammatory drug; PUFA, 
polyunsaturated fatty acid; LA, linoleic acid;  ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; and DHA, 
docosahexaenoic acid.  Values were adjusted for age (continuous), BMI (continuous), years menopausal (continuous), 
alcohol intake (none, <12g/day, ≥12g/day; indicator variable), and current smoker (nonsmoker vs. smoker). The 
unstratified analysis was also adjusted for current NSAID use (yes vs. no). 7 participants were excluded because years 
since menopause were undeterminable. p for interaction (fatty acid tertile x NSAID use) was significant for total n-6 
(p<0.02) and suggestive for AA:EPA+DHA (p<0.12). Linear trend tests were performed by treating the fatty acid tertile 
groups as continuous variables 
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4.1 ABSTRACT 
Laboratory and epidemiologic evidence suggest that nonsteroidal anti-inflammatory drug 
(NSAID) use may be inversely related to the risk of breast cancer; however, the 
mechanism by which NSAIDs may protect against the development of this disease is 
uncertain.  The objective
 
of this observational study was to assess the relationship 
between current NSAID use and endogenous estradiol levels, an established breast cancer 
risk factor.  To evaluate this aim, we conducted a cross-sectional
 
investigation among 260 
postmenopausal women who were not recently exposed to exogenous hormones.  
Information on current NSAID use (aspirin, COX-2 inhibitors and other NSAIDs 
combined) was collected using a questionnaire at the time of blood draw. Estradiol was 
quantified in serum by radioimmunoassay.  General linear models were used to evaluate 
the association between NSAID use and serum total estradiol.  The age- and BMI-
adjusted geometric mean serum estradiol concentration among NSAID users (N=124) 
was significantly lower than non-users of NSAIDs (N=136) (17.8 pmol/L vs. 21.3 
pmol/L; p=0.03). Further adjustment for additional potential confounding factors did not 
substantially alter estimates (17.7 pmol/L vs. 21.2 pmol/L; p=0.03).  To our knowledge, 
this report is the first to examine the relationship between NSAID use and serum estradiol 
in postmenopausal women.  These cross-sectional findings suggest that NSAID use may 
be associated with lower circulating estradiol levels, potentially representing
 
one 
mechanism through which NSAIDs exert protective effects on breast cancer. 
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4.2 INTRODUCTION 
Although breast cancer is a major public health problem, little is known
 
about preventing 
this disease.  Experimental studies have reported a protective effect of nonsteroidal anti-
inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, against mammary 
carcinogenesis [308-310] and accumulating evidence from both case-control and cohort 
studies suggests that use of NSAIDs may be associated with a modest decreased risk of 
breast cancer in women [193, 194, 196, 311-314].  However, findings are mixed [315-
321].  Clarifying the association between NSAID use and the development of breast 
cancer is potentially of great importance clinically.  NSAIDs are widely used, readily 
available and inexpensive agents.  If they were shown to be chemopreventive, they could 
have a substantial impact on public health. 
Although the mechanisms by which NSAIDs may protect against breast cancer 
are not fully understood, data suggest that the protective effect may be attributed, in part, 
to NSAIDs’ ability to decrease the formation of prostaglandin E2 (PGE2) by blocking 
cyclooxygenase (COX)-1 and/or COX-2 activity. One possible mechanism by which the 
COX/PGE2 cascade promotes breast cancer is via increasing estrogen production, as 
exposure to endogenous estrogens has been shown to play a causal role in the 
development of some breast cancers [41].   
PGE2 upregulates aromatase activity [200], the enzyme that converts androgens 
to estrogens, and leads to increased estrogen synthesis. In postmenopausal women, 
aromatatic conversion of androgens is the primary source of circulating estrogens, and 
suppression of this enzyme has been shown to have a profound effect on both circulating 
estrogen levels [322] and breast cancer recurrence [213].  Recently, dose dependent 
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decreases in aromatase activity were observed in breast cancer cells following treatment 
with NSAIDs, a COX-1 selective inhibitor, and COX-2 selective inhibitors [201].  
Therefore, NSAIDs may offer protection against breast cancer by reducing a woman’s 
exposure to estrogen via the inhibition of aromatase activity. Indeed, laboratory results 
have shown that estradiol production is decreased in breast cells that are exposed to the 
selective COX-2 inhibitor Celecoxib [202]. 
While the above-mentioned pathway through which NSAIDs may decrease the 
development of breast cancer has previously been highlighted [323, 324], the association 
between NSAID use and circulating estradiol in women is currently unknown.  
Therefore, in this cross-sectional investigation, we asked whether differences in serum 
estradiol levels could be observed between self-reported NSAID users and nonusers in a 
population of postmenopausal women not taking hormone therapy (HT).  
4.3 MATERIALS AND METHODS 
4.3.1 Study Population 
We used data from controls drawn from the Mammograms and Masses Study (MAMS), a 
case-control study of estrogen metabolites, mammographic breast density and breast 
cancer risk.  Details of the study methodologies have been presented elsewhere [296].  In 
brief, 869 cancer-free women and 264 recently diagnosed breast cancer cases were 
recruited into the MAMS through the Magee Womens Hospital Mammographic 
Screening and Diagnostic Imaging Program in the greater Pittsburgh area (Pennsylvania, 
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USA) between September 2001 and May 2005.  Women who were 18 years or older, 
who reported no previous personal history of cancer, with the exception of nonmelanoma 
skin cancer, and who could provide written informed consent were eligible for study 
enrollment. Participants in the MAMS include; 1) breast cancer cases who were recruited 
from the Magee-Womens Surgical Clinic for an initial evaluation after newly diagnosed 
primary breast cancer (n=264); 2) controls who were undergoing outpatient needle breast 
biopsy through the Breast Biopsy Service at Magee-Womens Hospital (Pittsburgh, PA), 
but who were not subsequently diagnosed with breast cancer (n=313); 3)  “healthy” 
controls who received screening mammography through Magee-Womens Hospital or 
through Pittsburgh Magee Womancare Centers (n=538) and; 4) an additional 18 
participants whose blood was dedicated solely to an ancillary study of intra-individual 
cytokine and hormone level reproducibility. To increase recruitment of the “healthy” 
control group, study flyers were attached to screened negative mammogram reports 
mailed to patients between November 2003 and April 2005.  The MAMS is approved by 
the University of Pittsburgh’s Institutional Review Board and all participants provided 
written informed consent at the time of study entry.  
4.3.2 Subsample Selection 
Participants were selected for the present study if they met the following eligibility 
criteria: 1) healthy controls recruited only via study flyers through Magee-Womens 
Hospital or through Pittsburgh Magee Womancare Centers between 2003-2005 (n=453), 
because these participants completed a self-administered questionnaire on the day of 
blood draw; 2) postmenopausal, defined as having no menstrual bleeding during the year 
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prior to enrollment, having undergone a bilateral oophorectomy, or having a 
hysterectomy without bilateral oophorectomy and aged 50 years or older.  We measured 
follicle-stimulating hormone (FSH) for women under 55 years of age at blood draw who 
had a hysterectomy without bilateral oophorectomy (n=5); all five participants had FSH 
levels above 40mIU/ml (range: 49.1-185.2), consistent with FSH elevation in the 
postmenopausal range; 3) not using HT within three months of enrollment; and 4) did not 
report using vaginal estrogen creams, oral contraceptives,  selective estrogen receptor 
modulators (SERMs) or corticosteroids on the day of blood draw.  Ninety-eight 
premenopausal women, 55 postmenopausal women using exogenous hormones, 24 
women using SERMs, 5 participants on corticosteroids, and 1 participant later found to 
have a personal history of breast cancer were excluded from the study. Two hundred and 
seventy participants met the above-mentioned criteria. 
4.3.3 Covariate Information  
A standardized, self-administered questionnaire was used to gather exposure information.  
Participants in the subsample completed the questionnaire at study enrollment on the day 
of blood draw. Information collected included demographic data, current use of 
medication and supplements, reproductive history, family medical history, past 
exogenous hormone use, and lifestyle factors such as smoking status and alcohol intake. 
Alcohol use (grams/day) in the past year was calculated as previously reported [298].   
Age of onset of menopause was defined according to the methods formerly described by 
the Women’s Health Initiative [299], where age at menopause corresponded to the age of 
a woman’s last natural menstrual bleeding, bilateral oophorectomy, or age a woman 
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began using HT. For a hysterectomized woman without a bilateral oophorectomy, age at 
menopause was the earliest age at which she began using HT or first had menopausal 
symptoms.  If neither occurred and her age at hysterectomy was 50 years or older, then 
age at menopause was her age at hysterectomy. Age at menopause was undeterminable in 
7 participants. Years since menopause were calculated by subtracting the age at 
menopause from the age at enrollment. 
4.3.4 Assessment of NSAID Use 
The primary exposure variable “current NSAID use” was collected on the day of blood 
draw. On the self-administered questionnaire, participants were asked to report all 
prescribed and over-the-counter medications that were currently being used. The question 
asked, “Are you CURRENTLY taking any medications (prescription or over the counter, 
including aspirin and ibuprofen)?” If a participant responded affirmatively, she was 
prompted to “please list them in this table.”  Dosage data were collected, but not analyzed 
as many participants knew only the number of tablets taken rather than the actual dose.  
The questionnaire was reviewed for completeness by a trained research nurse (study 
coordinator), who queried participants if further clarification was needed.  Each 
medication reported in the table was subsequently assigned a code using a therapeutic 
classification system as indexed in the Nurse Practitioners' Prescribing Reference, which 
is updated quarterly [325].  Participants
 
who listed aspirin, COX-2 inhibitor, or other non-
aspirin NSAID use on the questionnaire were considered "current NSAID users." 
Participants who did not list using a NSAID were considered “current NSAID non-
users.”  Because acetaminophen is generally reported to be a poor inhibitor of the COX -
 77 
1/COX-2 enzymes [297] and its mechanism of action has yet to be resolved,  we 
classified acetaminophen users as non-users of NSAIDs (n=12) unless they also reported 
taking a NSAID (n=6).  
Two additional NSAID exposure variables were considered in relation to estradiol 
levels, a secondary exposure variable and a NSAID variable constructed from the 
primary and secondary variables. The secondary NSAID exposure variable was from the 
participant’s yes-or-no response to the study phlebotomist’s question at blood draw, 
“Have you taken any aspirin or anti-inflammatory agents in the last 48 hours?”   No effort 
was undertaken to determine the specific agent the participant had used. Therefore, this 
variable is more subjective in that responses were based solely upon each individual’s 
perception of what constitutes an anti-inflammatory agent and aspirin. The secondary 
exposure variable was used in conjunction with the primary NSAID exposure variable to 
construct a third variable labeled “consistent NSAID use.”  “Consistent NSAID users” 
listed on the questionnaire that they were currently taking a medication that was an 
aspirin, COX-2 inhibitor, or non-aspirin NSAID and also verbally reported that they took 
an aspirin or other anti-inflammatory agent in the past 48 hours. “Consistent NSAID non-
users” did not list using any NSAID nor did they state having taken an aspirin or anti-
inflammatory agent in the past 48 hours. This latter variable was created as an attempt to 
reduce potential NSAID use/non-use misclassification.  None of the participants in this 
analysis were missing any of the NSAID exposure variable data.  Exposure data were 
collected and coded without knowledge of estradiol levels. 
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4.3.5 Clinical Measures 
The study coordinator obtained physical measurements (height and weight) and recorded 
information on a standardized form.  After the participant removed her shoes and heavy 
clothing, weight was measured at a standing position to the nearest 0.1 kg using a 
standard balance beam; standing height was measured at full inspiration to the nearest 0.1 
cm. All anthropometric measurements were taken twice and were repeated if the first two 
measurements differed by more than 0.5 cm or 0.5 kg.  The mean
 
of the measurements 
was used in the analysis. Body mass index (BMI) was calculated as weight (kg) divided 
by the square of height in meters (m
2
).   
 Forty milliliters (mL) of peripheral non-fasting blood was collected from the 
participants at study enrollment. All samples were processed on site at the Magee 
Womens Hospital Satellite General Clinical Research Center according to standard 
protocols. After processing, the samples were aliquotted into 1 mL cryovials in which red 
blood cells, serum, plasma and buffy coat were separated. Samples were stored at or 
below -70°C prior to laboratory analyses. 
4.3.6 Laboratory Analyses  
Serum samples were used for the quantification of total estradiol (Sex hormone binding 
globulin and albumin-bound plus unbound estradiol) and were assayed at the Royal 
Marsden Hospital in England. Estradiol concentrations were measured by 
radioimmunoassay after ether extraction, using a highly specific rabbit antiserum raised 
against an estradiol-6-carboxymethyloxime-bovine serum albumin conjugate (EIR, 
 79 
Wurenlingen, Switzerland) and Third Generation Estradiol [I125] reagent DSL 39120 
(Diagnostic Systems Laboratories Inc., Texas USA) [302]. The assay detection limit was 
3pmol/L by calculation
 
from the 95% confidence limits of the zero standard.  A random 
subset of 27 replicate quality control samples was included to assess reproducibility; the 
calculated coefficient of variation between duplicates for estradiol was 14.5%.  
Laboratory personnel were masked to both subject identification and quality control 
status.  
4.3.7 Statistical Analyses 
Wilcoxon’s rank sum test was used to compare selected continuous characteristics 
between current users and non-users of NSAIDs and the chi-square test or the Fisher’s 
exact test were used to assess differences in categorical variables.  The Kruskal-Wallis 
test was used to test for significant differences in continuous characteristics across 
estradiol tertile categories.  A log transformation was applied to serum estradiol 
concentrations to obtain
 
homoscedacity and an approximately normal distribution for 
linear model residuals. One participant was excluded from analyses because her total 
estradiol level was deemed unreliable by the laboratory.  An additional 9 participants 
with estradiol levels greater than 150 pmol/L, were removed from analyses because such 
high levels likely indicated the women were not postmenopausal or did not correctly 
report current hormone use.  All analyses were replicated with the 9 data points included; 
however, findings did not change appreciably and therefore the 9 participants were not 
included in the reported results (Appendix B). Thus, the final sample included 260 
women. 
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Cohen's kappa statistic was calculated as a measure of agreement between the 
primary and secondary NSAID exposure variables. Differences in mean log estradiol 
levels between users and nonusers of NSAIDs were tested by Student’s t-test.  The 
general linear model (GLM) approach was performed to calculate multivariable-adjusted 
estradiol levels and to assess differences in levels between NSAID users and non-users.  
Adjusted means and confidence intervals for each NSAID category were quantified using 
the least squares mean option of PROC GLM.  Two adjusted models are presented.  The 
first model was adjusted for age and BMI, which were deemed necessary covariates 
given their previously reported associations with both NSAID use [326] and estradiol 
levels [327, 328].  The second model was further adjusted for variables found to be 
associated with NSAID use or estradiol levels within the study population (univariate 
association p<0.15).  The final multivariable model was adjusted for age (continuous), 
BMI (continuous), years since menopause (continuous), race (white vs. non-white), and 
regular alcohol intake in the past year (none, <12g/day, ≥ 12g/day, entered as an indicator 
variable).  The geometric mean concentrations were calculated by taking the anti-log of 
the least squares means after adjustment.  Additional adjustment for family history of 
breast cancer, past HT use, smoking status, and various reproductive factors yielded 
similar results, and are not presented.   
For each model, a plot of the studentized residuals versus the predicted values was 
examined to check whether the equality of variance assumption was met.  A normal 
probability plot of the residuals was examined to assess normality.   Assumptions of 
normality and homogeneity of variance were met for all models presented. Tests of 
statistical significance were two-tailed and, given the exploratory nature of this work, we 
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reported
 
our results at the p<0.05 significance level, rather than correct for multiple 
comparisons. All analyses were performed using SAS software version 9.1 (SAS 
Institute, Inc., Cary, North Carolina). 
4.4 RESULTS 
Characteristics of the study population by current NSAID use are shown in Table 10.  
The majority of participants (66.9%) were overweight or obese (BMI ≥ 25kg/m2), white 
(93.1%), and non-smokers (94.2%).  Overall, 124 (47.7%) participants reported current 
NSAID use at the time of blood draw (Table 11).  In this study, 25.0%, 12.3%, and 2.3% 
participants reported using only aspirin, non-aspirin NSAIDs and COX-2 selective 
inhibitors, respectively, whereas 8.1% reported using at least two different types of 
NSAIDs (data not shown). One hundred forty (53.8%) women reported that they took 
aspirin or another anti-inflammatory agent within 48 hours of blood draw.  One hundred 
(38.5%) participants listed current use of a NSAID on the baseline questionnaire and 
verbally reported aspirin or anti-inflammatory use within 48 hour of blood draw, and 96 
(37.0%) reported no use of NSAIDs in both settings. The agreement between the primary 
and secondary exposure variables was moderate with a kappa value of 0.51.  
With the exception of race, NSAID users and nonusers were statistically similar 
with regard to all other demographic characteristics (Table 10). Current users of NSAIDs 
were more likely to be white than non-users (96.8% vs. 89.7%; p=0.03).  Demographic 
differences between users and nonusers for all NSAID exposure variables (primary, 
secondary and constructed) were similar, with the exception of BMI.  Participants who 
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reported aspirin or anti-inflammatory drug use within the past 48 hours and those who 
were consistent users were heavier than participants who reported no use of NSAIDs 
(Appendix B). 
The geometric mean serum estradiol concentration for the study population was 
19.5 pmol/L, with levels ranging from 3.3-140.0 pmol/L. As illustrated in Table 12, 
higher serum estradiol levels were associated with increasing BMI (p<0.0001) and 
negatively associated with alcohol intake (p=0.003). Although not statistically 
significant, it was observed that women with higher circulating estradiol levels were on 
average fewer years from menopause (p=0.11). With the exception of alcohol intake, all 
associations persisted after controlling for BMI (data not shown). The association 
between alcohol intake and estradiol diminished after controlling for BMI. 
After adjustment for age and BMI, current NSAID use was significantly inversely 
associated with serum estradiol concentrations (17.8 pmol/L vs. 21.3 pmol/L; p=0.03) 
(Table 13), with approximately 16.4% lower levels in users than nonusers of NSAIDs.   
The age-and BMI-adjusted association between use of the secondary NSAID exposure 
variable (aspirin or anti-inflammatory agent in the past 48 hours) and estradiol was 
suggestive of an inverse effect, but this finding was not statistically significant (18.5 
pmol/L vs. 20.9 pmol/L; p=0.14).  A slightly stronger association between NSAID use 
and estradiol levels was observed when comparing consistent users to consistent nonusers 
(17.5 pmol/L vs. 21.5 pmol/L; p=0.03). Further adjustment for race, alcohol intake and 
years menopausal only slightly increased the strength of association observed in the age- 
and BMI- adjusted analyses. The effects were similar across BMI subgroups (Appendix 
B). 
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 Figure 5 presents the adjusted geometric mean serum estradiol concentration by 
sub-category of NSAID use as defined by the cross-tabulation of the primary and 
secondary NSAID exposure variables.  Three categories were defined, the two 
concordant groups (i.e. No NSAIDs on medication list/ No NSAIDs verbally; Yes 
NSAIDs on medication list/ Yes NSAIDs verbally) remained as separate exposure 
categories, whereas the two discordant groups (i.e. No NSAIDs on medication list/ Yes 
NSAIDs verbally; Yes NSAIDs on medication list/ No NSAIDs verbally) were collapsed 
into a single category.  The three groups had significantly different adjusted geometric 
mean estradiol levels (p trend = 0.02).  As was expected, mean estradiol was lowest for 
participants who reported NSAID use for both measures, and highest for participants who 
did not report use for either measure.   
To assess the possible effects of acetaminophen use on the findings, all analyses 
were repeated excluding acetaminophen users from the NSAID non-user groups (n=12).  
Results did not differ substantially (Appendix B).    
4.5 DISCUSSION 
In this cross-sectional investigation we observed lower circulating estradiol levels among 
postmenopausal women reporting NSAID use.  Specifically, we observed approximately 
16% lower estradiol levels among current users than non-users. Decreased estradiol 
levels were consistent regardless of how NSAID use was assessed (i.e. self-reported 
current NSAID use on questionnaire, verbal reporting of use in past 48 hours, and the 
agreement between these two variables).  Further, the strength of association was slightly 
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stronger when comparing participants who reported NSAID use at both the time of blood 
draw and within 48 hours of blood draw to those who reported no use of NSAIDs for 
both measures. Associations were independent of age, BMI, and other potential 
confounding variables. As elevated serum estradiol levels have been linked to breast 
cancer risk, these results provide support to the growing body of evidence linking NSAID 
use to decreased breast cancer incidence. 
Although findings in the literature are not completely consistent, results of several 
epidemiologic studies suggest that use of aspirin, non-aspirin NSAIDs and COX-2 
inhibitors may reduce the risk of breast cancer (reviewed in [329]).  The inconsistent 
findings among studies may be explained, in part, by differences in the definition of 
NSAID use, dosage and frequency data, and NSAID assessment periods. Notably, some 
studies suggest the decreased risk is stronger among estrogen receptor positive (ER+) 
breast cancers [192, 330] and, if true, would strengthen the hypothesis of an estrogen 
modulatory effect by NSAIDs.  However, this relationship is not consistently observed 
[314, 331]. 
The mechanisms underlying the protective effects of these anti-inflammatory 
agents have been extensively investigated in the laboratory environment but have been 
less commonly explored in an epidemiological setting. Establishing the relationship 
between NSAID use and the various biochemical markers (i.e. steroid hormones, growth 
factors, and cytokines) involved in the pathogenesis of breast cancer in humans is 
essential in order to determine the effects these agents have on the development of breast 
cancer.  The reduced risk of breast cancer observed among NSAID users in prior studies 
may, in part, be mediated through NSAIDs favorable effects on PGE2 production.  
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Decreased PGE2 synthesis may result in suppressed estradiol production in 
postmenopausal women and subsequently reduced breast cancer risk.  In accordance with 
this biologic paradigm, we observed that postmenopausal participants reporting NSAID 
use had lower estradiol levels. We know of no other epidemiological study that has 
reported this relationship.  As NSAID use is modifiable, a chemoprotective action 
attributed to its use could have a considerable public health impact.  However, the risk-to-
benefit ratio would need to be considered since NSAIDs have potentially serious side 
effects [332, 333].     
The present study has limitations that deserve attention and that should be 
considered when evaluating the study findings. First, as this is a cross-sectional 
investigation, we cannot ascertain the temporal relationship between NSAID use and 
serum estradiol, meaning that causal conclusions cannot be made. Multiple measurements 
of NSAID use and serum estradiol would have resulted in more precise estimates.  
Additional limitations of this study include our inability to assess duration of NSAID use 
or dosage information, as duration of NSAID use was not collected and dosage data were 
deemed unreliable as many participants listed number of tablets taken rather than the 
actual dose. Women exposed to a longer duration of NSAID use or larger doses may have 
more pronounced effects on circulating estradiol levels than occasional NSAID users (i.e. 
as-needed) or those consuming smaller doses (i.e. low-dose aspirin). The sample size was 
not large enough to assess the effect of the different types of NSAIDs (e.g. aspirin, non-
aspirin NSAIDs, and selective COX-2 inhibitors) on serum estradiol. Further, we cannot 
rule out exposure misclassification.  The result of nondifferential misclassification of our 
exposure variable (NSAID use vs. NSAID non-use) would most likely bias the findings 
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toward the null hypothesis and possibly underestimate the true association between 
NSAID use and serum estradiol. We attempted to reduce misclassification by repeating 
analyses limiting the sample to women who consistently reported NSAID use or nonuse.  
Further, although we attempted to control for potential confounders in the statistical 
analyses, we cannot rule out the possibility that women who are users of NSAIDs had a 
factor in common that we did not measure that is related to lower serum estradiol levels.  
Finally, the lack of ethnic diversity and exclusion of premenopausal women in our 
sample limits the generalizability of the results.  
Strengths of our study include the use of standardized instruments, reproducible 
measures of total estradiol, and the assessment of NSAID use on the same day as blood 
draw.  The last strength is important, because the effect of NSAIDs on the inhibition of 
COX enzymes and PGE2 formation occurs rapidly [334]. Finally, the observed 
distribution of postmenopausal total estradiol levels and the self-reported prevalence of 
NSAID use in this population were similar to previous reports [328, 335].  Thus, study 
findings may be generalizable to similar populations. In our study, 33% MAMS 
participants (aged 42-85) reported aspirin use and 19% other NSAID use at study 
enrollment.  The third National Health and Nutrition Survey (NHANES III) described a 
similar prevalence of aspirin and NSAID use [335].  In this population, women aged 45-
64 reported 36% and 25% monthly use of aspirin and other NSAIDs, respectively and 
women aged 65-74 reported 42% aspirin and 16% other NSAID use. 
In summary, we believe that we are the first to report on the association between 
NSAID use and postmenopausal estradiol levels.  We found NSAID users to have 
significantly lower serum estradiol concentrations than non-users which may account for 
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the protective effect NSAID use has been observed to exhibit on breast cancer 
development.  However, continued research efforts are needed to verify our findings.  
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Table 10.  Distribution of selected characteristics by NSAID use among postmenopausal women in the 
Mammograms and Masses Study (MAMS)   
Characteristic NSAID  user (N=124) NSAID non-user (N=136) p 
Age at blood draw (years), mean (SD) 62.6 (8.1) 62.9 (8.7) 0.91 
BMI (kg/m2), mean (SD) 28.6 (6.0) 28.3 (6.1) 0.63 
Age at menopause (years), mean (SD)* 48.7 (4.4) 48.7 (5.7) 0.57 
Years menopausal, mean (SD)* 14.1 (9.8) 14.2 (10.3) 0.94 
Surgical menopause, %*   0.38 
  No  90.2 86.8  
  Yes 9.8 13.2  
Age at menarche, %*   0.88 
  <12 years 19.4 17.8  
  12-13 years 57.3 56.3  
  ≥14 years 23.4 25.9  
Race, %   0.03 
  White 96.8 89.7  
  Non-white 3.2 10.3  
Family history of breast cancer, %*†   0.98 
  No  86.9 86.8  
  Yes 13.1 13.2  
Prior hormone therapy use, %   0.86 
  No  37.9 39.0  
  Yes 62.1 61.0  
Previous breast biopsy, %   0.83 
  No  85.5 84.6  
  Yes 14.5 15.4  
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Table 10 (continued)    
Characteristic NSAID  user (N=124) NSAID non-user (N=136) p 
Regular alcohol intake in past year, %   0.10 
  None 66.1 77.9  
  < 12 g/day 21.8 14.0  
  ≥ 12 g/day 12.1 8.1  
Smoking status, %   0.88 
  Never  59.7 61.8  
  Former 33.9 33.1  
  Current 6.5 5.2  
Parous,  %   0.50 
  No  21.0 17.7  
  Yes 79.0 82.4  
Age at first full-term pregnancy,  % ‡   0.94 
  < 30 years 81.6 81.3  
  ≥ 30 years 18.4 18.8  
Ever breast fed for > 1 month,  % ‡   0.52 
  No   50.0 54.5  
  Yes  50.0 45.5   
NOTE: Percentages may not add up to 100% due to rounding. NSAID, nonsteroidal anti-inflammatory drug; BMI, body 
mass index 
*missing  n=7 for age at menopause; n=7 for years menopausal; n=1 for surgical menopause; n =1 for age at menarche;  
n=2 for family history of breast cancer  
† family history of breast cancer in mother or sister 
‡ among parous women 
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Table 11. Self-reported NSAID use in the Mammograms and Masses Study 
(MAMS) 
 
NSAID use N (%) 
Primary exposure variable  
  Current use*  
    Non-user 136 (52.3) 
    User 124 (47.7) 
  
Secondary exposure variable  
   Past 48 hour use†  
    Non-user 120 (46.2) 
    User 140 (53.8) 
  
Constructed exposure variable  
   Consistent use‡  
    Non-user  96 (36.9) 
    User 100 (38.5) 
NOTE: NSAID, nonsteroidal anti-inflammatory drug   
*Current use:  Based on participant’s self-reported current medication list 
†Past 48 hour use:  Based on participant’s verbal response to the question “Have you 
taken an aspirin or other anti-inflammatory drug in the past 48 hours?”   
‡Consistent use:  The agreement between current NSAID use and past 48 hour use.    
Non-user=Participant’s current medication list did not indicate use of a NSAID and the 
participant verbally responded that she did not consume an aspirin or anti-inflammatory 
agent within 48 hours of blood draw. User= Participant’s current medication list 
indicated use of a NSAID, and the participant verbally responded that she consumed an 
aspirin or anti-inflammatory agent within 48 hours of blood draw.    
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Table 12. Distribution of selected characteristics by tertile of serum estradiol levels among postmenopausal women in the 
Mammograms and Masses Study (MAMS) 
         Estradiol concentrations  
Characteristic Tertile 1 (n=91) Tertile 2 (n=81) Tertile 3 (n=88) p 
Age at blood draw (years), mean (SD) 63.8 (8.5) 62.6 (8.5) 61.9 (8.2) 0.38 
BMI (kg/m2), mean (SD) 25.4 (4.41) 27.3 (4.9) 32.6 (6.2) <0.0001 
Age at menopause (years), mean (SD)* 48.3 (4.53) 49.0 (5.0) 48.8 (5.7) 0.27 
Years menopausal, mean (SD)* 15.6 (9.74) 13.5 (10.2) 13.1 (10.1) 0.11 
Surgical menopause, %*    0.64 
  No 87.8 86.4 90.9  
  Yes 12.2 13.6 9.1  
Age at menarche, %*    0.49 
  <12 years 14.3 17.3 24.1  
  12-13 years 60.4 59.3 50.6  
  ≥14 years 25.3 23.5 25.3  
Race, %    0.46 
  White 95.6 92.6 90.9  
  Other 4.4 7.4 9.1  
Family history of breast cancer, %*†    0.95 
  No 86.8 87.7 86.1  
  Yes 13.2 12.4 14.0  
Prior hormone therapy use, %    0.30 
  No 33.0 38.3 44.3  
  Yes 67.0 61.7 55.7  
Previous breast biopsy, %    0.48 
  No 82.4 84.0 88.6  
  Yes 17.6 16.1 11.4  
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Table 12 (continued)   
         Estradiol concentrations  
Characteristic Tertile (n=91) Tertile 2 (n=81) Tertile (n=88) p 
Regular alcohol intake in past year, %    0.003 
  None 60.4 72.8 84.1  
  < 12 g/day 28.6 13.6 10.2  
  ≥ 12 g/day 11.0 13.6 5.7  
Smoking status    0.46 
  Never 58.2 56.8 67.1  
  Former 37.4 37.0 26.1  
  Current 4.4 6.2 6.8  
Parous,  %    0.47 
  No 23.1 18.5 15.9  
  Yes 76.9 81.5 84.1  
Age at first full-term pregnancy,  % ‡    0.93 
  < 30 years 80.0 81.8 82.4  
  ≥ 30 years 20.0 18.2 17.6  
Ever breast fed for > 1month,  % ‡    0.75 
  No 54.3 48.5 54.1  
  Yes 45.7 51.5 46.0   
NOTE: Percentages may not add up to 100% due to rounding. BMI, body mass index 
*missing n=7 for age at menopause; n=7 for years menopausal; n=1 for surgical menopause; n =1 for age at menarche;  n=2 for family 
history of breast cancer 
† family history of breast cancer in mother or sister 
‡ among parous women 
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Table 13. Unadjusted and adjusted geometric mean estradiol levels (95% confidence interval) according to NSAID use 
 Serum estradiol concentrations (pmol/L) 
All Participants Model 1* p Model 2†  p Model 3‡ p 
Primary exposure variable       
  Current use   0.11  0.03  0.03 
     NSAID Non-user (N=136) 21.0 (18.4, 24.0)  21.3 (19.0, 23.7)  21.2 (18.9, 23.7)  
     NSAID User (N=124) 18.0 (15.7, 20.7)  17.8 (15.9, 20.0)  17.7 (15.7, 19.9)  
       
Secondary exposure variable       
  Past 48 hour use  0.94  0.14  0.07 
     NSAID Non-user (N=120) 19.5 (16.9, 22.4)  20.9 (18.5, 23.5)  21.1 (18.7, 23.8)  
     NSAID User (N=140) 19.6 (17.2, 22.3)  18.5 (16.5, 20.6)  18.1 (16.2, 20.3)  
       
Constructed exposure variable       
  Consistent  use   0.39  0.03  0.02 
     NSAID Non-user (N=96) 20.3 (17.3, 23.8)  21.5 (18.9, 24.4)  21.4 (18.8, 24.4)  
     NSAID User (N=100) 18.4 (15.8, 21.5)  17.5 (15.4, 19.8)  17.2 (15.1, 19.6)  
NOTE: NSAID, nonsteroidal anti-inflammatory drug; BMI, body mass index.  Current use:  Based on participant’s medication list. Past 48 
hour use:  Participant’s verbal response to the question, “Have you taken an aspirin or other anti-inflammatory drug in the past 48 hours?”  
Consistent NSAID use:  The agreement between current NSAID and past 48 hours use.   
*Unadjusted model 
†Adjusted for age at blood draw (continuous) and BMI (continuous) 
‡Missing N=7; Adjusted for age at blood draw (continuous), BMI (continuous), race (white, nonwhite), years menopausal (continuous), and 
current alcohol intake (none, <12 g, ≥12 g, indicator variable) 
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Figure 5. Adjusted geometrc mean estradol according to self-reported NSAID use 
Serum total estradiol was adjusted for age at blood draw, BMI, race, years menopausal, 
and current alcohol intake in a general linear model (n=7 missing data).  
No/No=Participant’s current medication list did not indicate use of a NSAID and the 
participant verbally responded that she did not take aspirin or an anti-inflammatory agent 
within 48 hours of blood draw (n=96).  No/Yes=Participant’s current medication list did 
not indicate use of a NSAID, but participant verbally responded that she took aspirin or 
an anti-inflammatory agent within 48 hours of blood draw (n=40).  Yes/No=Participant’s 
current medication list indicated use of a NSAID, but the participant verbally responded 
that she did not take aspirin or an anti-inflammatory agent within 48 hours of blood draw 
(n=24). Yes/Yes=Participant’s current medication list indicated use of a NSAID, and the 
participant verbally responded that she did not take aspirin or an anti-inflammatory agent 
within 48 hours of blood draw (n=100).  
 
p trend = 0.02 
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5.1 ABSTRACT 
Diets low in omega-6 (n-6) fatty acids and/or rich in omega-3 (n-3) fatty acids may 
protect against breast cancer development.  Mammographic breast density is one of the 
strongest risk factors for breast cancer, and may be affected by dietary intake.  Therefore, 
the aim of this study was to examine the association between the essential n-6 and n-3 
fatty acids and mammographic breast features, specifically percent breast density, dense 
breast area, and nondense area of the breast.  Data were included from 248 breast cancer 
free, postmenopausal women who were not using hormone therapy.  Mammographic 
breast density, dense area of the breast and nondense areas of the breast were assessed by 
planimetry. Fatty acids in erythrocytes were measured by gas-liquid chromatography.  
Spearman’s rank order correlation coefficients were used to evaluate the relationships 
between fatty acid measures and mammographic characteristics.  Erythrocyte n-6 fatty 
acids, n-3 fatty acids, and the n-6:n-3 ratios were not associated with percent breast 
density or dense area of the breast before or after adjustment for age and body mass index 
(BMI).  Several fatty acid measures were associated with the nondense area of the breast; 
however, the associations did not persist after controlling for the effects of age and BMI. 
This is the first study to report on the relationship between erythrocyte fatty acids and 
mammographic features. These results suggest that if n-6 and n-3 fatty acids influence 
breast cancer development then the effect may not be through influencing 
mammographic breast density.   
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5.2 INTRODUCTION 
Over the past two decades, mammographic breast density has become acknowledged as 
one of the strongest, independent risk factors for breast cancer.  The majority of 
epidemiological studies report approximately a four- to six-fold increased risk of breast 
cancer when comparing women with extensive areas of density to women whose breasts 
are composed primarily of fatty tissue [110, 23].  Moreover, increased density also 
reduces the sensitivity of screening mammography [336, 337], thus it is important to 
identify factors that can reduce dense breast tissue. Several characteristics that have been 
related with increased density have also been linked to increased breast cancer risk, such 
as nulliparity, late age at first full term birth, late age of menopause, and hormone therapy 
(HT) use [70, 65, 72].  Data also exist suggesting that dietary habits can influence breast 
density [278, 280], though this area of research has not been sufficiently explored.  
Experimental and epidemiological studies have found a positive association 
between n-6 fatty acids and an inverse association between n-3 fatty acids with the risk of 
breast cancer [252, 253, 264, 266].  Additionally metabolic byproducts of the n-6 and n-3 
fatty acids have also been linked with breast cancer.  Both n-6 and n-3 fatty acids serve as 
substrates for prostaglandins.  Prostaglandin E2 (PGE2), a metabolic product of n-6 
arachidonic acid (AA; 20:4n-6) metabolism, is unregulated in breast tumors [185-187].  
On the contrary, the prostaglandin product of n-3 eicosapentaenoic acid (EPA; 20:5n-3) 
metabolism is of the 3 series (PGE3) and is not a potent stimulator of breast cancer cell 
growth [176].  
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One potential mechanism through which these essential fatty acids could 
influence breast density is via increased estrogen production within the breast.  PGE2 
stimulates the CYP19 gene [200] which is transcribed and translated into aromatase, the 
key enzyme in the biosynthesis of estrogen in postmenopausal women [203].  Although 
circulating levels of estrogen in postmenopausal women drop substantially after the 
menopause, tissue levels of estrogen are considerably greater than even premenopausal 
tissue levels, which is likely the result of aromatase activity [328].  Dense areas of the 
breast are believed to represent proliferation of breast epithelial and/or stromal tissue 
[339].  Estrogen, a steroid hormone with known mitogenic effects, drives cellular 
division in breast epithelial cells [340].  Thus, excessive intake of n-6 fatty acids may 
increase breast cell proliferation via localized estrogen exposure which may be reflected 
on a mammogram by areas of density.  On the other hand, consumption of n-3 fatty acids 
results in reduced PGE2 synthesis, and therefore may not amplify estrogen production or 
cellular division within the breast.   
There are few studies that have assessed the role of the n-6 and n-3 fatty acids on 
mammographic breast density.  N-6 intake has been associated with increased density 
[281], and n-3 intake with reduced density [282], however findings are not consistent 
[279, 281-283].  All studies, thus far, have measured dietary fat intake via self-report 
dietary assessment instruments, and limitations of these assessment tools and nutrient 
composition tables are well-known. Biomarkers of the essential n-6 and n-3 fatty acid 
intake have the advantage of being free of error due to human memory and can reflect 
recent intake of individual fatty acids [161].  Therefore, in the present study, we 
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examined the associations between erythrocyte n-6 and n-3 fatty acids with percent 
mammographic breast density and other mammographic characteristics. 
5.3 MATERIALS AND METHODS 
5.3.1 Study Population 
The data presented were collected as part of the Mammograms and Masses Study 
(MAMS), the methods of which have previously been reported [296].  The MAMS is a 
case-control study of estrogen metabolites, mammographic breast density and breast 
cancer risk. MAMS recruited a total of 869 cancer-free women and 264 recently 
diagnosed breast cancer cases through the Magee Womens Hospital Mammographic 
Screening and Diagnostic Imaging Program in the Pittsburgh area (Pennsylvania, USA) 
during 2001-2005.  Study participants were women aged 18 years or older who reported 
no previous personal history of cancer, with the exception of nonmelanoma skin cancer. 
Only MAMS controls who were recruited via study flyers (n=453) attached to screened 
negative mammogram reports (2003-2005) were included in the present analysis, as these 
participants completed a self-administered questionnaire on the day of blood draw.  Prior 
to enrollment, written informed consent and a signed mammogram release form were 
obtained from each woman.  The MAMS protocol was approved by the Institutional 
Review Board of the University of Pittsburgh.  
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5.3.2 Subsample Selection 
In addition to the above eligibility criteria of the parent study, the participants were only 
selected for this ancillary study if they met the following entry criteria: postmenopausal 
(having had no menstrual bleeding during prior year or having undergone a bilateral 
oophorectomy); no use of hormone therapy (HT) within 3 months of study enrollment; 
and not using vaginal estrogen creams, oral contraceptives, corticosteroids or selective 
estrogen receptor modulators (SERMs) at blood sampling. Additionally, because MAMS 
utilized routine mammograms, the timing of the film does not coincide with the timing of 
the baseline blood draw, therefore participants whose time between film date and blood 
date was greater than 120 days (~4 months), the lifetime of a red blood cell, were also 
excluded. Of those who were excluded, 98 were premenopausal, 84 were using 
exogenous hormones, corticosteroids or SERMs, 1 control was later diagnosed with 
breast cancer, and 13 participants did not have an available mammogram taken within 
120 days of blood draw.  Additionally, we excluded 9 participants with estradiol levels 
greater than 150pmol/L as it indicated they might be pre- or peri-menopasual, or 
misreported current hormone use.  Two hundred forty-eight women met the inclusion 
criteria for the present analysis. 
5.3.3 Data Collection 
A standardized, self-administered questionnaire was administered at blood sampling, and 
collected information on participant demographics, current use of medications and 
supplements, reproductive history, family history of breast cancer, past hormone therapy 
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use, and various lifestyle habits (smoking status and alcohol intake). Participants
 
who 
reported using aspirin, COX-2 inhibitors, or other non-aspirin NSAIDs were considered 
"current NSAID users."  Participants who did not list using any of these agents on the 
questionnaire were considered “current NSAID non-users.”   Regular alcohol use 
(grams/day) in the past year was calculated as previously reported [298].  Age was 
defined as a participant’s age at the time of blood draw, rather than her age at 
mammogram.  Age of menopause was calculated as the age at last natural menstrual 
bleeding or bilateral oophorectomy.  However, for a hysterectomized woman without a 
bilateral oophorectomy, age at menopause corresponded to the earliest age at which she 
began using HT or first had menopausal symptoms. If neither occurred and her age at 
hysterectomy was 50 years or older, then age at menopause was her age at hysterectomy 
[299]. Years since menopause were calculated by subtracting a woman’s age at 
menopause from her age at study enrollment.  
Height and weight were measured by trained clinical staff, after participants 
removed shoes and heavy clothing. Weight was measured to the nearest 0.1 kg using a 
standard balance beam. Standing height was measured at full inspiration to the nearest 
0.1 cm. The measurements were repeated, and the average of the values was used in the 
analyses. Weight and height measurements were used to calculate body mass index 
(BMI, weight in kg divided by height in meters squared (m
2
)).   
A 40 mL non-fasting blood sample was donated by each participant. Samples 
were processed immediately on site according to a standardized protocol. After 
processing, the samples were fractioned into 1 mL cryovials of red blood cell, serum, 
plasma and buffy coat aliquots.  Samples were stored at or below -70°C until assayed. 
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5.3.4 Erythrocyte Fatty Acid Analysis 
Fatty acids in erythrocytes were analyzed by gas-liquid chromatography at the University 
of Pittsburgh’s Heinz Laboratory. Total lipids (500μl of packed red blood cells) were 
extracted as previously described [300].  In brief, the samples and an internal standard 
were homogenized in 4 ml of methanol.  Two ml of chloroform and 1.1 ml of water were 
added to the samples after 15 min.  The samples were centrifuged at 1200 g for 30 min at 
16°C and the upper phase of the sample was discarded.  The lower phase was dried under 
nitrogen and resuspended in 1.5 ml 14% boron trifluoride methanol.  Samples were 
heated at 90°C for 40 min and extracted after cooling with 4.0 ml pentane and 1.5 ml 
water.  The samples were vortexed and the organic phase recovered [301].  The extracts 
were dried under nitrogen, resuspended in 50 μl heptane and 2 ul injected into a capillary 
column (SP-2380, 105 m x 53 mm ID, 0.20 um film thickness).  Gas chromatographic 
analyses were performed with a Perkin Elmer Clarus 500 equipped with a flame 
ionization detector.  The operating conditions were: oven temperatures programmed at 
140°C for 35 min, 8°C/min to 220°C, and held for 12 min; the injector and detector 
temperatures were both at 260°C; and helium, the carrier gas, was at 15 psi.  Fatty acid 
identification was based on the retention time data obtained for the authentic standards 
(Sigma).  Erythrocyte fatty acids are expressed as a percentage by weight of total fatty 
acids.  Inter-assay coefficients of variations (CV) were calculated from 27 masked 
duplicate samples.  The inter-assay coefficients of variation for the erythrocyte fatty acid 
measures reported ranged from 1.7-15.2%.  CVs’s were 1.7% for linoleic acid (LA; 
18:2n-6), 3.4 % for AA, and 1.7% for total n-6 fatty acids.  CV’s were 15.2% for alpha-
linolenic acid (ALA; 18:3n-3), 5.3% for EPA, 7.5% for docosahexaenoic acid (DHA; 
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22:6n-3) and 5.3% for total n-3 fatty acids.  The CVs for the total n-6: n-3, LA:ALA, 
AA:EPA, and AA:EPA+DHA ratios were 5.2%, 11.1%, 4.5% and 5.7% respectively.   
5.3.5 Mammographic Breast Density Assessment 
The craniocaudal view of the mammographic film corresponding closest to the 
participant’s date of blood draw was obtained and copied after radiologic evaluation had 
ruled out malignancy. The film copies were deidentified and sent to a single expert 
reviewer (Ms. Martine Salane) for assessment of breast density. A transparent overlay 
was placed on top of the film, and using a wax pencil, the reviewer outlined the total area 
of the breast and areas of dense tissue.  Biopsy scars, Cooper’s ligaments and breast 
masses were not considered in the reading. Next, using a compensating planimeter 
(LASICO, Los Angeles, CA), the reviewer traced the outlined areas to compute total area 
of the breast (cm
2
) and dense breast area (cm
2
). Percent breast density was calculated by 
dividing the dense breast area by the total area of the breast multiplied by 100. Nondense 
area (cm
2
) of the breast was determined by subtracting dense breast area from the total 
area of the breast. To determine the reproducibility of the mammographic readings 
twenty-one randomly selected mammograms (7 from each tertile of density) were read 
blindly a second time by the reader and the intraclass correlation coefficient (ICC)
 
was 
calculated. The ICC was calculated from an F value that was derived by dividing the 
mean square error terms for the between-participant variance by that of the within-
participant variance. Calculated ICC values were excellent at ρ=0.92, ρ=0.99 and ρ=0.96 
for area of density, total area of the breast, and percent breast density, respectively.   
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Mammograms were also visually assessed for quality of film (excellent, good, fair, and 
poor). 
5.3.6 Statistical Analyses 
Percent breast density, dense breast area, and nondense area of the breast were examined 
as continuous variables.  Descriptive results for selected, participant characteristics are 
expressed as a mean and standard deviation (SD) or as a frequency and percentage (%).  
Medians and interquartile ranges were determined for the mammographic features. 
Differences in continuous variables between tertiles of percent density were determined 
using Kruskal-Wallis.  Differences in categorical variables between tertiles of breast 
density were compared using the chi-square analysis, unless expected cell sizes were less 
than 5, in which case the Fisher’s exact test was used.  Pearson’s correlation coefficients 
were calculated to determine the relationship between percent breast density, dense breast 
area, and nondense area of the breast; a square root transformation was applied to the 
three mammographic features to normalize distributions for this statistical test. 
Correlation relationships between erythrocyte n-6 and n-3 fatty acid measures and 
mammographic characteristics were examined with Spearman’s correlation coefficients, 
with no adjustments and adjusting for the effects of age and BMI.  Data were analyzed 
using SAS statistical program version 9.1 (SAS Institute, Cary, NC).  All statistical tests 
were two-sided, and an alpha level of 0.05 was set a priori in order to determine 
statistical significance. 
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5.4 RESULTS 
As shown in Table 14, the mean (SD) age of the study population was 63.0 (8.4) years, 
mean BMI was 28.6 (6.1) kg/m
2
, the mean time since menopause was 14.3 (10.1) years, 
and 93.6% were white. The average time interval between the mammogram and blood 
collection was 35 days, with a range of 8-114 days (data not shown).  The median 
(interquartile range) percent breast density was 23.7 (13.4 to 39.7)%, dense area was 35.8 
(21.7 to 54.6) cm
2
, and nondense breast area was 104.2 (65.2 to 169.2) cm
2
.  Percent 
mammographic density was strongly correlated with both dense breast area (r=0.80; 
p<0.0001) and nondense area of the breast (r=-0.77; p<0.0001) (Table 15). 
The characteristics of the study participants, by tertiles of percent breast density, 
are shown in Table 16.  Women with denser breasts were more likely to have reported 
prior HT use, regular use of alcohol in the past year, and had a breast biopsy.  Contrary to 
prior reports, parous women in our population who breastfed for more than 1 month had 
greater percent breast density.  BMI, time since menopause, and current use of cigarettes 
were inversely related with percent breast density.  Although, a significant difference was 
noted for age at menopause across tertiles of density, the relationship between the two 
variables was not clear. 
Mean erythrocyte fatty acid compositions for the participants are described in 
Table 17.  Study participants had a greater concentration of n-6 fatty acids as compared 
to n-3 fatty acids incorporated into their erythroctytes.  The mean (SD) total n-6 fatty 
acids was 38.3 (2.6)% and total n-3 was 7.9 (2.1)%.  N-6 AA and LA were the most
 
abundant fatty acids, with AA composing 16.1 (1.9)% of the total erythrocyte fatty acid 
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content and LA 15.8 (2.4)%.  Of the n-3 fatty acids, DHA accounted for the greatest 
percentage of the total fatty acids at 4.5 (1.5)%. 
Unadjusted and adjusted Spearman rank correlation coefficients were determined 
and presented in Table 18.  No association was observed between any one of the 
erythrocyte fatty acid measures and percent breast density or dense breast area in either 
the unadjusted or adjusted analyses.  N-6 LA, total n-3 and all individual n-3 fatty acids 
were inversely correlated with nondense area of the breast before adjustments were made 
for age and BMI. However, none of these associations persisted after adjusting for these 
variables. The n-6:n-3 ratios were all positively and significantly correlated with 
nondense area of the breast, but associations diminished after correcting for covariates.  
Adjustment for additional factors in a general linear model did not produce any 
statistically significant findings (Appendix C).   
In a secondary analysis, we excluded participants (n=128) whose date of 
mammogram was more than 30 days before blood sampling as well as participants whose 
mammographic films were rated as poor quality.  Findings did not differ substantially 
(Appendix C).   
5.5 CONCLUSIONS 
 In this cross-sectional investigation, we assessed the association between the n-6 and n-3 
fatty acids in erythrocytes and percent breast density and other mammographic features. 
To our knowledge, we are the first to report on these relationships.  In contrast with what 
we had predicted, no association was found between any fatty acid measure and percent 
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breast density.  Further, a relationship was not observed between the n-6 or the n-3 fatty 
acids and dense breast area. These null associations remained after limiting the study 
population to women whose mammograms were taken within 30 days of blood draw.  
Although several fatty acid measures were significantly related to nondense area of the 
breast, these associations disappeared after controlling for the confounding effects of age 
and BMI.   
A few epidemiological studies have reported on the association between dietary 
intake of the n-6 and n-3 fatty acids and mammographic breast density, and all measured 
diet via self-report.  Women with the highest mammographic density pattern reported 
significantly higher consumption of n-6 PUFAs when compared to women with the 
lowest mammographic pattern [281]; however, another study reported no association 
between the n-6 fatty acid LA and breast density [282].  No difference in breast density 
was observed when comparing quartiles of total n-3 intake or long chain n-3 fatty acids 
[279, 281, 283].  Consumption of fish, which is typically high in the long chain n-3 fatty 
acids, has not been linked to mammographic density in postmenopausal women [282-
284]. Only one study has investigated the effects of the n-3 fatty acid, ALA, with breast 
density and a significant inverse association was observed [282].  
Several limitations of this study should be mentioned.  First, blood was not drawn 
on the same day that the mammogram was taken (range 8-114 days); however, 
erythrocyte n-3 and n-6 fatty acids reflect dietary intake over the preceding weeks or 
months [161]. Further, the dietary intake within our study population may have been too 
similar to detect a difference in mammographic features. Study results have reduced 
generalizibility due to the study population being entirely postmenopausal and 
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predominately white. The cross-sectional nature of this study does not allow temporal 
relationships between fatty acid intake and mammographic characteristics to be 
established. Finally, as information on NSAID use at the time of mammogram was not 
collected, we were unable to accurately determine if the relationship between erythrocyte 
fatty acid measures and breast density is modified by NSAID use (Appendix C).  This 
may be of some concern given that differences in the strengths of the relationships 
between fatty acid measures and estradiol concentrations differed by NSAID use in this 
population (Research article 1, unpublished data).  Study strengths include the use of a 
single expert reader with excellent reproducibility for breast density assesment, the use of 
a validated biochemical marker of dietary n-6 and n-3 fatty acids which is capable of 
reflecting recent dietary intake [161], and standardized measurement of participant 
characteristics. 
In conclusion, in the present study we found no evidence of an association 
between n-6 or n-3 fatty acids and mammographic breast density in postmenopausal 
women.  Thus our results suggest that if the n-6 and n-3 fatty acids affect the risk of 
breast cancer, it may not be through altering mammographic breast density.   However, 
considering the biological plausibility of an association between the essential n-6 and n-3 
fatty acids and breast density and the study limitations noted above, further studies are 
necessary to confirm these findings. Understanding the possible influences of dietary 
intake on mammographic breast density may contribute understanding to the etiology of 
breast cancer, and could aid in improving the sensitivity of mammograms, which are 
hindered by dense breast tissue [341]. 
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Table 14. Selected demographic, anthropometric, and lifestyle characteristics of the 
study population  
Characteristics (N=248)  
Means (SD)  
Age at blood sampling (years) 63.0 (8.4) 
Age at menopause (years)* 48.7 (5.2) 
Years menopausal* 14.3 (10.1) 
BMI (kg/m
2
) 28.6 (6.1) 
  
Frequencies (%)  
Race  
White 232 (93.6) 
Non-white 16 (6.5) 
Age at menarche (years)*  
<12 47 (19.0) 
12-13 139 (56.3) 
≥13 61 (24.7) 
Family history of breast cancer* †  
No 214 (87.0) 
Yes 32 (13.0) 
Surgical Menopause*  
No 221 (89.5) 
Yes 26 (10.5) 
Past hormone therapy use  
No 97 (39.1) 
Yes 151 (60.9) 
Past year regular alcohol intake (g/day)  
None 179 (72.2) 
<12  45 (18.2) 
≥12  24 (9.7) 
Current Smoker  
No 234 (94.4) 
Yes 14 (5.7) 
Current NSAID use  
No 129 (52.2) 
Yes 119 (47.8) 
Ever pregnant  
No 41 (16.5) 
Yes 207 (83.5) 
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Table 14 (continued)  
Characteristics  
Number of live births‡  
1 28 (14.1) 
2 83 (41.7) 
≥3 88 (44.2) 
Age at first full term pregnancy‡  
<30 163 (81.9) 
≥30 36 (18.1) 
Ever breastfed >1 month‡  
No 103 (51.8) 
Yes 96 (48.2) 
Ever breast biopsy  
No 212 (85.5) 
Yes 36 (14.5) 
  
Median (IQR)  
Percent breast density 23.7 (13.4 – 39.7) 
Dense breast area (cm
2
) 35.8 (21.7 – 54.6) 
Nondense breast area (cm
2
) 104.2 (65.2 – 169.2) 
NOTE:  Percentages (%) may not add up to 100% due to rounding.  BMI, body mass 
index; NSAID, nonsteroidal anti-inflammatory drug; IQR, interquartile range 
*missing n=6 for age at menopause, n=6 for years menopausal, n=1 for age at menarche 
n=2 for family history of breast cancer, and n=1 for surgical menopause 
†family history of breast cancer in mother of sister 
‡ among parous women 
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Table 15. Pearson’s correlation coefficients between mammographic features 
  Dense breast area (cm
2
) Nondense breast area (cm
2
) 
Percent breast density 0.80 (<0.0001) -0.77 (<0.0001) 
Dense breast area (cm
2
)  -0.28 (<0.0001) 
Note:  A square root transformation was applied to percent breast density, dense 
breast area, and nondense breast area 
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Table 16. Characteristics of participants by tertile of percent breast density  
 
Characteristics (n=248) 
Tertile 1 
(<16.46) 
Tertile 2 
(16.47-34.24) 
Tertile 3 
(≥34.25) p 
Means (SD)     
Age at blood sampling (years) 64.1 (8.7) 62.7 (8.2) 62.2 (8.1) 0.31 
Age at menopause (years)* 49.3 (4.7) 47.8 (5.3) 49.1 (5.4) 0.03 
Years menopausal* 14.9 (9.6) 14.9 (9.8) 13.1 (10.9) 0.15 
BMI (kg/m
2
) 31.1 (6.6) 29.3 (5.7) 25.2 (4.2) <0.0001 
     
Frequencies (%)     
Race    0.73 
White 77 (91.7) 77 (93.9) 78 (95.1)  
Non-white 7 (8.3) 5 (6.1) 4 (4.9)  
Age at menarche (years)*    0.90 
<12 18 (21.7) 16 (19.5) 13 (15.9)  
12-13 46 (55.4) 46 (56.1) 47 (57.3)  
≥13 19 (22.9) 20 (24.4) 22 (26.8)  
Family history of breast cancer* †    0.44 
No 69 (83.1) 72 (88.9) 73 (89.0)  
Yes 14 (16.9) 9 (11.1) 9 (11.0)  
Surgical Menopause*    0.29 
No 77 (92.8) 74 (90.2) 70 (85.4)  
Yes 6 (7.2) 8 (9.8) 12 (14.6)  
Past hormone therapy use    0.05 
No 40 (47.6) 24 (29.3) 33 (40.2)  
Yes 44 (52.4) 58 (70.7) 49 (59.8)  
Past year regular alcohol intake (g/day)    0.05 
None 68 (81.0) 61 (74.4) 50 (61.0)  
<12 g/day 11 (13.1) 15  (18.3) 19 (23.2)  
≥12 g/day 5 (6.0) 6 (7.3) 13 (15.9)  
Current Smoker    0.13 
No 76 (90.5) 80 (97.6) 78 (95.1)  
Yes 8 (9.5) 2 (2.4) 4 (4.9)  
Current NSAID use    0.77 
No 45 (53.6) 40 (48.8) 44 (53.7)  
Yes 39 (46.4) 42 (51.2) 38 (46.3)  
Ever pregnant    0.31 
No 10 (11.9) 14 (17.1) 17 (20.7)  
Yes 74 (88.1) 68 (82.9) 65 (79.3)  
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Table 16 (continued)     
Characteristics 
 Tertile 1 
(<16.46) 
Tertile 2 
(16.47-34.24) 
Tertile 3 
(≥34.25) p 
Number of live births‡    0.93 
1 11 (15.3) 8 (12.3) 9 (14.5)  
2 29 (40.3) 26 (40.0) 28 (45.2)  
≥3 32 (44.4) 31 (47.7) 25 (40.3)  
Age at first full term pregnancy‡    0.32 
<30 61 (84.7) 55 (84.6) 47 (75.8)  
≥30 11(15.3) 10 (15.4) 15 (24.2)  
Ever breastfed >1 month‡    0.07 
No 43 (59.7) 35 (53.9) 25 (40.3)  
Yes 29 (40.3) 30 (46.2) 37 (59.7)  
Ever breast biopsy    0.02 
No 79 (94.1) 68 (82.9) 65 (79.3)  
Yes 5 (6.0) 14 (17.1) 17 (20.7)   
NOTE: BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug.  Percentages 
(%) may not add up to 100% due to rounding.  
*missing n=6 for age at menopause, n=6 for years menopausal, n=1 for age at menarche, 
n=2 for family history of breast cancer, and n=1 for surgical menopause 
†family history of breast cancer in mother of sister 
‡ among parous women 
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Table 17. Mean fatty acid composition in erythrocytes   
Fatty acids (wt. %) mean (SD) 
n-6 PUFAs*  
Total n-6 38.3 (2.6) 
18:2n-6 (LA) 15.8 (2.4) 
20:4n-6 (AA) 16.1 (1.9) 
n-3 PUFAs†  
Total n-3 7.9 (2.1) 
18:3n-3 (ALA) 0.2 (0.1) 
20:5n-3 (EPA) 0.9 (0.4) 
22:6n-3 (DHA) 4.5 (1.5) 
6:3 Ratios  
Total n-6:n-3 5.2 (1.5) 
LA:ALA 72.8 (19.5) 
AA:EPA 21.7 (8.9) 
AA:EPA+DHA 3.3 (1.2) 
NOTE: N=248. Fatty acids are reported as a percentage 
by weight of the total fatty acids (weight percent, 
wt.%). PUFA, polyunsaturated fatty acid;  LA, linoleic 
acid; AA, arachidonic acid; ALA, alpha-linolenic acid; 
EPA, eicosapentaenoic acid; and DHA, 
docosahexaenoic acid 
*18:2n-6+18:n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-
6+22:5n-6 
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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Table 18. Unadjusted and adjusted Spearman correlation coefficients between 
erythrocyte n-6 and n-3 fatty acids and mammographic characteristics  
 Fatty acids (n=248) % breast density dense area nondense area 
N-6 PUFAs    
Total n-6* -0.006 (0.93) 0.001 (0.99) 0.03 (0.69) 
 0.02 (0.75) -0.01 (0.87) -0.04 (0.51) 
    
18:2n-6 (LA) 0.08 (0.22) -0.04 (0.51) -0.17 (0.006) 
 -0.02 (0.78) -0.06 (0.34) -0.08 (0.22) 
    
20:4n-6 (AA) 0.01 (0.85) 0.07 (0.25) 0.08 (0.23) 
 0.08 (0.20) 0.08 (0.22) -0.02 (0.79) 
N-3 PUFAs    
Total n-3† 0.10 (0.11) 0.01 (0.88) -0.18 (0.004) 
 0.02 (0.77) 0.02 (0.77) -0.04 (0.51) 
    
18:3n-3 (ALA) 0.04 (0.52) -0.05 (0.46) -0.12 (0.06) 
 -0.04 (0.55) -0.06 (0.39) -0.02 (0.76) 
    
20:5n-3 (EPA) 0.07 (0.28) -0.04 (0.48) -0.18 (0.004) 
 -0.02 (0.70) -0.04 (0.51) -0.05 (0.45) 
    
22:6n-3 (DHA) 0.10 (0.12) 0.04 (0.57) -0.14 (0.03) 
 0.03 (0.64) 0.05 (0.47) -0.02 (0.80) 
6:3 Ratios    
Total n-6:n-3 -0.09 (0.15) -0.01 (0.91) 0.16 (0.009) 
 -0.01 (0.84) -0.02 (0.78) 0.02 (0.65) 
    
LA:ALA -0.02 (0.75) 0.03 (0.61) 0.07 (0.29) 
 0.02 (0.74) 0.03 (0.63) 0.004 (0.95) 
    
AA:EPA -0.06  (0.32) 0.05 (0.39) 0.19 (0.003) 
 0.04 (0.51) 0.05 (0.40) 0.04 (0.52) 
    
AA:EPA+DHA -0.08 (0.18) 0.003 (0.96) 0.17 (0.008) 
  0.01 (0.88) -0.003 (0.96) 0.01 (0.83) 
NOTE: PUFA, polyunsaturated fatty acid; LA, linoleic acid; AA, arachidonic acid; ALA, alpha-
linolenic acid; EPA, eicosapentaenoic acid; and DHA, docosahexaenoic acid. First line is 
unadjusted estimates.  Partial correlations estimates adjusted for age and BMI, and appear 
immediately below the unadjusted correlations. P between parentheses.   
*18:2n-6+18:n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3  
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6.0 GENERAL DISCUSSION 
Breast cancer incidence rates in the United States are among the highest in the world [1].  
This year alone, it is estimated that approximately 178,480 new cases of invasive and 
62,030 new cases of in situ breast cancer will be diagnosed in women residing in the 
United States [2].  Despite substantial advances in treatment for this disease, breast 
cancer still ranks second in female cancer mortality [2], and therefore, it is important to 
identify modifiable factors associated with this disease.   
One of the most investigated nutritional associations with breast cancer risk is 
dietary fat, yet despite decades of intensive experimental and epidemiological research, 
our understanding on the role of fat consumption in the etiology of breast cancer is 
deficient.  Cross-national and migrant studies of breast cancer rates indicate that dietary 
fat may be partially responsible for the large population differences in breast cancer risk 
[6-8], yet case-control and cohort findings repeatedly produce inconsistent results [29]. It 
has been implicated that type of fat consumed may be more important than total fat 
intake, and if specific fatty acids were found to possess unique breast cancer 
chemopreventive properties it would help to determine the ideal proportions of each type 
of fat to be consumed and potentially reduce the burden of this disease. Yet, in spite of its 
clear public health importance, no consensus exists as to which fats are harmful and 
which fats are beneficial.   
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Research has shown circulating estradiol concentrations and mammographic 
breast density to be strong risk factors for postmenopausal breast cancer [41, 61]. Women 
with the highest levels of estradiol or highest percentage of breast density are at increased 
risk of developing breast cancer [41, 61].  Unlike the majority of other well-established 
risk factors, both circulating estradiol and breast density have been shown to be 
modifiable [270, 278].  Dietary habits that alter circulating estradiol levels and/or 
mammographic breast density may also alter breast cancer risk, although this has yet to 
be proven.  Nonetheless, determining factors that influence these breast cancer risk 
factors may lead to a greater understanding of breast cancer pathogenesis.   
Prostaglandin E2 (PGE2), the metabolic product of omega-6 (n-6) arachidonic 
acid (AA), stimulates biosynthesis of estrogen by upregulation of the enzyme aromatase 
[200].  Consumption of omega-3 (n-3) fatty acids inhibits the synthesis of PGE2 [176, 
179].  Therefore, in theory, a diet rich in n-3 fatty acids and/or low in n-6 fatty acids 
should decrease estradiol production by suppressing PGE2 activation of aromatase.  Such 
an event may ultimately result in a reduction of estrogen dependent breast cancer 
occurrence.   For that reason, we sought to determine the relationship between n-6 and n-
3 fatty acids and two hormonally influenced breast cancer risk factors, specifically, serum 
total estradiol concentrations and percent mammographic breast density.  Given that 
nonsteroidal anti-inflammatory drugs (NSAIDs) also reduce the synthesis of PGE2 [334], 
we further assessed the relationship between current NSAID use and serum total estradiol 
concentrations. NSAID use data was not available at the time of mammogram; therefore, 
the relationship between NSAID use and mammographic density could not accurately be 
assessed.   
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The Mammogram and Masses Study (MAMS), a case-control study on the 
hormonal determinants of breast density, provided a unique opportunity to assess the 
relationship between fatty acids, NSAID use, and modifiable breast cancer risk factors.  
Our first study tested the association between the essential n-6 and n-3 fatty acids in 
erythrocytes and serum total estradiol concentrations. The second study assessed the 
relationship between current NSAID use and serum total estradiol levels. Finally, the 
third study investigated the association between the erythrocyte n-6 and n-3 fatty acids 
and mammographic features.  The three research projects utilized a population of breast 
cancer-free, postmenopausal women not using hormone therapy (HT). We are unaware of 
any studies that have previously reported on any one of these study aims.   
6.1 RESEARCH ARTICLE 1 
The aim of the first research article was to investigate the relationship between 
erythrocyte n-6 and n-3 fatty acids and serum total estradiol concentrations.  Exposure to 
endogenous estrogens has been consistently linked to increased postmenopausal breast 
cancer risk [41]; therefore, lifestyle factors related to reducing a woman’s exposure to 
estrogens may lead to the prevention of breast cancer.  We believe this to be the first 
study to report on the association between fatty acids in biological specimens with 
circulating endogenous estradiol levels.   
The study population consisted of 260 breast cancer free, postmenopausal women 
not using exogenous hormones who were recruited between 2003 and 2005 in Pittsburgh, 
Pennsylvania.  Study results revealed a statistically significant inverse association 
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between total n-3 fatty acids and serum estradiol concentrations (p<0.05).  Further, total 
n-6 fatty acids (p=0.02), the total n-6:n-3 ratio (p=0.06) and the ratio of n-6 arachidonic 
acid (AA) to n-3 fatty acids eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) 
(p<0.01) were positively associated with total estradiol.  These statistically significant 
relationships were only noted among women not reporting current use of NSAIDs.   
Among NSAID users, the ratio of n-6 linolenic acid (LA) to n-3 alpha-linolenic acid 
(ALA) was positively related to estradiol concentrations (p=0.01), and was primarily a 
result of the inverse relationship between ALA and estradiol (p=0.05). Because 
circulating postmenopausal estradiol concentrations are positively related to breast cancer 
risk, our results provide a mechanism through which the essential n-6 and n-3 PUFAs 
may impact breast cancer development.  
6.2 RESEARCH ARTICLE 2 
Research article 2 assessed the relationship between current NSAID use and serum total 
estradiol concentrations in a population of postmenopausal women. Our interest in 
evaluating this association stemmed from our previous finding that n-3 fatty acids were 
inversely related with circulating estradiol levels. Similarly to n-3 fatty acid intake, 
NSAID use decreases the production of PGE2 [334], thus reducing upreguation of 
aromatase and hence biosynthesis of estrogen [200].   Therefore, if it is through PGE2 
inhibition that n-3 fatty acids lower estradiol levels, then we would also expect to observe 
reduced estradiol levels among users of NSAIDs.  Discovering an inverse association 
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between NSAID use and circulating estradiol levels would provide additional support to 
the mechanism proposed by which the n-6 and n-3 fatty acids are related to breast cancer. 
Participants recruited between 2003 and 2005 into the MAMS study who were 
breast cancer free, postmenopausal, and not using exogenous hormones were selected for 
this ancillary study (n=260).  As hypothesized, the geometric mean serum estradiol 
concentration among NSAID users (N=124) was significantly lower than non-users of 
NSAIDs (N=136) (17.8 pmol/L vs. 21.3 pmol/L; p=0.03). Lower estradiol levels were 
noted regardless of how NSAID use was defined (i.e. self-reported current NSAID use on 
questionnaire, verbal reporting of use in past 48 hours, and the agreement between these 
two variables). 
Many studies have assessed the relationship between NSAID use and breast 
cancer [329], but we unaware of any published reports that document the relationship 
between NSAID use and circulating estradiol concentrations.  The detection of lower 
estradiol levels among NSAID users is consistent with the notion that NSAIDs are 
protective against breast cancer, via reducing estrogen exposure.   
6.3 RESEARCH ARTICLE 3 
Research article 3 evaluated the association between the n-6 and n-3 fatty acids in 
erythrocytes and mammographic breast density, a hormonally responsive breast cancer 
risk factor [72].  Breast density is believed to represent cellular division of mammary 
epithelial cells [339], and estrogen has been shown to drive cellular division in breast 
epithelial cells [340].  Therefore dense tissue, as reflected on a mammogram, may 
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represent the stimulatory effect of estrogen on epithelial cell proliferation.  Since n-6 and 
n-3 fatty acids may be capable of altering estrogen synthesis, via influencing PGE2 
production, these fatty acids may also influence breast density.  For instance, consuming 
n-6 fatty acids may increase mammographic breast density by encouraging cellular 
proliferation via increasing estrogen production.  On the contrary, intake of n-3 fatty 
acids may result in lower breast density, as estrogen synthesis is not stimulated and 
cellular division not amplified. To test the hypotheses that erythrocyte n-6 fatty acid 
content is positively related and erythrocyte n-3 fatty acid content is inversely related to 
mammographic breast density we undertook an observational study in 248 breast cancer-
free women enrolled in the MAMS study.  All women selected for this ancillary study 
were postmenopausal, reported no use of HT within 3 months of study entry, and had a 
mammographic exam within 120 days (the lifetime of an erythrocyte) of blood draw.   
Contrary to our hypotheses, the results of this study do not support the premise 
that n-6 and n-3 fatty acids influence mammographic breast density.  No statistically 
significant relationship was found between any of the fatty acids measures (n-6 fatty 
acids, n-3 fatty acids, and 6:3 ratios) and measurements of breast density (percent density 
or dense breast area).  These findings suggest that if n-6 and n-3 fatty acids influence 
breast cancer development then the effect may not be through affecting mammographic 
breast density.  Future studies are needed to gain a better understanding of the true 
relationship between the essential fatty acids and mammographic breast features. 
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6.4 SUMMARY  
In summary, we attempted to clarify the relationship between the n-6 and n-3 fatty acids 
and NSAIDs with two well-established breast cancer risk factors, specifically, serum total 
estradiol concentrations and mammographic breast density. As hypothesized, we 
observed a positive relationship between n-6 fatty acids and serum estradiol 
concentrations and inverse associations between both the n-3 fatty acids and NSAID use 
and serum estradiol. These findings are consistent with extensive experimental data and a 
growing body of epidemiological evidence.  Interestingly, the majority of associations 
observed between the essential fatty acids and estradiol concentrations were observed in 
NSAID nonusers, but not among current NSAID users. Contrary to our hypotheses, we 
did not observe an association between any one of the fatty acid measures with 
mammographic density (percentage or absolute). Therefore, if the n-6 and n-3 fatty acids 
influence breast cancer risk, it may not be through affecting breast density.  To our 
knowledge, none of the aforementioned relationships have previously been explored.  
6.5 STRENGTHS AND LIMITATIONS 
Some important limitations of this study must be acknowledged.  The primary weakness 
of this study is that it is cross-sectional in nature and does not allow us
 
to determine 
temporal associations. The use of multiple measurements of fatty acids, NSAID use, 
serum estradiol and mammographic breast density over time might better characterize 
these women.  Our biological samples were stored at -70°C, and reliability of erythrocyte 
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fatty acids at this temperature has only been reported in one study.  Correlation was high 
for all PUFAs (r >0.90), but analyses were reported only after a 12 month time frame 
[342]. Some of our samples were stored for longer than one year before analysis (8 
months-25 months) and we are unsure of the effects of longer storage at -70°C on the 
individual fatty acid levels; however, storage at -80°C for up to 48 months does not result 
in significant decreases in any of the n-6 or n-3 PUFAs [343]. A final weakness of this 
study is the homogeneity of the study population, thus potentially limiting the 
generalizibility of the study findings.  
Regardless of the aforementioned limitations, study strengths should also be 
noted. Strengths of our study include the use of standardized instruments; reproducible 
measures of fatty acids, total estradiol and mammographic breast density; assessment of 
NSAID use on the same day as blood draw and; the use of a biochemical marker of 
dietary intake. Above all, we believe no other epidemiological study has previously 
explored these study aims. 
6.6 FUTURE DIRECTIONS 
The findings from this project, could spawn research in multiple areas with potential 
research aims including, but not limited to the following: 1) establish the relationship 
between NSAID use and breast density; 2) investigate the relationships between fatty 
acids and NSAID use on modifiable breast cancer risk factors (estradiol and breast 
density) in premenopausal women and minority populations; 3) assess the relationship 
between circulating PGE2 levels and both estradiol concentrations and mammographic 
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breast density; 4) determine if an interaction exists between the n-6 and n-3 PUFAs, and 
genetic polymorphisms in the COX-2 and CYP19 (aromatase) genes with serum estradiol 
and breast density; 5) determine if  an interaction exists between NSAID use and genetic 
polymorphisms in the COX-2 gene with serum estradiol and breast density;  6) test the 
association between fatty acids in breast adipose tissue, a long-term marker of fatty acid 
intake, and mammographic breast density and; 7) conduct a clinical trial assessing fish oil 
supplementation and NSAID use on modifiable breast cancer risk factors (estradiol and 
breast density). 
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7.0 PUBLIC HEALTH SIGNFICANCE  
The public health burden of breast cancer is substantial, with approximately 178,480 
incident invasive cases and 40,460 deaths from breast cancer expected to occur among 
women in 2007.  Age is a major determinant of breast cancer and with a rapidly aging 
population the affliction of breast cancer will likely worsen. Therefore, primary 
prevention of this disease is a much desired and sought after public health goal. 
The relationships between circulating levels of estradiol, mammographic density, 
and breast cancer risk are greatly documented; hence, agents capable of altering these 
well-established risk factors could have a substantial impact on public health.  In this 
body of research, we observed a positive relationship between erythrocyte n-6 fatty acids 
and serum estradiol.  We further observed inverse associations between n-3 fatty acids 
and NSAID use with circulating estradiol concentrations.  To date, there has been no 
epidemiological study to investigate these relationships and the discovery of modifiable 
behaviors that favorably alter breast cancer risk factors is needed. If confirmed, these 
findings could aid in the development of chemopreventive guidelines, and ultimately 
prevent the development of estrogen-dependent breast cancer. 
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APPENDIX A: ERYTHROCYTE OMEGA-6 AND OMEGA-3 FATTY ACIDS 
AND POSTMENOPAUSAL SERUM ESTRADIOL ADDITIONAL ANALYSES 
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Figure A6. Distribution of erythrocyte total n-6 fatty acids in the study population.  
 
In this boxplot, the edges of the box correspond to 25th and 75th percentiles.  The 
horizontal line in the middle of the box corresponds to the median. The vertical bars 
above and below the box correspond to percentiles 10 and 90.  
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Figure A7. Distribution of erythrocyte LA in the study population. 
 
In this boxplot, the edges of the box correspond to 25th and 75th percentiles.  The 
horizontal line in the middle of the box corresponds to the median. The vertical bars 
above and below the box correspond to percentiles 10 and 90. Open circles beyond the 
box correspond to outliers (values between 1.5 and 3 box lengths from the upper or lower 
edge of the box). 
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Figure A8. Distribution of erythrocyte AA in the study population. 
 
In this boxplot, the edges of the box correspond to 25th and 75th percentiles.  The 
horizontal line in the middle of the box corresponds to the median. The vertical bars 
above and below the box correspond to percentiles 10 and 90. Open circles beyond the 
box correspond to outliers (values between 1.5 and 3 box lengths from the upper or lower 
edge of the box). 
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Figure A9. Distribution of erythcoyte total n-3 fatty acids in the study population. 
 
In this boxplot, the edges of the box correspond to 25th and 75th percentiles.  The 
horizontal line in the middle of the box corresponds to the median. The vertical bars 
above and below the box correspond to percentiles 10 and 90. Open circles beyond the 
box correspond to outliers (values between 1.5 and 3 box lengths from the upper or lower 
edge of the box). 
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Figure A10. Distribution of erythrocyte ALA in the study population. 
 
In this boxplot, the edges of the box correspond to 25th and 75th percentiles.  The 
horizontal line in the middle of the box corresponds to the median. The vertical bars 
above and below the box correspond to percentiles 10 and 90. Open circles beyond the 
box correspond to outliers (values between 1.5 and 3 box lengths from the upper or lower 
edge of the box) and stars correspond to extremes (values beyond 3 box lengths from 
the edge of the box). 
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Figure A11. Distribution of erythrocyte EPA in the study population. 
In this boxplot, the edges of the box correspond to 25th and 75th percentiles.  The 
horizontal line in the middle of the box corresponds to the median. The vertical bars 
above and below the box correspond to percentiles 10 and 90. Open circles beyond the 
box correspond to outliers (values between 1.5 and 3 box lengths from the upper or lower 
edge of the box) and stars correspond to extremes (values beyond 3 box lengths from 
the edge of the box). 
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Figure A12. Distribution of erythrocyte DHA in the study population. 
 
In this boxplot, the edges of the box correspond to 25th and 75th percentiles.  The 
horizontal line in the middle of the box corresponds to the median. The vertical bars 
above and below the box correspond to percentiles 10 and 90. Open circles beyond the 
box correspond to outliers (values between 1.5 and 3 box lengths from the upper or lower 
edge of the box). 
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Figure A13. Distribution of the erythrocyte total 6:3 ratio in the study population. 
 
In this boxplot, the edges of the box correspond to 25th and 75th percentiles.  The 
horizontal line in the middle of the box corresponds to the median. The vertical bars 
above and below the box correspond to percentiles 10 and 90. Open circles beyond the 
box correspond to outliers (values between 1.5 and 3 box lengths from the upper or lower 
edge of the box). 
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Figure A14. Distrubution of the erythrocyte LA:ALA ratio in the study population. 
 
In this boxplot, the edges of the box correspond to 25th and 75th percentiles.  The 
horizontal line in the middle of the box corresponds to the median. The vertical bars 
above and below the box correspond to percentiles 10 and 90. Open circles beyond the 
box correspond to outliers (values between 1.5 and 3 box lengths from the upper or lower 
edge of the box). 
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Figure A15. Distribution of the erythrocyte AA:EPA ratio in the study population. 
 
In this boxplot, the edges of the box correspond to 25th and 75th percentiles.  The 
horizontal line in the middle of the box corresponds to the median. The vertical bars 
above and below the box correspond to percentiles 10 and 90. Open circles beyond the 
box correspond to outliers (values between 1.5 and 3 box lengths from the upper or lower 
edge of the box). 
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Figure A16. Distribution of the erythrocyte AA:EPA+DHA ratio in the study 
population. 
 
In this boxplot, the edges of the box correspond to 25th and 75th percentiles.  The 
horizontal line in the middle of the box corresponds to the median. The vertical bars 
above and below the box correspond to percentiles 10 and 90. Open circles beyond the 
box correspond to outliers (values between 1.5 and 3 box lengths from the upper or lower 
edge of the box). 
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Figure A17. Distribution of erythrocyte individual n-6 and n-3 fatty acids in the 
study population. 
 
In this boxplot, the edges of the box correspond to 25th and 75th percentiles.  The 
horizontal line in the middle of the box corresponds to the median. The vertical bars 
above and below the box correspond to percentiles 10 and 90. Open circles beyond the 
box correspond to outliers (values between 1.5 and 3 box lengths from the upper or lower 
edge of the box) and stars correspond to extremes (values beyond 3 box lengths from 
the edge of the box). 
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Table A19. Coefficients of variation for erythrocyte n-6 and n-3 fatty acids   
Fatty Acid (wt. %) Mean (SD) Coefficient of Variation (%) 
n-6 PUFAs    
    Total n-6 PUFAs* 38.3 (2.6) 1.7 
    18:2n-6 (LA) 15.8 (2.4) 4.6 
    20:4n-6 (AA) 16.0 (2.0) 3.4 
n-3 PUFAs    
    Total n-3 PUFAs† 7.9 (2.0) 5.3 
    18:3n-3 (ALA) 0.2 (0.1) 15.2 
    20:5n-3 (EPA) 0.9 (0.4) 5.3 
    22:6n-3 (DHA) 4.5 (1.5) 7.5 
6:3 Ratios   
    Total n-6:n-3 5.2 (1.5) 5.2 
    LA:ALA 72.7 (19.3) 11.1 
    AA:EPA 21.8 (9.0) 4.5 
    AA:EPA+DHA 3.3 (1.2) 5.7 
NOTE: Fatty acids are reported as a percentage by weight of the total fatty acids (weight 
percent, wt. %). PUFA, polyunsaturated fatty acid;  LA, linoleic acid; AA, arachidonic 
acid; ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; and DHA, 
docosahexaenoic acid 
*18:2n-6+18:3n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+ 22:5n-6 
†
18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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Table A20. Spearman correlation coefficients among erythrocyte n-6 and n-3 fatty acids   
  
18:3 
n-6 
20:2 
n-6 
20:3 
n-6 
20:4 
n-6 
22:4 
n-6 
22:5 
n-6 
18:3 
n-3 
20:4 
n-3 
20:5 
n-3 
22:5 
n-3 
22:6 
n-3 
Total 
 n-6* 
Total  
n-3
†
 
18:2n-6 0.16 0.29 0.14 -0.45 -0.36 -0.25 0.60 0.10 -0.06 -0.34 -0.24 0.46 -0.24 
18:3n-6  -0.27 0.17 -0.10 -0.15 -0.08 0.28 0.06 0.03 -0.21 -0.29 -0.25 -0.06 
20:2n-6   0.05 -0.22 0.01 -0.01 0.16 0.16 -0.17 -0.12 -0.05 0.12 -0.08 
20:3n-6    -0.27 -0.01 0.19 0.04 0.47 -0.19 -0.10 -0.31 0.09 -0.28 
20:4n-6      0.51 0.37 -0.38 -0.39 -0.15 0.09 -0.08 0.45 -0.09 
22:4n-6      0.72 -0.36 -0.32 -0.51 -0.01 -0.44 0.42 -0.45 
22:5n-6       -0.31 -0.19 -0.70 -0.22 -0.54 0.39 -0.59 
18:3n-3         0.31 0.17 -0.09 -0.10 0.15 -0.01 
20:4n-3         0.21 0.02 0.06 -0.25 0.13 
20:5n-3           0.55 0.70 -0.42 0.82 
22:5n-3           0.38 -0.29 0.57 
22:6n-3             -0.49 0.96 
Total  n-6*             -0.51 
NOTE:  Correlations coefficients calculated on 260 postmenopausal participants in the Mammograms and 
Masses Study (MAMS) 
*18:2n-6+18:3n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
†
18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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Table A21. Relationship between erythrocyte n-6 and n-3 fatty acids and family 
history of breast cancer  
 
Family history of  
breast cancer  
Fatty Acids (wt. %) 
yes 
(n=34) 
no 
(n=224) p 
Total n-6 PUFA* 38.4 (2.4) 38.3 (2.7) 0.83 
18:2n-6 (LA) 15.7 (2.3) 15.8 (2.5) 0.78 
20:4n-6 (AA) 16.1 (1.9) 16.0 (2.0) 0.90 
Total n-3 PUFA† 8.0 (1.7) 7.9 (2.1) 0.37 
18:3n-3 (ALA) 0.3 (0.1) 0.2 (0.1) 0.30 
20:5n-3 (EPA) 0.9 (0.3) 0.9 (0.5) 0.16 
22:6n-3 (DHA) 4.5 (1.3) 4.5 (1.5) 0.83 
Total n-6:n-3 5.0 (1.2) 5.3 (1.6) 0.44 
LA:ALA 68.1 (16.1) 73.4 (19.8) 0.12 
AA:EPA 20.0 (7.7) 22.1 (9.1) 0.20 
AA:EPA+DHA 3.2 (1.0) 3.3 (1.2) 0.63 
NOTE: Data are expressed as mean (SD). Fatty acids are reported as a percentage by 
weight of the total fatty acids (weight percent, wt. %). PUFA, polyunsaturated fatty 
acid; LA, linoleic acid; AA, arachidonic acid; ALA, alpha-linolenic acid; EPA, 
eicosapentaenoic acid; DHA, docosahexaenoic acid 
*18:2n-6+18:3n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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Table A22. Relationship between erythrocyte n-6 and n-3 fatty acids and 
postmenopausal hormone therapy use 
 Ever hormone therapy use  
Fatty Acids (wt. %) 
yes 
(n=160) 
no 
(n=100) p 
Total n-6 PUFA* 38.2 (2.7) 38.4 (2.6) 0.63 
18:2n-6 (LA) 15.9 (2.5) 15.6 (2.3) 0.36 
20:4n-6 (AA) 15.9 (2.0) 16.3 (2.0) 0.20 
Total n-3 PUFA† 7.9 (2.1) 7.8 (1.9) 0.74 
18:3n-3 (ALA) 0.2 (0.1) 0.2 (0.1) 0.27 
20:5n-3 (EPA) 0.9 (0.4) 0.9 (0.4) 0.35 
22:6n-3 (DHA) 4.5 (1.6) 4.5 (1.5) 0.69 
Total n-6:n-3 5.2 (1.5) 5.3 (1.5) 0.86 
LA:ALA 71.8 (19.0) 74.0 (20.0) 0.47 
AA:EPA 21.2 (8.9) 22.8 (9.0) 0.13 
AA:EPA+DHA 3.3 (1.1) 3.4 (1.3) 0.71 
NOTE: Data are expressed as mean (SD). Fatty acids are reported as a percentage by 
weight of the total fatty acids (weight percent, wt. %). PUFA, polyunsaturated fatty 
acid; LA, linoleic acid; AA, arachidonic acid; ALA, alpha-linolenic acid; EPA, 
eicosapentaenoic acid; DHA, docosahexaenoic acid 
*18:2n-6+18:3n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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Table A23. Relationship between erythrocyte n-6 and n-3 fatty acids and current 
smoking status 
 Current smoker  
Fatty Acids (wt. %) 
yes 
(n=15) 
no 
(n=245) p 
Total n-6 PUFA* 39.9 (2.1) 38.2 (2.6) 0.02 
18:2n-6 (LA) 16.2 (1.8) 15.8 (2.5) 0.36 
20:4n-6 (AA) 16.6 (2.5) 16.0 (2.0) 0.29 
Total n-3 PUFA† 6.5 (1.4) 8.0 (2.1) 0.007 
18:3n-3 (ALA) 0.2 (0.1) 0.2 (0.1) 0.64 
20:5n-3 (EPA) 0.6 (0.2) 0.9 (0.4) 0.006 
22:6n-3 (DHA) 3.6 (1.2) 4.6 (1.5) 0.02 
Total n-6:n-3 6.5 (1.8) 5.2 (1.5) 0.005 
LA:ALA 81.3 (23.7) 72.1 (19.0) 0.16 
AA:EPA 29.1 (9.0) 21.4 (8.8) 0.003 
AA:EPA+DHA 4.3 (1.5) 3.3 (1.1) 0.004 
NOTE: Data are expressed as mean (SD). Fatty acids are reported as a percentage by 
weight of the total fatty acids (weight percent, wt. %). PUFA, polyunsaturated fatty 
acid; LA, linoleic acid; AA, arachidonic acid; ALA, alpha-linolenic acid; EPA, 
eicosapentaenoic acid; DHA, docosahexaenoic acid 
*18:2n-6+18:3n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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Table A24. Relationship between erythrocyte n-6 and n-3 fatty acids and race  
 Race  
Fatty Acids (wt. %) 
white  
(n=242) 
non-white 
(n=18) p 
Total n-6 PUFA* 38.2 (2.6) 39.6 (2.5) 0.03 
18:2n-6 (LA) 15.8 (2.5) 16.0 (2.0) 0.54 
20:4n-6 (AA) 15.9 (1.9) 17.1 (2.7) 0.08 
Total n-3 PUFA† 7.8 (2.0) 8.4 (2.5) 0.39 
18:3n-3 (ALA) 0.2 (0.1) 0.3 (0.1) 0.99 
20:5n-3 (EPA) 0.9 (0.4) 0.9 (0.7) 0.53 
22:6n-3 (DHA) 4.5 (1.5) 5.0 (1.6) 0.17 
Total n-6:n-3 5.2 (1.5) 5.1 (1.4) 0.80 
LA:ALA 72.6 (18.8) 73.8 (26.3) 0.97 
AA:EPA 21.6 (8.7) 24.9 (11.5) 0.22 
AA:EPA+DHA 3.3 (1.2) 3.2 (1.1) 0.86 
NOTE: Data are expressed as mean (SD). Fatty acids are reported as a percentage 
by weight of the total fatty acids (weight percent, wt. %). PUFA, polyunsaturated 
fatty acid; LA, linoleic acid; AA, arachidonic acid; ALA, alpha-linolenic acid; 
EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid 
*18:2n-6+18:3n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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Table A25. Relationship between erythrocyte n-6 and n-3 fatty acids and alcohol 
intake 
 Past year alcohol intake  
Fatty Acids (wt. %) 
none 
(n=188) 
<12g/day 
(n=46) 
≥12g/day 
(n=26) p 
Total n-6 PUFA* 38.5 (2.6) 38.1 (2.3) 37.0 (3.0) 0.05 
18:2n-6 (LA) 15.6 (2.5) 16.7 (2.1) 15.9 (2.2) 0.01 
20:4n-6 (AA) 16.3 (2.0) 15.4 (1.8) 15.2 (1.9) 0.007 
Total n-3 PUFA† 7.7 (2.0) 8.2 (2.2) 8.5 (2.0) 0.07 
18:3n-3 (ALA) 0.2 (0.1) 0.2 (0.1) 0.3 (0.1) 0.17 
20:5n-3 (EPA) 0.8 (0.4) 1.0 (0.5) 1.1 (0.5) <0.001 
22:6n-3 (DHA) 4.4 (1.5) 4.7 (1.6) 4.8 (1.4) 0.22 
Total n-6:n-3 5.4 (1.5) 5.0 (1.5) 4.6 (1.3) 0.04 
LA:ALA 73.2 (19.2) 72.5 (19.2) 69.0 (20.8) 0.73 
AA:EPA 23.3 (8.9) 18.9 (8.4) 16.3 (6.7) <0.0001 
AA:EPA+DHA 3.5 (1.2) 3.0 (1.1) 2.8 (1.0) 0.01 
NOTE: Data are expressed as mean (SD). Fatty acids are reported as a percentage by 
weight of the total fatty acids (weight percent, wt. %).  PUFA, polyunsaturated fatty 
acid; LA, linoleic acid; AA, arachidonic acid; ALA, alpha-linolenic acid; EPA, 
eicosapentaenoic acid; DHA, docosahexaenoic acid 
*18:2n-6+18:3n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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Table A26. Relationship between erythrocyte n-6 and n-3 fatty acids and age 
Fatty Acids (wt. %) r p 
Total n-6 PUFA* -0.24 0.0001 
18:2n-6 (LA) -0.25 <0.0001 
20:4n-6 (AA) 0.05 0.38 
Total n-3 PUFA† 0.19 0.003 
18:3n-3 (ALA) -0.10 0.10 
20:5n-3 (EPA) 0.12 0.06 
22:6n-3 (DHA) 0.19 0.002 
Total n-6:n-3 -0.22 0.0003 
LA:ALA -0.05 0.42 
AA:EPA -0.10 0.12 
AA:EPA+DHA -0.16 0.01 
NOTE: Fatty acids are reported as a percentage by weight of the total fatty 
acids (weight percent, wt. %). r=Spearman correlation coefficient. PUFA, 
polyunsaturated fatty acid; LA, linoleic acid; AA, arachidonic acid; ALA, 
alpha-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic 
acid 
*18:2n-6+18:3n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
 
 147 
 
Table A27. Relationship between erythrocyte n-6 and n-3 fatty acids and BMI 
Fatty Acids (wt. %) r p 
Total n-6 PUFA* 0.12 0.05 
18:2n-6 (LA) -0.11 0.08 
20:4n-6 (AA) 0.10 0.12 
Total n-3 PUFA† -0.24  <0.0001 
18:3n-3 (ALA) -0.14 0.03 
20:5n-3 (EPA) -0.21 0.0005 
22:6n-3 (DHA) -0.21 0.0006 
Total n-6:n-3 0.24 0.0001 
LA:ALA 0.12 0.05 
AA:EPA 0.22 0.0003 
AA:EPA+DHA 0.24 0.0001 
NOTE: Fatty acids are reported as a percentage by weight of the total fatty 
acids (weight percent, wt. %). r=Spearman correlation coefficient. BMI, body 
mass index; PUFA, polyunsaturated fatty acid; LA, linoleic acid; AA, 
arachidonic acid; ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; 
DHA, docosahexaenoic acid 
*18:2n-6+18:3n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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Table A28. Relationship between erythrocyte n-6 and n-3 fatty acids and years since 
onset of menopause 
Fatty Acids (wt. %) r p 
Total n-6 PUFA* -0.20 0.001 
18:2n-6 (LA) -0.22 0.0004 
20:4n-6 (AA) 0.04 0.50 
Total n-3 PUFA† 0.17 0.006 
18:3n-3 (ALA) -0.09 0.14 
20:5n-3 (EPA) 0.09 0.13 
22:6n-3 (DHA) 0.18 0.004 
Total n-6:n-3 -0.20 0.002 
LA:ALA -0.03 0.65 
AA:EPA -0.08 0.19 
AA:EPA+DHA -0.15 0.02 
NOTE: Fatty acids are reported as a percentage by weight of the total fatty acids 
(weight percent, wt. %). r=Spearman correlation coefficient. PUFA, polyunsaturated 
fatty acid; LA, linoleic acid; AA, arachidonic acid; ALA, alpha-linolenic acid; EPA, 
eicosapentaenoic acid; DHA, docosahexaenoic acid 
*18:2n-6+18:3n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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Table A29. Mean fatty acid composition in erythrocytes according to NSAID use 
 Mean fatty acid (SD)  
Fatty Acids (wt. %) 
NSAID non-users 
(N=136) 
NSAID users 
(N=124) p 
Total n-6 PUFA* 38.3 (2.8) 38.4 (2.5) 0.79 
18:2n-6 (LA) 16.0 (2.5) 15.6 (2.4) 0.27 
20:4n-6 (AA) 15.8 (2.1) 16.2 (1.8) 0.11 
Total n-3 PUFA† 7.8 (2.0) 8.0 (2.1) 0.51 
18:3n-3 (ALA) 0.3 (0.1) 0.2 (0.1) 0.04 
20:5n-3 (EPA) 0.9 (0.4) 0.9 (0.5) 0.26 
22:6n-3 (DHA) 4.5 (1.5) 4.5 (1.5) 0.98 
Total n-6:n-3 5.3 (1.5) 5.2 (1.5) 0.73 
LA:ALA 70.6 (19.1) 75.0 (19.4) 0.07 
AA:EPA 22.2 (9.1) 21.4 (8.9) 0.46 
AA:EPA+DHA 3.3 (1.2) 3.4 (1.2) 0.65 
NOTE: Data are expressed as mean (SD). Fatty acids are reported as a percentage by 
weight of the total fatty acids (weight percent, wt. %).  NSAID, nonsteroidal anti-
inflammatory drug; PUFA, polyunsaturated fatty acid; LA, linoleic acid; AA, 
arachidonic acid; ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; DHA, 
docosahexaenoic acid 
*18:2n-6+18:3n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
 
 150 
 
Table A30. Spearman correlation coefficients between n-6 and n-3 fatty acids in 
erythrocytes and serum estradiol concentrations 
 
NSAID non-users  
(N=136) 
NSAID users  
(N=124) 
 Fatty acids (wt. %) r p r p 
n-6 PUFAs      
    Total n-6 PUFAs* 0.27 0.001 0.04 0.67 
    18:2n-6 (LA) -0.04 0.65 -0.13 0.14 
    20:4n-6 (AA) 0.18 0.04 0.11 0.21 
n-3 PUFAs      
    Total n-3 PUFAs† -0.25 0.003 -0.18 0.04 
    18:3n-3 (ALA) -0.14 0.10 -0.24 0.01 
    20:5n-3 (EPA) -0.22 0.01 -0.22 0.01 
    22:6n-3 (DHA) -0.22 0.009 -0.11 0.22 
6:3 Ratios     
    Total n-6:n-3 0.27 0.001 0.18 0.05 
    LA:ALA 0.16 0.07 0.23 0.01 
    AA:EPA 0.24 0.004 0.24 0.01 
    AA:EPA+DHA 0.28 0.0008 0.16 0.07 
NOTE:). Fatty acids are reported as a percentage by weight of the total fatty acids 
(weight percent, wt. %).  NSAID, nonsteroidal anti-inflammatory drug; PUFA, 
polyunsaturated fatty acid; LA, linoleic acid; AA, arachidonic acid; ALA, alpha-
linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid 
*18:2n-6+18:3n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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Table A31. Correlations between fatty acids and estradiol  
 Serum estradiol (pmol/L)   
Fatty Acid (wt. %) r p 
14:0 -0.05 0.43 
15:0 0.14 0.03 
16:0 -0.05 0.45 
17:0 -0.01 0.89 
18:0 0.07 0.24 
16:1t -0.01 0.82 
18:1 t-1 -0.09 0.13 
18:1 t-2 0.02 0.74 
18:1 t-3 0.02 0.80 
18:1 t-4 -0.02 0.79 
18:1 t-5 -0.09 0.14 
18:2 tt -0.04 0.53 
16:1n7c -0.03 0.66 
18:1n9c -0.05 0.41 
18:1n7c -0.11 0.08 
20:1n9 0.10 0.11 
24:1n9 0.12 0.05 
Note: Fatty acids are reported as a percentage by weight 
of the total fatty acids (weight percent, wt. %). r= 
Spearman correlation coefficient. Adjusted for age 
(continuous) and BMI (continuous) 
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Figure A18. Geometric mean serum estradiol concentrations (pmol/L) by tertile of 
the AA:EPA+DHA ratio according to NSAID use  
 
NOTE:  AA:EPA+DHA= Arachidonic acid to Eicosapentaenoic acid+Docosahexaenoic 
acid ratio. A log transformation was applied to estradiol concentrations.  Adjusted for age 
(continuous), BMI (continuous), years menopausal (continuous), alcohol intake (none, 
<12g/day, ≥12g/day) and current smoker (yes vs. no).  Geometric means (95% CI) of 
estradiol for increasing tertile of the AA:EPA+DHA ratio among participants not taking 
NSAIDs [17.7 (14.8, 21.1); 21.5 (17.8, 26.0); and 24.9 (20.6, 20.0)]. Geometric means 
(95% CI) of estradiol for increasing tertile of the AA:EPA+DHA ratio among participants 
taking NSAIDs [19.9 (15.7, 25.5); 16.2 (13.2, 20.0); and 18.1 (14.5, 22.7)].   
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Figure A19. Geometric mean serum estradiol concentrations (pmol/L) by tertile of 
the LA:ALA ratio according to NSAID use  
 
NOTE: LA:ALA=linoleic acid to alpha-linolenic acid ratio. log transformation was 
applied to estradiol concentrations. Adjusted for age (continuous), BMI (continuous), 
years menopausal (continuous), alcohol intake (none, <12g/day, ≥12g/day) and current 
smoker (yes vs. no).  Geometric means (95% CI) of estradiol for increasing tertile of 
the LA:ALA ratio among participants not taking NSAIDs [20.4 (17.0, 24.3); 20.5 (17.0, 
24.7); and 22.4 (18.2, 27.4)].  Geometric means (95% CI) of estradiol for increasing 
tertile of the AA:EPA+DHA ratio among participants taking NSAIDs [14.2 (11.3, 17.9); 
18.1 (14.5, 22.5); and 21.1 (17.3, 25.8)].   
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Table A32. Spearman correlation coefficients between erythroyte n-6 and n-3 fatty 
acids and serum estradiol concentrations (pmol/L) including 9 participants with 
estradiol levels >150pmol/L 
 
 
Fatty Acid (wt. %) r p 
n-6 PUFAs    
  Total n-6 PUFAs* 0.15 0.01 
  18:2n-6 (LA) -0.06 0.35 
  20:4n-6 (AA) 0.13 0.03 
n-3 PUFAs    
  Total n-3 PUFAs† -0.21 0.0004 
  18:3n-3 (ALA) -0.18 0.003 
  20:5n-3 (EPA) -0.23 0.002 
  22:6n-3 (DHA) -0.17 0.007 
6:3 Ratios   
  Total n-6:n-3 0.22 0.0003 
  LA:ALA 0.19 0.002 
  AA:EPA 0.24 <0.0001 
  AA:EPA+DHA 0.21   0.0005 
NOTE: N=269. Fatty acids are reported as a percentage by weight of the total fatty acids 
(weight percent, wt. %).  PUFA, polyunsaturated fatty acid;  LA, linoleic acid;  AA, 
arachidonic acid; ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; and DHA, 
docosahexaenoic acid 
*18:2n-6+18:3n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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APPENDIX B: NSAID USE AND SERUM TOTAL ESTRADIOL IN 
POSTMENOPAUSAL WOMEN ADDITIONAL ANALYSES 
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Table B33. Distribution of selected characteristics by categories of NSAID use among postmenopausal women  
 Past 48 hour use   Consistent use   
Characteristic 
User 
(N=140) 
Non-user 
(N=120) p 
User 
(N=100) 
Non-user 
(N=96) p 
Age at blood draw (years), mean (SD) 63.2 (8.6) 62.3 ( 8.1) 0.38 62.3 (8.1) 61.9 (8.1) 0.53 
BMI (kg/m2), mean (SD) 29.3 (6.4) 27.5 (5.4 0.03 29.2 (6.3) 27.8 (5.7) 0.13 
Age at menopause (years), mean (SD)* 48.8 (4.5) 48.6 (5.7) 0.73 48.5 (4.6) 48.3 (6.1) 0.65 
Years menopausal, mean (SD)* 14.4 (9.7) 13.7 (10.4) 0.37 14.0 (10.0) 13.6 (10.7) 0.55 
Surgical menopause, %*   0.23   0.26 
No  90.7 85.8  88.9 83.3  
Yes 9.4 14.2  11.1 16.7  
Age at menarche, %*   0.56   0.63 
<12 years 20.1 16.7  18.0 14.6  
12-13 years 57.6 55.8  62.0 60.4  
≥14 years 22.3 27.5  20.0 25.0  
Race, %   0.22   0.06 
White 95.0 90.8  96.0 88.5  
Non-white 5.0 9.2  4.0 11.5  
Family history of breast cancer, %*†   0.16   0.41 
No  84.1 90.0  85.7 89.6  
Yes 15.9 10.0  14.3 10.4  
Prior hormone therapy use, %   0.83   0.82 
No  37.9 39.2  37.0 38.5  
Yes 62.1 60.8  63.0 61.5  
Previous breast biopsy, %   1.00   0.90 
No  85.0 85.0  85.0 84.4  
Yes 15.0 15.0  15.0 15.6  
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Table B33 (continued)     
 Past 48 hour use   Consistent use   
Characteristic 
User 
(N=140) 
Non-user 
(N=120) p 
User 
(N=100) 
Non-user 
(N=96) p 
Regular alcohol intake in past year, %   0.76   0.28 
None 70.7 74.2  68.0 78.1  
< 12 g/day 19.3 15.8  22.0 14.6  
≥ 12 g/day 10.0 10.0  10.0 7.3  
Smoking status, %   0.54   0.91 
Never  61.4 60.0  63.0 63.5  
Former 34.3 32.5  32.0 30.2  
Current 4.3 7.5  5.0 6.3  
Parous,  %   0.33   0.38 
No  21.4 16.7  25.0 19.8  
Yes 78.6 83.3  75.0 80.2  
Age at first full-term pregnancy,  % ‡   0.39   0.60 
< 30 years 83.6 79.0  81.3 77.9  
≥ 30 years 16.4 21.0  18.7 22.1  
Ever breast fed for > 1month,  % ‡   0.32   0.33 
No  49.1 56.0  44.0 52.0  
Yes 50.9 44.0   56.0 48.1   
NOTE: BMI=body mass index; NSAID=nonsteroidal anti-inflammatory drug. Percentages’s may not add up to 100% due to rounding 
*missing  n=7 for age at menopause; n=7  for years menopausal; n=1 for surgical menopause; n =1 for age at menarche;  n=2 for 
family history of breast cancer  
† family history of breast cancer in mother or sister      
‡ among parous women       
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Table B34. Geometric mean estradiol concentration (95% confidence interval) according to NSAID use, excluding participants 
in non-user group that reported taking acetaminophen and/or prescription narcotic analgesics at blood draw 
 Serum estradiol concentrations (pmol/L) 
Participants (n=248) Model 1* p Model 2†  p Model 3‡ p 
Primary exposure variable       
  Current use   0.11  0.03  0.03 
     NSAID Non-user (N=124) 21.1 (18.4, 24.2)  21.3 (19.0, 23.9)  21.2 (18.9, 23.9)  
     NSAID User (N=124) 18.0 (15.7, 20.7)   17.8 (15.9, 20.0)   17.7 (15.7, 19.9)   
       
Constructed exposure variable       
  Consistent  use   0.50  0.05  0.04 
     NSAID Non-user (N=88) 19.9 (16.9, 23.5)  21.1 (18.4, 24.1)  21.1 (18.4, 24.1)  
     NSAID User (N=100) 18.4 (15.8, 21.5)  17.5  (15.5, 19.9)  17.2  (15.1, 19.6)  
NOTE: BMI=body mass index; NSAID=nonsteroidal anti-inflammatory drug.  Current use:  Based on participant’s medication list. Past 48 
hour use:  Participant’s verbal response to the question, “Have you taken an aspirin or other anti-inflammatory drug in the past 48 hours?”  
Consistent NSAID use:  The agreement between current NSAID and past 48 hours use.   
*Unadjusted model 
†Adjusted for age at blood draw (continuous) and BMI(continuous) 
‡ Missing N=7; Adjusted for age at blood draw (continuous), BMI (continuous), race (white, nonwhite), years menopausal (continuous), 
and current alcohol intake (none, <12 g/day, ≥12 g/day, indicator variable) 
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Table B35. Geometric mean estradiol concentration (95% confidence interval) according to NSAID use including 9 
participants with estradiol levels >150pmol/L 
 
 
Serum estradiol concentrations (pmol/L) 
Participants (n=269) Model 1* p Model 2†  p Model 3‡ p 
Primary exposure variable       
  Current use   0.06  0.03  0.03 
     NSAID Non-user (N=142) 23.8 (20.4, 27.7)  24.1 (20.9, 27.7)  24.0 (20.8, 27.7)  
     NSAID User (N=127) 
 
19.2 (16.3, 22.6)  19.0 (16.4, 22.0)  18.9 (16.2, 22.0)  
Secondary exposure variable       
  Past 48 hour use  0.48  0.10  0.06 
     NSAID Non-user (N=126) 22.5 (19.1, 26.4)  23.6 (20.3, 27.4)  23.9 (20.6, 27.8)  
     NSAID User (N=143) 20.7 (17.8, 24.2)  19.8 (17.2, 22.8)  19.5 (16.9, 22.5)  
       
Constructed exposure variable       
  Consistent  use   0.16  0.03  0.03 
     NSAID Non-user (N=102) 24.2 (20.0, 29.2)  25.1 (21.1, 29.9)  25.1 (21.0, 30.0)  
     NSAID User (N=103) 19.9 (16.5, 24.1)  19.2 (16.1, 22.8)  18.9 (15.8, 22.7)  
NOTE: BMI=body mass index; NSAID=nonsteroidal anti-inflammatory drug.  Current use:  Based on participant’s medication list. Past 48 
hour use:  Participant’s verbal response to the question, “Have you taken an aspirin or other anti-inflammatory drug in the past 48 hours?”  
Consistent NSAID use:  The agreement between current NSAID and past 48 hours use.   
*Unadjusted model 
†Adjusted for age at blood draw (continuous) and BMI(continuous) 
‡Missing N=7; Adjusted for age at blood draw (continuous), BMI (continuous), race (white, nonwhite), years menopausal (continuous), and 
current alcohol intake (none, <12 g/day, ≥12 g/day, indicator variable) 
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Table B36. Geometric mean estradiol concentration (95% confidence interval) according to type of NSAID use 
 Serum estradiol concentrations (pmol/L) 
NSAID use Model 1* p Model 2†  p Model 3‡ p 
Aspirin  0.19  0.05  0.04 
     Non-user (N=136) 20.8 (18.6, 23.3)  21.3 (19.2, 23.7)  21.4 (19.2, 23.8)  
     User (N=58) 
 
18.8 (14.8, 23.8)  17.6 (15.1, 20.5)  17.5 (14.9, 20.5)  
Non-Aspirin NSAIDs  0.42  0.20  0.45 
     Non-user (N=136) 21.0 (18.5, 24.0)  21.2 (19.0, 23.7)  20.8 (18.6, 23.3)  
     User (N=32) 18.6 (14.2, 24.4)  18.0 (14.3, 22.6)  18.8 (14.8, 23.8)  
NOTE: BMI=body mass index; NSAID=nonsteroidal anti-inflammatory drug.   
*Unadjusted model 
†Adjusted for age at blood draw (continuous) and BMI(continuous) 
‡Missing n=5 for aspirin user/nonuser analysis and N=2 for non-aspirin user/nonuser analysis; Adjusted for age at blood draw (continuous), 
BMI (continuous), race (white, nonwhite), years menopausal (continuous), and current alcohol intake (none, <12 g/day, ≥12 g/day, indicator 
variable) 
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Table B37. Adjusted geometric mean estradiol concentrations (95% confidence interval) 
stratified by BMI subgroup according to categories of NSAID use 
NSAID exposure category 
Adjusted geometric mean serum estradiol (pmol/L)* 
BMI <27.03 
(n=125) p 
BMI ≥ 27.03 
(n=128) p 
Current NSAID use 
 
 0.22  0.07 
  NSAID Non-user 14.5 (12.5, 16.8)  30.9 (26.0, 36.6)  
  NSAID User 12.6 (10.7, 14.8)  24.6 (20.6, 29.3)  
     
48 hour NSAID use  0.10  0.27 
  NSAID Non-user  14.8 (12.8, 17.2)  30.1 (24.8, 36.5)  
  NSAID User  12.3 (10.5, 14.4)  26.1 (22.2, 30.6)  
     
Consistent NSAID use  0.07  0.10 
  NSAID Non-user 15.0 (12.5, 17.8)  30.4 (24.8, 37.2)  
  NSAID User 11.7 (9.6, 14.2)  24.2 (20.1, 29.0)  
NOTE: BMI=body mass index; NSAID=nonsteroidal anti-inflammatory drug. Median BMI 
based on entire population (n=260).  Interaction terms between NSAID use  and BMI were not 
statistically significant for any of the NSAID categories (all p-values ≥ 0.17)  
*Missing N=7; Adjusted for age at blood draw (continuous), BMI (continuous), race (white, 
nonwhite), years menopausal (continuous), and current alcohol intake (none, <12g/day, 
≥12g/day, indicator variable).   
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Figure B20. Adjusted geometric mean estradiol according to self-reported NSAID use 
   
Serum total estradiol was adjusted for age at blood draw, BMI, race, years menopausal, and 
current alcohol intake in a general linear model.  No/No=Participant’s current medication list did 
not indicate use of a NSAID and the participant verbally responded that they did not consume an 
aspirin or anti-inflammatory agent within 48 hours of blood draw (N=96; mean=21.4; 
95%CI=18.7, 24.5).  No/Yes= Participant’s current medication list did not indicate use of 
NSAID, but participant verbally responded that they consumed an aspirin or anti-inflammatory 
agent within 48 hours of blood draw (N= 24; mean=20.6; 95%CI=16.7, 25.4).   Yes/No= 
Participant’s current medication list indicated use of a NSAID, but the participant verbally 
responded that they did not consume an aspirin or anti-inflammatory agent within 48 hours of 
blood draw (N=40; mean=19.9; 95%CI=15.1, 26.1).   Yes/Yes= Participant’s current medication 
list indicated use of a NSAID, and participant verbally responded that they consumed an aspirin 
or anti-inflammatory agent within 48 hours of blood draw (N=100; mean=17.2; 95%CI=15.1, 
19.6).    
P=0.02 
P=0.14 
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APPENDIX C: ERYTHROCYTE OMEGA-6 AND OMEGA-3 FATTY ACIDS AND 
MAMMOGRAPHIC BREAST DENSITY ADDITIONAL ANALYSES 
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Table C38. Geometric mean (95% confidence interval) breast density according to tertile of 
erythrocyte fatty acid composition 
  
Fatty acids (wt. %) Percent density* p trend† Dense area* p trend† 
n-6 PUFAs     
Total n-6 ‡  0.29  0.71 
≤37.32 24.1 (20.6, 28.0)  35.9 (30.3, 41.9)  
37.33-39.49 23.7 (20.3, 27.4)  34.4 (29.1, 40.1)  
≥39.50 27.2 (23.4, 31.2)  37.5 (31.9, 43.7)  
     
18:2n-6 (LA)  0.32  0.20 
≤14.69 27.2 (23.4, 31.2)  38.5 (32.8, 44.8)  
14.70-16.84 23.5 (20.1, 27.2)  36.3 (30.9, 42.2)  
≥16.85 24.3 (20.8, 28.1)  33.1 (27.8, 38.8)  
     
20:4n-6 (AA)  0.07  0.16 
≤15.24 22.6 (19.3, 26.3)  31.9 (26.8, 37.5)  
15.25-16.57 24.7 (21.3, 28.5)  38.4 (32.8, 44.5)  
≥16.58 27.6 (23.8, 31.6)  37.5 (31.9, 43.6)  
     
n-3 PUFAs     
Total n-3 §  0.54  0.64 
≤6.68 25.2 (21.6, 29.1)  36.9 (31.3, 43.0)  
6.69-8.41 26.2 (22.6, 30.0)  36.0 (30.6, 41.8)  
≥8.42 23.6 (20.1, 27.3)  34.9 (29.5, 40.8)  
     
18:3n-3 (ALA)  0.16  0.20 
≤0.19 27.3 (23.6, 31.2)  38.8 (33.2, 44.9)  
0.20-0.25 24.0 (20.6, 27.8)  35.3 (29.9, 41.1)  
≥0.26 23.6 (20.1, 27.3)  33.6 (28.3, 39.3)  
     
20:5n-3 (EPA)  0.22  0.21 
≤0.64 24.8 (21.2, 28.5)  36.6 (31.1, 42.6)  
0.65-0.90 28.9 (25.2, 32.9)  40.1 (34.4, 46.2)  
≥0.91 21.5 (18.3, 25.1)  31.4 (26.3, 37.0)  
     
22:6n-3 (DHA)  0.80  0.78 
≤3.69 24.7 (21.1, 28.6)  35.1 (29.7, 41.1)  
3.70-4.86 26.1 (22.5, 30.0)  36.3 (30.9, 42.2)  
≥4.87 24.1 (20.6, 27.8)  36.3 (30.8, 42.2)  
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Table C38 (continued)    
 
Fatty acids Percent density* p for trend† Dense area* p for trend† 
6:3 Ratios     
Total n-6:n-3  0.21  0.57 
≤4.48 22.5 (19.1, 26.1)  34.3 (28.9, 40.2)  
4.49-5.73 26.7 (23.1, 30.5)  36.7 (31.3, 42.6)  
≥5.74 25.8 (22.2, 29.8)  36.7 (31.1, 42.8)  
     
LA:ALA  0.40  0.47 
≤64.00 24.5 (21.1, 28.3)  35.8 (30.4, 41.6)  
64.01-78.05 23.7 (20.2, 27.4)  33.3 (28.1, 39.0)  
≥78.06 26.8 (23.1, 30.8)  38.8 (33.1, 45.0)  
     
AA:EPA  0.17  0.28 
≤16.92 22.5 (19.1, 26.2)  32.6 (27.3, 38.3)  
16.93-25.89 26.1 (22.6, 30.0)  38.1 (32.6, 44.1)  
≥25.90 26.3 (22.6, 30.3)  37.1 (31.5, 43.3)  
     
AA:EPA+DHA  0.21  0.35 
≤2.67 22.7 (19.3, 26.4)  34.1 (28.8, 40.0)  
2.68-3.77 26.2 (22.6, 30.0)  35.6 (30.2, 41.4)  
≥3.78 26.1 (22.4, 30.0)  38.1 (32.4, 44.2)  
NOTE: N=248. Fatty acids are reported as a percentage by weight of the total fatty acids (weight 
percent, wt. %).  PUFA, polyunsaturated fatty acid; LA, linoleic acid; AA, arachidonic acid; 
ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; and DHA, docosahexaenoic acid. Tertile 
cutpoints were determined from entire study population (n=248). Values were adjusted for age 
(continuous), BMI (continuous), age at menopause (continuous), alcohol intake (none, <12g/day, 
≥12g/day), current smoker (yes vs.no), previous breast biopsy (yes vs. no), nulliparous (yes vs. 
no), ever breastfed for > 1 month (yes vs. no), and past hormone therapy use (yes vs. no). 7 
participants were excluded for missing variables 
*Square root transformation was applied to percent density and dense breast area 
† Linear trend tests were performed by treating the fatty acid tertile groups as continuous 
variables 
‡18:2n-6+18:n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
§18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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Table C39. Spearman correlation coefficients between erythrocyte n-6 and n-3 fatty acids 
and mammographic features including 9 participants with estradiol levels >150pmol/L 
 Fatty acids (wt.%) Percent density Dense area Nondense area 
N-6 PUFAs    
Total n-6* -0.01 (0.88) -0.02 (0.81) 0.02 (0.81) 
 0.01 (0.83) -0.03 (0.61) -0.05 (0.42) 
    
18:2n-6 (LA) 0.07 (0.24) -0.07 (0.29) -0.19 (0.002) 
 -0.03 (0.68) -0.08 (0.20) -0.09 (0.16) 
    
20:4n-6 (AA) <0.01 (0.99) 0.07 (0.25) 0.09 (0.14) 
 0.07 (0.24) 0.08 (0.23) -0.01 (0.89) 
N-3 PUFAs    
Total n-3† 0.11 (0.08) 0.04 (0.57) -0.16 (0.008) 
 0.03 (0.63) 0.05 (0.46) <0.01 (0.95) 
    
18:3n-3 (ALA) 0.04 (0.56) -0.06 (0.34) -0.13 (0.04) 
 -0.04 (0.55) -0.06 (0.30) -0.03 (0.59) 
    
20:5n-3 (EPA) 0.06 (0.32) -0.03 (0.59) -0.16 (0.01) 
 -0.02 (0.72) -0.03 (0.64) -0.03 (0.59 
    
22:6n-3 (DHA) 0.11 (0.07) 0.07 (0.29) -0.13 (0.04) 
 0.05 (0.44) 0.08 (0.21) <0.01 (0.95) 
6:3 Ratios    
Total n-6:n-3 -0.10 (0.11) -0.03 (0.61) 0.15 (0.02) 
 -0.03 (0.69) -0.04 (0.48) 0.01 (0.82) 
    
LA:ALA -0.02 (0.74) 0.03 (0.62) 0.07 (0.27) 
 0.01 (0.82) 0.03 (0.65) 0.02 (0.79) 
    
AA:EPA -0.06 (0.33) 0.05 (0.46) 0.18 (0.005) 
 0.04 (0.55) 0.04 (0.50) 0.03 (0.61) 
    
AA:EPA+DHA -0.10 (0.11) -0.02 (0.70) 0.16 (0.01) 
  -0.01 (0.89) -0.03 (0.60) <0.01 (0.97) 
NOTE: N=257. Fatty acids are reported as a percentage by weight of the total fatty acids (weight 
percent, wt. %).  PUFA, polyunsaturated fatty acid;  LA, linoleic acid; AA, arachidonic acid; 
ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; and DHA, docosahexaenoic acid. 1st line 
is unadjusted estimates. 2nd line is estimates adjusted for age and BMI. P between parentheses.   
*18:2n-6+18:n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3  
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Table C40. Partial Spearman correlation coefficients between erythrocyte n-6 and n-3 fatty 
acids and mammographic characteristics among women (n=120) whose date of 
mammogram was <30 days from blood draw and film quality not rated as poor 
 Fatty acids (wt.%) Percent density Dense area Nondense area 
N-6 PUFAs    
Total n-6* -0.03 (0.77) -0.03 (0.77) 0.10 (0.26) 
18:2n-6 (LA) 0.14 (0.13) 0.10 (0.27) -0.08 (0.37) 
20:4n-6 (AA) -0.10 (0.27) -0.04 (0.66) 0.14 (0.12) 
    
N-3 PUFAs    
Total n-3
†
 -0.03 (0.77) -0.004 (0.96) -0.04 (0.64) 
18:3n-3 (ALA) 0.15 (0.11) 0.15 (0.11) -0.07 (0.46) 
20:5n-3 (EPA) 0.05 (0.60) 0.05 (0.60) -0.11 (0.22) 
22:6n-3 (DHA) -0.03 (0.73) -0.01 (0.92) -0.02 (0.79) 
    
6:3 Ratios    
Total n-6:n-3 0.02 (0.85) 0.001 (0.99) 0.06 (0.51) 
LA:ALA -0.12 (0.21) -0.12 (0.19) 0.06 (0.49) 
AA:EPA -0.08 (0.40) -0.07 (0.45) 0.15 (0.11) 
AA:EPA+DHA -0.01 (0.92) -0.01 (0.90) 0.08 (0.41) 
NOTE: N=120. Fatty acids are reported as a percentage by weight of the total fatty acids 
(weight percent, wt. %).  PUFA, polyunsaturated fatty acid;  LA, linoleic acid; AA, 
arachidonic acid; ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; and DHA, 
docosahexaenoic acid.  Adjusted for age (continuous) and BMI (continuous). P values between 
parentheses 
*18:2n-6+18:n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6  
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3   
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Table C41.  Mammographic features by self-reported current NSAID use 
Mammographic feature (n=248)   NSAID non-user NSAID user p  
Percent breast density Model 1* 24.2 (21.0, 27.6) 25.2 (21.8, 28.8) 0.69 
 Model 2† 24.1 (21.3, 27.1) 25.2 (22.2, 28.4) 0.60 
 Model 3‡ 24.6 (21.8, 27.5)  25.4 (22.4, 28.5) 0.72 
     
Dense area (cm
2
) Model 1* 34.6 (30.3, 39.1) 36.5 (32.0, 41.4) 0.55 
 Model 2† 34.6 (30.3, 39.1) 36.5 (32.0, 41.4) 0.55 
 Model 3‡ 35.0 (30.8, 39.5)  37.0 (32.4, 41.9) 0.54 
     
Nondense area (cm
2
) Model 1* 117.6 (104.9, 131.1) 111.0 (98.1, 124.7) 0.49 
 Model 2† 118.2 (109.2, 127.6) 110.4 (101.4, 119.9) 0.24 
  Model 3‡ 116.6 (107.8 125.7) 110.8 (101.7, 120.2) 0.38  
NOTE: NSAID, nonsteroidal anti-inflammatory drug. A square root transformation was applied to 
percent breast density, dense area, and nondense area of the breast 
*Model 1 unadjusted      
†Model 2 adjusted for age (continuous) and BMI (continuous)  
‡Model 3 adjusted for age (continuous), BMI (continuous), age at menopause (continuous), 
alcohol intake (none, <12g/day, ≥12g/day), current smoker (yes vs.no), previous breast biopsy 
(yes vs. no), nulliparous (yes vs. no), ever breastfed for > 1 month (yes vs. no), and past hormone 
therapy use (yes vs. no)  
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Table C42. Partial Spearman correlations between erythrocyte fatty acids and mammographic features by current NSAID use 
 NSAID non-user (n=129) NSAID user (n=119) 
  % density dense areas nondense areas % density dense areas nondense areas 
N-6 PUFAs       
Total n-6* 0.02 (0.84) -0.02 (0.80) 0.05 (0.58) 0.02 (0.86) 0.01 (0.89) -0.02 (0.83) 
       
18:2n-6 (LA) -0.01 (0.95) -0.08 (0.38) -0.09 (0.29) -0.03 (0.75) -0.02 (0.85) -0.05 (0.59) 
       
20:4n-6 (AA) 0.13 (0.15) -0.03 (0.76) -0.03 (0.76) 0.03 (0.72) 0.01 (0.91) 0.002 (0.98) 
N-3 PUFAs       
Total n-3† 0.10 (0.25) 0.04 (0.63) -0.12 (0.17) -0.06 (0.53) -0.01 (0.89) 0.04 (0.65) 
       
18:3n-3 (ALA) 0.003 (0.97) -0.07 (0.45) -0.12 (0.20) -0.08 (0.41) -0.03 (0.75) 0.07 (0.44) 
       
20:5n-3 (EPA) 0.12 (0.18) 0.05 (0.59) -0.14 (0.12) -0.16 (0.09) -0.12 (0.18) 0.05 (0.60) 
       
22:6n-3 (DHA) 0.10 (0.25) 0.07 (0.43) -0.09 (0.34) -0.03 (0.74) 0.02 (0.82) 0.04 (0.64) 
6:3 Ratios       
Total n-6:n-3 -0.08 (0.39) -0.04 (0.68) 0.09 (0.30) 0.05 (0.63) 0.01 (0.93) -0.03 (0.73) 
       
LA:ALA -0.04 (0.68) 0.03 (0.76) 0.13 (0.15) 0.09 (0.32) 0.05 (0.63) -0.12 (0.21) 
       
AA:EPA -0.06 (0.50) 0.01 (0.94) 0.11 (0.20) 0.15 (0.11) 0.11 (0.26) -0.05 (0.60) 
       
AA:EPA+DHA -0.04 (0.62) -0.003 (0.98) 0.08 (0.35) 0.05 (0.58) -0.002 (0.98) -0.04 (0.65) 
NOTE: Fatty acids are reported as a percentage by weight of the total fatty acids (weight percent, wt. %).  PUFA, polyunsaturated fatty 
acid;  LA, linoleic acid; AA, arachidonic acid; ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; and DHA, docosahexaenoic 
acid.   Adjusted for age (continuous) and BMI (continuous). P values between parentheses 
*18:2n-6+18:n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6    
†18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3     
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Table C43. Geometric mean (95% confidence interval) percent breast density according to 
tertile of erythrocyte fatty acid composition among participants reporting no current 
NSAID use 
Fatty acids (wt. %) Percent density* p for trend† Dense area (cm2)* p for trend† 
n-6 PUFAs     
Total n-6 ‡  0.35  0.84 
≤37.32 23.0 (18.7, 27.8)  34.3 (27.5, 41.8)  
37.33-39.49 23.5 (18.8, 28.8)  34.3 (27.0, 42.5)  
≥39.50 26.5 (21.6, 31.9)  35.4 (28.2, 43.5)  
     
18:2n-6 (LA)  0.26  0.17 
≤14.69 28.3 (23.0, 34.2)  38.7 (30.7, 47.5)  
14.70-16.84 21.8 (17.6, 26.3)  35.3 (28.5, 42.8)  
≥16.85 23.8 (19.3, 28.8)  30.9 (24.3, 38.2)  
     
20:4n-6 (AA)  0.04  0.07 
≤15.24 21.1 (17.2, 25.4)  29.1 (23.3, 35.6)  
15.25-16.57 24.7 (19.7, 30.4)  39.1 (31.1, 48.1)  
≥16.58 27.9 (22.9, 33.4)  37.7 (30.4, 45.8)  
     
n-3 PUFAs     
Total n-3 §  0.65  0.78 
≤6.68 21.7 (17.2, 26.7)  34.1 (26.9, 42.2)  
6.69-8.41 27.9 (23.1, 33.2)  37.2 (30.0, 45.1)  
≥8.42 23.5 (18.9, 28.5)  32.7 (25.8, 40.5)  
     
18:3n-3 (ALA)  0.29  0.36 
≤0.19 26.3 (21.4, 31.7)  36.8 (29.5, 45.0)  
0.20-0.25 24.4 (19.6, 29.6)   35.5 (28.2, 43.6)  
≥0.26 22.7 (18.5, 27.3)  32.2 (25.9, 39.2)  
     
20:5n-3 (EPA)  0.34  0.78 
≤0.64 20.3 (16.3, 24.8)  31.2 (24.7, 38.4)  
0.65-0.90 30.0 (25.0, 35.4)  40.9 (33.4, 49.2)  
≥0.91 23.3 (18.8, 28.3)  32.3 (25.5, 40.0)  
     
22:6n-3 (DHA)  0.41  0.71 
≤3.69 22.5 (18.1, 27.4)  33.6 (26.7, 41.3)  
3.70-4.86 25.3 (20.2, 30.9)  34.8 (27.2, 43.2)  
≥4.87 25.4 (20.8, 30.5)  35.7 (28.7, 43.4)  
 171 
Table C43 (continued)    
 
Fatty acids (wt. %) Percent density* p for trend† Dense area* p for trend† 
6:3 Ratios     
Total n-6:n-3  0.76  0.82 
≤4.48 23.1 (18.5, 28.1)  34.5 (27.4, 42.4)  
4.49-5.73 26.0 (21.1, 31.4)  33.7 (26.6, 41.6)  
≥5.74 24.0 (19.3, 29.3)  35.9 (28.4, 44.2)  
     
LA:ALA  0.87  0.87 
≤64.00 24.4 (20.1, 29.1)  34.4 (28.0, 41.6)  
64.01-78.05 24.8 (20.0, 30.1)  36.2 (28.8, 44.4)  
≥78.06 23.8 (18.9, 29.2)   33.4 (26.0, 41.6)  
     
AA:EPA  0.90  0.69 
≤16.92 23.2 (18.9, 28.0)  32.4 (25.9, 39.7)  
16.93-25.89 26.8 (21.7, 32.4)  38.0 (30.3, 46.6)  
≥25.90 23.4 (18.8, 28.5)  34.2 (27.1, 42.1)  
     
AA:EPA+DHA  0.71  0.40 
≤2.67 23.2 (18.9, 27.9)  32.9 (26.4, 40.1)  
2.68-3.77 25.8 (20.9, 31.1)  34.0 (26.9, 41.9)  
≥3.78 24.4 (19.7, 29.6)  37.5 (30.0, 45.8)  
NOTE: N=127. Fatty acids are reported as a percentage by weight of the total fatty acids (weight 
percent, wt. %).  NSAID, nonsteroidal anti-inflammatory drug; PUFA, polyunsaturated fatty acid; 
LA, linoleic acid; AA, arachidonic acid; ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; 
and DHA, docosahexaenoic acid. Tertile cutpoints were determined from entire study population 
(n=248).  Values were adjusted for age (continuous), BMI (continuous), age at menopause 
(continuous), alcohol intake (none, <12g/day, ≥12g/day), current smoker (yes vs.no), previous 
breast biopsy (yes vs. no), nulliparous (yes vs. no), ever breastfed for > 1 month (yes vs. no), past 
hormone therapy use (yes vs. no).  
*Square root transformation was applied to percent density and dense breast area 
† Linear trend tests were performed by treating the fatty acid tertile groups as continuous variables 
‡18:2n-6+18:n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
§18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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Table C44.  Geometric mean (95% confidence interval) mammographic features according 
to tertile of erythrocyte fatty acid composition among women reporting NSAID use at 
blood draw 
Fatty acids (wt.%) Percent density* p for trend† Dense area (cm2)* p for trend† 
n-6 PUFAs     
Total n-6 ‡  0.50  0.76 
≤37.32 25.5 (19.5, 32.3)  38.7 (29.2, 49.7)  
37.33-39.49 23.5 (18.6, 29.0)  33.6 (26.0, 42.1)  
≥39.50 28.6 (22.5, 35.4)  40.8 (31.4, 51.4)  
     
18:2n-6 (LA)  0.92  0.81 
≤14.69 25.8 (20.4, 31.9)  38.3 (29.8, 47.9)  
14.70-16.84 25.8 (20.1, 32.2)  36.9 (28.1, 46.9)  
≥16.85 25.4 (19.8, 31.8)  36.7 (28.0, 46.6)  
     
20:4n-6 (AA) 25.4 (19.2, 32.3) 0.75 37.1 (27.5, 48.1) 0.95 
≤15.24 25.0 (20.1, 30.6)  38.1 (30.2, 47.0)  
15.25-16.57 26.8 (21.0, 33.2)  36.7 (27.9, 46.6)  
≥16.58     
     
n-3 PUFAs     
Total n-3 §  0.28  0.84 
≤6.68 29.4 (23.4, 36.2)  40.2 (31.1, 50.6)  
6.69-8.41 23.3 (18.1, 29.2)  33.1 (25.0, 42.3)  
≥8.42 24.5 (19.0, 30.6)  38.8 (29.9, 48.9)  
     
18:3n-3 (ALA)  0.56  0.53 
≤0.19 27.7 (22.2, 33.8)  40.3 (31.7, 49.9)  
0.20-0.25 24.0 (18.9, 29.8)  35.4 (27.3, 44.5)  
≥0.26 25.3 (19.3, 32.0)  36.1 (26.9, 46.7)  
     
20:5n-3 (EPA)  0.01  0.08 
≤0.64 31.1 (24.9, 38.0)  43.6 (34.0, 54.5)  
0.65-0.90 26.8 (21.3, 33.0)  38.1 (29.4, 47.9)  
≥0.91 20.2 (15.4, 25.6)  31.4 (23.5, 40.3)  
     
22:6n-3 (DHA)  0.32  0.82 
≤3.69 28.1 (21.9, 35.1)  37.6 (28.3, 48.2)  
3.70-4.86 25.7 (20.4, 31.5)  35.7 (27.7, 44.7)  
≥4.87 23.5 (18.0, 29.8)  39.2 (29.9, 49.8)  
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Table C44 (continued) 
 
Fatty acids (wt.%) Percent density† p for trend‡ Dense area† p for trend‡ 
6:3 Ratios     
Total n-6:n-3  0.13  0.55 
≤4.48 22.0 (16.7, 28.0)  34.9 (26.3, 44.9)  
4.49-5.73 26.4 (21.0, 32.5)  37.9 (29.4, 47.5)  
≥5.74 28.8 (22.8, 35.4)  39.2  (30.2, 49.4)  
     
LA:ALA  0.21  0.24 
≤64.00 24.1 (18.4, 30.6)  36.4 (27.4, 46.7)  
64.01-78.05 23.4 (18.3, 29.1)  31.9 (24.2, 40.6)  
≥78.06 29.3. (23.7, 35.4)  43.8 (35.0, 53.5)  
     
AA:EPA  0.09  0.34 
≤16.92 22.1 (16.5, 28.6)  33.9 (24.8, 44.4)  
16.93-25.89 24.9 (19.8, 30.6)  37.0 (28.9, 46.0)  
≥25.90 30.0 (18.9, 28.6)  41.0 (31.7, 51.6)  
     
AA:EPA+DHA  0.24  0.76 
≤2.67 22.9 (17.0, 29.7)  37.4 (27.6, 48.7)  
2.68-3.77 25.3 (19.9, 31.3)  35.4 (27.2, 44.6)  
≥3.78 28.4 (22.5, 35.1)  39.5 (30.4, 49.7)  
NOTE: N=114. Fatty acids are reported as a percentage by weight of the total fatty acids (weight 
percent, wt.%). NSAID, nonsteroidal anti-inflammatory drug; PUFA, polyunsaturated fatty acid; 
LA, linoleic acid; AA, arachidonic acid; ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; 
and DHA, docosahexaenoic acid. Tertile cutpoints were determined from entire study population 
(n=248).  Values were adjusted for age (continuous), BMI (continuous), age at menopause 
(continuous), alcohol intake (none, <12g/day, ≥12g/day), current smoker (yes vs.no), previous 
breast biopsy (yes vs. no), nulliparous (yes vs. no), ever breastfed for > 1 month (yes vs. no), past 
hormone therapy use (yes vs. no).  
*Square root transformation was applied to percent density and dense breast area 
† Linear trend tests were performed by treating the fatty acid tertile groups as continuous variables 
‡18:2n-6+18:n-6+20:2n-6+20:3n-6+20:4n-6+22:4n-6+22:5n-6 
§18:3n-3+20:4n-3+20:5n-3+22:5n-3+22:6n-3 
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Table C45. Spearman correlation coefficients between erythrocyte fatty acids not of the n-6 
or n-3 families and mammographic features  
 
 Percent breast density Dense breast area Nondense breast area 
Fatty acid (wt. %) r (p) r (p) r (p) 
14.0 -0.04 (0.50) -0.07 (0.24) 0.02 (0.81) 
15.0 0.07 (0.27) -0.07 (0.28) -0.02 (0.71) 
16.0 0.003 (0.96) -0.02 (0.76) 0.005 (0.94) 
17.0 0.10 (0.12) 0.13 (0.05) -0.02 (0.77) 
18.0 -0.02 (0.78) 0.001 (0.99) 0.004 (0.96) 
16:1t -0.05 (0.40) -0.07 (0.30) 0.03 (0.61) 
18:1 t-1 -0.07 (0.25) -0.07 (0.29) 0.05 (0.46) 
18:1 t-2 -0.09 (0.17) -0.05 (0.41) 0.12 (0.06) 
18:1 t-3 -0.13 (0.05) -0.10 (0.13) 0.12 (0.06) 
18:1 t-4 -0.13 (0.05) -0.09 (0.14) 0.10 (0.10) 
18:1 t-5 -0.12 (0.07) -0.09 (0.14) 0.11 (0.10) 
18:2 tt -0.08 (0.21) -0.14 (0.02) -0.01 (0.87) 
16:1n7c -0.001 (0.98) -0.04 (0.55) 0.009 (0.89) 
18:1n9c 0.02 (0.80) 0.01 (0.84) 0.007 (0.92) 
18:1n7c 0.05 (0.47) 0.04 (0.55) 0.02 (0.81) 
20:1n9 -0.02 (0.71) -0.01 (0.84) 0.06 (0.37) 
24:1n9 0.04 (0.55) 0.08 (0.21) 0.02 (0.79) 
NOTE: N=248. Fatty acids are reported as a percentage by weight of the total fatty acids (weight 
percent, wt. %).  Adjusted for age (continuous) and BMI (continuous) 
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Table C46. Spearman correlation coefficients between erythrocyte fatty acids not of the n-6 
or n-3 families and mammographic features among women whose date of mammogram 
was <30 days from blood draw and film quality not rated as poor 
 Percent breast density Dense breast area Nondense breast area 
Fatty acid (wt.%) r (p) r (p) r (p) 
14.0 0.03 (0.73) -0.02 (0.87) -0.04 (0.68) 
15.0 0.15 (0.11) 0.15 (0.10) -0.05 (0.62) 
16.0 0.03 (0.77) -0.01 (0.93) -0.02 (0.80) 
17.0 0.13 (0.17) 0.17 (0.07) -0.06 (0.49) 
18.0 -0.10 (0.28) -0.06 (0.53) 0.05 (0.56) 
16:1t 0.03 (0.76) -0.01 (0.93) -0.07 (0.47) 
18:1 t-1 0.02 (0.87) -0.02 (0.81) -0.08 (0.41) 
18:1 t-2 -0.12 (0.20) -0.14 (0.13) 0.06 (0.55) 
18:1 t-3 -0.14 (0.14) -0.14 (0.13) 0.08 (0.37) 
18:1 t-4 -0.16 (0.07) -0.18 (0.05) 0.06 (0.52) 
18:1 t-5 -0.11 (0.22) -0.10 (0.29) 0.10 (0.30) 
18:2 tt -0.02 (0.79) -0.16 (0.08) -0.12 (0.20) 
16:1n7c 0.10 (0.29) 0.02 (0.79) -0.06 (0.51) 
18:1n9c 0.23 (0.01) 0.12 (0.20) -0.25 (0.01) 
18:1n7c 0.10 (0.29) 0.04 (0.67) -0.06 (0.53) 
20:1n9 0.09 (0.32) 0.03 (0.75) -0.01 (0.89) 
24:1n9 -0.14 (0.14) -0.05 (0.61) 0.22 (0.20) 
NOTE: N=120. Fatty acids are reported as a percentage by weight of the total fatty acids 
(weight percent, wt. %).  Adjusted for age (continuous) and BMI (continuous) 
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Table C47.  Spearman’s correlation coefficients between serum estradiol concentration and 
mammographic features 
  Serum estradiol  
Mammographic characteristic r* p r† p 
Percent breast density -0.29 <0.0001 -0.08 0.24 
Dense breast area (cm
2
) -0.06 0.37 -0.07 0.29 
Nondense breast area (cm
2
) 0.42 <0.0001 0.08 0.19 
*Unadjusted Spearman's correlation coefficients 
†Age- and BMI-adjusted Spearman's correlation coefficients 
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